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Amplification is essential in order to achieve low limits of detection (LOD) within analyte 
detection assays. Over recent years, chemists have developed a multitude of amplification 
methodologies for the detection of a variety of analytes with varying signal readouts. Typically, 
these methodologies are focussed upon one of four main amplification strategies; target, label, 
signal or receptor amplification. Herein, a thorough review of the current literature has been 
compiled highlighting both the advantages and disadvantages of each strategy. 
 Despite the increasing number of amplification methodologies being described, there is 
still significant demand for improving analyte assay efficiency and sensitivity. In particular, rapid 
and sensitive protein detection that can be performed at the point-of-care (POC) setting is highly 
desirable for the effective treatment and control of infectious diseases. In collaboration with 
medical diagnostics company Atlas Genetics Ltd., a new electrochemical substrate for the 
ratiometric detection of alkaline phosphatase (ALP), a commonly-used enzyme label within 
enzyme-linked immunosorbent assays (ELISA), was developed capable of delivering an ALP LOD 
of 0.3 pM within 30 minutes. When applied to the detection of C-reactive protein (CRP), a model 
biomarker used to diagnose inflammation, the substrate was shown to be significantly more 
reproducible than a commonly-used commercially-available electrochemical ALP substrate. 
 In order to improve the sensitivity of an ELISA, a novel signal amplification methodology 
was then developed. Based upon a double-catalyst signal amplification strategy, an organometallic 
transfer hydrogenation catalyst was utilised in combination with the enzyme label to afford a 
hybrid synthetic and biological amplification cascade. To achieve selective enzyme-triggered 
catalyst activation, an enzyme substrate termed a proligand was synthesised. In the presence of the 
enzyme, self-immolation of the proligand occurs to release a ligand, capable of binding to an 
iridium pre-catalyst to generate a ligand-accelerated active catalyst. Catalyst activity could be 
observed through ratiometric electrochemical analysis through the use of an electroactive aldehyde 
as the catalyst substrate. An ALP LOD of 7.6 pM after 33 minutes was obtained for this 
amplification methodology but when applied to the detection of CRP however, a significant 
background reaction, found to be caused by the iridium pre-catalyst, limited sensitivity. The 
versatility of the signal amplification methodology was nevertheless demonstrated through the 
enzyme-triggered catalytic reduction of a range of different aldehydes with alternative signal 
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Molecular Amplification in Sensing 
1.0  Introduction 
Amplification is the process whereby a small input signal is converted to a large output signal by 
means of an amplifier. Amplifiers are most commonly associated with electronics where they are 
used to increase the power of an electric signal for functions such as increasing audio volume. 
Amplifiers are also found within certain aspects of optics, fluidics and mechanics. In nature, living 







 Typically, these amplified physical responses to an external stimulus are achieved 
through enzyme cascade mechanisms (Scheme 1.1).
4
 Specific enzyme cascades are initiated when a 
signalling molecule (i.e. a hormone) is detected by a signal receptor, which in turn activates an 
associated enzyme. Once activated, the enzyme can catalyse the production of multiple signal relay 
molecules, which can go on to activate more enzymes and so on, resulting in an enzyme cascade. 
An example of this can be found within the fight-or-flight response exhibited by animals where, in 
response to a perceived threat, epinephrine is released by the body to activate an enzyme cascade 
for increasing blood sugar levels.
5
 Through this powerful amplification mechanism, the detection a 
single molecule of epinephrine by a receptor can lead to the production of thousands of glucose 
molecules; amplifications over several orders of magnitude are observed within milliseconds. 
 
 




Figure 1.1 Four main approaches to achieving amplification within sensing. 
 
 The use of amplification is also found within many biological and chemical sensing 
techniques.
6
 Since a single molecule is unable to generate a strong enough signal to be detected, 
some degree of amplification is paramount to achieving a detection protocol with high sensitivity. 
There is huge demand for the ability to detect of a large variety of different analytes in many areas 




 and environmental 
monitoring.
9
 There is also increasing pressure to improve the efficiency as well as the sensitivity of 
currently existing analyte detection assays. As such, more and more amplification methodologies 
for a range of different analytes are constantly being developed. The analytes requiring detection 
are often very structurally diverse and the readout method chosen for detection can also vary 
depending on the application. To accommodate for this, many different amplification 
methodologies have been developed to specifically detect the desired analyte with an appropriate 
sensitivity and using the readout method required. Despite the vast number of amplification 
methodologies published to date, they typically fall within one of four types of amplification 
 
3 
categories; target amplification, label amplification, signal amplification or receptor amplification 
(Figure 1.1). 
 Target amplification (Chapter 1.1) involves increasing the number of analyte‒receptor 
recognition events that occur per analyte. This can be done by increasing the analyte concentration 
prior to analyte recognition through analyte replication protocols, or by recycling the analyte after a 
signal has been produced post-analyte recognition. Additionally, analytes that can affect multiple 
labels or reporter molecules due to possessing catalytic properties themselves provide inherent 
target amplification within their detection assays. Label amplification (Chapter 1.2) focuses on 
increasing the number of labels per analyte recognition event. Since each label is responsible for 
providing a signal, the ability to amplify the number of labels that represent an analyte‒receptor 
recognition event leads to a signal increase. This can be done using polymerisation or nucleic acid 
replication techniques or through the use of nanostructures for either directly increasing label 
numbers or to provide a collective change in physical property to illicit a detectable response. 
Signal amplification (Chapter 1.3) is by far the most common approach to improving the sensitivity 
of a detection methodology and regards the use of amplifiers to enhance the signal produced from 
an analyte‒receptor recognition event. Receptor amplification (Chapter 1.4) utilises a number of 
scaffolds to amplify the amount of receptors bound to the signal-generating mechanism. This 
increases the probability of achieving an analyte‒receptor recognition event and, as a single 
binding event is able to affect the properties of the entire structure; an increased signal can be 
obtained in comparison to a single receptor system. Although the majority of amplification 
methodologies published to date are designed upon one of these four approaches, many are not 
exclusively bound to such parameters and categorised by which best describes the novel 
amplification method developed by the authors. This becomes apparent with regard to more recent 
amplification publications where the authors strive to achieve even greater detection sensitivity 
through a combination of strategies from different amplification categories. 
 
1.1 Target Amplification 
1.1.1  Target Replication 
One strategy to improve the limit of detection (LOD) of an assay is to simply increase the number 
of target molecules present. If few molecules of the target are present then an efficient replication 
technology, that is specific only to the analyte, would dramatically increase the concentration of 
target molecules to a detectable level. Traditionally, target replication has been specifically 
developed for the amplification of nucleic acids and there have been a substantial number of 
different strategies developed for this purpose.
10
 The polymerase chain reaction (PCR) is one such 






Scheme 1.2 The polymerase chain reaction (PCR) cycle. 
 
 PCR is used to amplify target strands of deoxyribonucleic acid (DNA) prior to detection 
and is carried out over a number of cycles (Scheme 1.2).
12
 Each cycle begins with denaturation of 
the double-stranded DNA at elevated temperatures in order to obtain the target DNA in single-
stranded form. This is followed by the annealing of DNA primers to the single-stranded DNA, 
which indicates the start of the specific sequence of DNA due to be replicated. Starting from the 
primer, an enzyme known as DNA polymerase elongates the nucleic acid sequence in a base-by-
base complementary fashion to the single-stranded DNA yielding two identical copies of double-
stranded DNA. These steps are repeated, often between 15 to 40 cycles, until amplification yields a 
detectable concentration of target DNA. As with every PCR cycle the amount of target DNA 
present is doubled, then DNA amplification using PCR is exponential; one of only a handful of 
sensing methodologies that truly exhibits exponential amplification. Because of this powerful 
amplification, and the fact that the process can be automated using thermal cyclers, PCR has been 
incorporated into many areas of science where sensitive DNA detection is paramount, such as 
forensics, evolutionary molecular biology and molecular diagnostics.
13
 Current research into PCR 
has been focused towards avoiding the use of thermostable polymerases and thermal cyclers in 
order to reduce the time, and improve the efficiency of the protocol. A number of isothermal 
nucleic acid amplification technologies have since emerged,
14–15
 which allows for nucleic acid 
sensing to be performed in the point-of-care (POC) setting.
16
 One limitation of PCR is that it is 
 
5 
specific only to the amplification of nucleic acids. Target amplification methodologies that 
demonstrate the exponential amplification of other analytes as yet remain undiscovered. 
 
1.1.2  Target Recycling 
In the majority of cases, analytes to be detected are unable to be replicated as a means of providing 
amplification. Target amplification can still be achieved however, if the analyte can be recycled 
after a signal has been produced by an analyte recognition event. By doing this, one target molecule 
is able to act upon multiple probe molecules which are responsible for providing the positive 




Scheme 1.3 Enzyme-assisted target recycling of nucleic acids. 
 
 An example of this is enzyme-assisted target recycling (EATR), which is also used 
primarily for nucleic acid detection (Scheme 1.3).
17
 In this approach, single-stranded target DNA 
hybridises with probe oligonucleotides, which are usually in a vast excess. The resulting double-
stranded DNA is acted upon by an enzyme that selectively cleaves the probe and in the process, 
releases a detectable signal.
18
 Enzyme-cleavage also results in the destabilisation of the complex 
which then separates and in doing so, releases the target single-stranded DNA capable of reacting 
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further with more DNA probes. Although EATR produces a linear amplification compared with the 
exponential amplification provided by PCR, fewer false-positives occur since the procedure is less 
sensitive towards DNA contaminants. Additional benefits of EATR over PCR include an improved 
robustness and reduced cost, making it a useful amplification methodology for affordable POC 
diagnostics. The same concept can also be achieved with ribozymes (nucleic acid enzymes) instead 





Scheme 1.4 Quadratic enzyme-assisted target recycling for small molecule detection. 
 
 Efforts have since been made towards removing the enzyme entirely through the 
development of self-cleaving probes.
20
 In their non-hybridised form, the probes are stable towards 
any inter- or intramolecular reactions with itself, giving no signal in the absence of the target. In the 
presence of the target, target-assisted self-cleavage (TASC) occurs, destabilising the complex and 
leading to recycling of the target along with the production of the signal, often via fluorescence. 
This ‘reagent-free’ approach towards DNA sensing has inspired the development of DNA-





Coupling substrate turnover with signal production allows for the reaction to be monitored over 
time and DNA templates have been shown to provide >200-fold increase in signal in 30 seconds 
over a nontemplated reaction, and can achieve a turnover number of 1500 times with a LOD of 0.5 
pM.
22
 Recently, a quadratic target recycling amplification procedure has been described by Huang 
et al. in which two recycling pathways operate sequentially for the ultrasensitive detection of 
certain antibiotics (Scheme 1.4).
23
 In this advancement, a hairpin DNA structure containing an 
aptamer probe, selectively binds to its target ampicillin. Once the hairpin has been opened by the 
target, a primer becomes bound and a polymerase replicates a complementary strand recycling the 
target in the process. The double helix produced as a result then enters its own EATR cycle 
producing multiple copies of short single-stranded DNA. This amplified sequence is then able to 
bind to electrochemically-labelled complementary sequences, preventing them from being detected 
at the electrode. Thus, a positive sample is observed in this case by a signal decrease. The use of a 
DNA aptamer for analyte recognition delivered excellent selectivity for the target, even in the 
presence of similar structures such as penicillin, and the LOD for this system was calculated to be 
1.09 pM after a 4.5 hour amplification period which boasts a 100-fold improvement over existing 
methods. 
 Target recycling methodologies have also found use within applications other than DNA 
detection. For example, two EATR cycles can cross-trigger one another to achieve simultaneous 
self-amplification for use towards a DNA-based artificial biochemical circuit.
24
 Additionally, 





1.1.3  Target Catalysis 
Another target amplification strategy is to utilise the catalytic attributes of the analyte being 
detected. Target catalysis, as an amplification methodology, is typically used for the detection of 
trace metal contaminants found in pharmaceutical ingredients and waste water streams. There has 
been a significant increase in the number of metal-catalysed cross-coupling reactions used in the 
pharmaceutical industry over recent years and as a result, metal impurities within drug compounds 
are becoming commonplace and are considered to pose a potential health risk.
26
 Palladium is the 
most commonly used element within metal-catalysed reactions towards the synthesis of 
pharmaceuticals and consequently, restrictions have been placed upon the amount of residual 
palladium allowed to be found in medicinal compounds.
27 
Unsurprisingly, the development of 
sensitive detection methodologies for palladium has been widely sought after. 
 Koide et al. were the first to exploit palladium’s catalytic ability as a method of providing 
amplification for its detection.
28
 Non-fluorescent compound 1 was designed with an allyl moiety 
for analyte recognition which, only in the presence of Pd
0
, undergoes deallylation via a 
Tsuji‒Trost-like mechanism (Scheme 1.5).29–31 Quantitative detection of the released, highly-
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fluorescent product 2 can be performed using a standard fluorometer allowing for a LOD of less 
than 1 ppm of palladium per mg sample. This efficient example of target amplification was 
successfully shown to detect residual Pd
0
 in pharmaceutical products as well as impregnated within 
used glass reactor vessels. In addition, the probe has been used within a high-throughput method 
for the detection of palladium within ore samples towards the more efficient and economical 




 is readily reduced to Pd
0
, both oxidation states of palladium 
are detected by this method. However, by changing the mechanism used for palladium detection to 
the metal-catalysed aromatic Claisen rearrangement,
33




 could be 
achieved.
34
 The similar reactivity of palladium and platinum however can cause selectivity issues, 
but through  careful selection of the solvents used in the assay and by maintaining a specific pH, 
this can also be overcome.
35
 Improvements to this detection methodology include the introduction 
of reducing agents and phosphine ligands in order to increase the catalytic activity of the palladium, 
which in turn has led to increased sensitivity of the assay.
36–37
 Furthermore, a bis-allyl ether 
derivative of 1 has been very recently reported that can significantly reduce background 





Scheme 1.5 Fluorogenic detection of palladium using a catalytic deprotection strategy.
 
 
 Alternative moities have also been shown to be selective for palladium detection as a 
propargyl derivative of compound 1 has been shown to be able to monitor palladium accumulation 
in living systems via fluorescence.
39
 Probes with different fluorescent scaffolds have also been used 
for palladium detection within cells.
40
 Among these, naphthalimide-derived probes are considered 
the most accurate since fluorescence detection is ratiometric.
41
 Palladium sensing is not confined to 
just allyl or propargyl deprotection as Jun and Ahn have utilised the catalytic cross-coupling 
capability of palladium to develop a ‘switch-on’ fluorescent detection method (Scheme 1.6).42 In 
this example of target catalysis, non-fluorescent probe 3 was designed comprising of an aryl iodide 





 Oxidative insertion into the carbon‒halide bond induces ring-opening of the spirolactam, 
and subsequent reductive elimination provides highly-conjugated fluorescent product 4 whilst 
simultaneously regenerating the active catalyst. This highly sensitive technique allows for the 
specific detection of palladium at concentrations as low as 2 ppb. Following the success of these 
initial reports, there has been extensive research into the development of alternative probes for both 






Scheme 1.6 Fluorogenic detection of palladium using a catalytic cross-coupling strategy. 
 
 In addition to the sensitive detection of metals, the detection of enzymes are also important 
especially within high-throughput screening for drug discovery as well as enzyme engineering.
46
 
Since a single enzyme is capable of generating multiple reporter molecules, amplification in the 
form of target catalysis is inherent within enzyme detection assays.
47
 The simplest and most 
effective strategy is to couple enzyme-responsive functional groups with water-soluble 
chromogenic or fluorogenic moieties to obtain enzyme substrates that selectively exhibit a change 
in physical property in the presence of an enzyme.
48
 For example, Sames et al. designed a range of 
fluorogenic probes for oxidoreductase enzyme detection based on this concept.
49
 During their 
investigation, they found that one probe in particular was a highly selective substrate for 3-α-
hydroxysteroid dehydrogenase (HSD), an enzyme responsible for the activation and deactivation of 
steroid hormones.
50
 This enabled fluorescence imaging to be performed on human cells in order to 
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monitor the up-regulation of HSD in response to panaxytriol,
51
 an active compound found in red 





Scheme 1.7 Fluorogenic enzyme assay for the detection of MAO. 
 
 By changing the enzyme-responsive trigger unit, the group were able to simply achieve a 
highly selective ‘switch-on’ fluorescent assay for monoamine oxidase (MAO) (Scheme 1.7),53 an 
enzyme associated with neurological and psychiatric diseases.
54
 In this enzyme detection assay, 
compound 5 was exposed to MAO which catalyses the aerobic oxidation of amines to the 
corresponding imines.
55
 This intermediate is then hydrolysed under the aqueous conditions required 
for enzyme activity to give aldehyde 6, which then undergoes intramolecular cyclisation and 
dehydration to afford highly fluorescent indole 7. Although not a particularly sensitive system due 
to the slow turnover rate of the enzyme, it did allow for the direct and continuous measurement of 
MAO activity in mitochondria, utilising target catalysis for amplification. 
 
1.2  Label Amplification 
1.2.1  Label Replication 
Since the majority of analytes requiring detection do not possess catalytic attributes or can be easily 
replicated, target amplification is therefore not a realistic amplification strategy. An alternative 
amplification method is amplifying the label after analyte‒probe recognition. This concept provides 
amplification by multiplying the number of labels per analyte recognition event. An example of 
this can be provided through a derivative of PCR, known as rolling circle amplification (RCA).
56
 
RCA is an isothermal nucleic acid amplification protocol which has found use in many applications 
within chemical biology, materials science and medicine.
57
 Typically, circular single-stranded 
DNA, called a template, is linearly replicated hundreds or thousands of times to give an extremely 
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long strand of single-stranded DNA. Since the same DNA sequence is repeated, multiple 
complementary probe strands are able to hybridise to the amplified single-stranded DNA label 





Scheme 1.8 Label amplification using RCA in a DNA-labelled immunoassay. 
 
 The application of RCA to immunoassays, known as immuno-RCA, allows for the 
sensitive detection of proteins through the labelling of probe antibodies with a specific DNA 
sequence (Scheme 1.8).
59
 In the presence of the analyte, hybridisation with the circular template 
enables replication of the label DNA sequence using RCA, which can then be detected by 
fluorescence through the hybridisation of multiple complementary DNA sequences tagged with a 
fluorophore. This strategy allows for an enormous ratio of fluorescent molecules per label, and 
therefore per analyte, and as such, delivers a highly sensitive detection system. Jiang et al., for 




 RCA has also been combined with oligonucleotide-functionalised nanoparticles for 
sensitive cancer cell detection by electrochemical methods with an obtained LOD of 10 cells per 
mL.
61
 Increasing the sensitivity of DNA-labelled immunoassays can also be achieved by using 
PCR as the amplification technique.
62 
Termed immuno-PCR, this technique delivers 100 to 10000-
fold increase in immunoassay sensitivity and has been applied to the sensitive detection of tumour 
markers, viral proteins and bacterial pathogens.
63–64
 However, to allow the label to be amplified by 
PCR, cleavage of the DNA label from the analyte‒probe complex is required which can be difficult 
to perform efficiently without denaturising the complex and creating unwanted contaminants that 




Scheme 1.9 HCR approach to label amplification. 
 
 A reagentless label replication strategy known as the hybridisation chain reaction (HCR) 
was developed by Dirks and Pierce, that involved two stable DNA hairpin structures that can 
coexist in solution until selectively triggered by the analyte.
65
 Once triggered, the two strands of 
DNA react with one another in an alternating end-over-end fashion. By introducing 2-aminopurine 
(2AP), a fluorescent adenine analogue,
66
 into the structure of one of the hairpin structures, HCR 
can be measured through fluorescent quenching. Alternatively, labelling both ends of both hairpin 
structures with pyrene enables a switch-on fluorescent DNA detection derivative (Scheme 1.9).
67
 
Of one the benefits of using pyrene is that fluorescence detection is ratiometric which minimises 
errors from environmental effects leading to a more accurate detection method. Not only is this 
amplification method isothermal and enzyme-free, it is also highly selective, as base-pair 
mismatches, base deletion or base insertion are all discriminated from the target, and highly 
sensitive as DNA detection is in the femtomolar range. These highly advantageous attributes has 
enabled HCR to be used for in situ amplification and fluorescent imaging within vertebrate 
embryos.
68
 Silver nanoparticles can also be used within a label-free derivative of HCR for 
amplified electrochemical DNA detection.
69
  
 A synthetic approach to label replication was developed by Bowman et al. who achieved 
an amplified response through molecular recognition-selective polymerisation (Scheme 1.10).
70
 In 
this approach, surface-bound biotin-labelled analytes are tagged with a macrophotoinitiator via an 
avidin complex. Irradiation of the surface in the presence of a monomer-containing solution 
induces polymerisation selectively from the photoinitiators, which therefore only occurs in the 
presence of the analyte. A 10 minute exposure to 365 nm wavelength light was enough to initiate 
polymers with a thickness greater than 100 nm, which is significant enough to see with the unaided 
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eye and allowed a DNA concentration of 0.5 fmol to be easily detected. It has been estimated that 




 can be achieved through this methodology.
71
 This 
polymerisation-based amplification has also been applied to the detection of the influenza virus 
through macrophotoinitiator-labelled immunoassays.
72
 To provide quantitative measurements, as 
opposed to the quantitative visual readout, fluorescent nanoparticles can also be incorporated into 
the polymer enabling DNA detection,
73
 and antibody detection,
74
 to be achieved through 
fluorescent polymerisation-based amplification. 
 
 
Scheme 1.10 Polymerisation-based label amplification. 
 
 
Scheme 1.11 Integer label amplification through triggered head-to-tail depolymerisation. 
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 In a conceptually opposite approach, self-immolative polymers that undergo triggered 
depolymerisation in the presence of a specific analyte have been developed by Shabat et al. for 
catalytic protein detection (Scheme 1.11).
75
 Typically, polymer chains comprised of between 15‒20 
pro-fluorescent monomer units and an analyte-responsive trigger unit at the head were synthesised. 
Cleavage of the head group occurs selectively in the presence of bovine serum albumin (BSA),
76
 
triggering continuous head-to-tail depolymerisation,
77
 with subsequent release of the monomer 
units and trapping of these aza-quinone-methide intermediates 8 with water, generates aniline 9 
with a consequential turn-on of fluorescence. Although full consumption and full elimination of the 
polymers is slow, a 1 mgmL
−1
 concentration of BSA could easily be distinguished from the 
background after an hour. Different monomers can easily be incorporated into the polymer 
allowing multiple signals to be released simultaneously upon a single trigger cleavage.
78
 This has 
lead to self-immolative polymers being used for a number of biomedical applications as well as for 




1.2.2  Label Multiplication 
In the majority of instances, label replication is typically restricted to the use of nucleic acids as 
labels as it relies upon nucleic acid amplification procedures such as PCR and RCA. However, 
these methods are dependent upon the successful conjugation of the DNA label to the antibody, 
which can be difficult to achieve without denaturising the antibody. Also, polymerisation methods 
can be irreproducible and quantification of analyte concentrations can be difficult. A more general 
approach to providing label amplification can be provided though multiplying the number of labels 
present after an analyte‒receptor recognition event. In this method, the label that indicates the 
presence of the target is able to capture multiple identical probes in the adjacent vicinity, thus 
multiplying the number of labels per target. This is exemplified by an amplification procedure 
designed to increase immunosensitivity known either as tyramide signal amplification (TSA),
81
 or 
catalysed reporter deposition (CARD).
82
  
 Typically, CARD is used to multiply the number of enzyme labels that represent the 
presence of a target protein after an initial analyte‒receptor complex has been labelled with an 
enzyme (Scheme 1.12).
83
 In this example, the target analyte is bound to a solid surface and 
identified with the corresponding antibody labelled with the enzyme horseradish peroxidase (HRP). 
In the presence of a biotin-labelled tyramine-derived substrate, the enzyme catalyses the formation 
of highly reactive tyramine radicals that react readily with any tyrosine units found within the 
adjacent protein structures.
84
 This results in the macromolecular structure being covered with many 
biotin molecules, each of which is able to bind another enzyme via its streptavidin conjugate 
utilising the high binding affinity between biotin and streptavidin.
85
 By employing this approach, 
one target is able to bind multiple enzyme labels which, upon addition of a pro-fluorescent 
substrate, leads to an amplified fluorescent output. This method is reported to deliver improved 
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sensitivity in comparison to other probe multiplication methods towards increasing immunoassay 
sensitivity such as the avidin‒biotin complex (ABC) approach.86  
 
 
Scheme 1.12 Catalysed reporter deposition (CARD). 
 
 The ABC approach to label multiplication typically utilises the multivalent characteristics 
of the streptavidin tetramer avidin, in order to increase the number of labels that represent a target 
molecule (Scheme 1.13).
87
 Similarly to CARD, target proteins are identified by appropriate 
antibodies after to being adsorbed onto a solid surface. Instead of being labelled with an enzyme 
however, the antibodies are labelled with biotin. The addition of a solution consisting of avidin and 
biotin-labelled HRP leads to a vast interlinked biotin‒avidin network containing multiple 
peroxidase enzymes per complex. As a result, when the enzyme network is exposed to a solution 
containing the enzyme substrate, an amplified response is observed compared to an immunoassay 
that uses just one enzyme per target analyte. This has led to the ABC approach to label 
amplification to be used for a number of applications such as affinity chromatography and enzyme 
localisation studies, as well as for diagnostics.
88
 However, like many immunoassay amplification 
methodologies, this system is susceptible to high background rates due to non-specific adsorption. 
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Scheme 1.13 Avidin‒biotin complex (ABC) approach to label amplification. 
 
 The concept of synthesising structures possessing multivalent characteristics in order to 
multiply the number of labels corresponding to a single target molecule has inspired the 
development of many other label amplification approaches. In particular, nanostructures have 
found considerable success as label amplifiers, especially within biosensors, due to their small size 
yet large collective surface area.
90–92 
For example, Rusling et al. described the use of carbon 
nanotubes as the label amplifier within an electrochemical immunosensor for sensitive cancer 
biomarker detection.
93
 In this approach, the carbon nanotubes function as a bridge between the 
antibody used for target identification, and the enzyme labels. The amount of enzyme labels per 
binding event was calculated to be approximately ninety, which allowed for a LOD of 4 pgmL
−1
 for 
the cancer biomarker, prostate specific antigen (PSA). Similarly, this technique was also used for 
the attomolar detection of DNA, which equates to just 80 copies.
94
 Gold nanoparticles, which are 
easier to functionalise than carbon nanotubes, have also been used as the label amplifier. The 
enzyme label to binding event ratio was found to dramatically increase through this change, since 
the use of 1 µm diameter gold nanoparticles allowed up to five hundred thousand enzyme labels to 
be attached per nanoparticle. Due to this massive label amplification, a LOD of 1 fgmL
−1
 was 
obtained for the detection of cancer biomarker interleukin-8 (IL-8).
95
 
 The ability to attach a large number of labels upon a single nanoparticle and that gold 
nanoparticles in particular are easier to functionalise through strong covalent gold–thiol bonds, has 
seen them incorporated into a large number of chemical and biological sensing methodologies for 
label amplification.
96
 One extremely sensitive approach was developed by Mirkin et al. who 
functionalised gold nanoparticles with multiple copies of oligonucleotides with identical sequences 
to obtain what are known as “bio-barcodes”.97 These bio-barcode nanoparticles were then used as 
label amplifiers for the sensitive protein detection (Scheme 1.14).
98
 In this approach, antibody-
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functionalised magnetic capture nanoparticles are used to identify target proteins which, in the 
presence of the analyte, are labelled with the bio-barcodes through the formation of a highly-stable 
sandwich complex. The complex is then separated from the mixture magnetically and the 
oligonucleotide labels are released from the nanoparticle either thermally by hydrolysis or 
chemically, using dithiothreitol (DTT).
99
 If necessary, the released oligonucleotides can also be 
amplified by PCR to further increase the sensitivity of the assay. Detection is often achieved 
scanometrically on a solid surface,
100
 or by fluorescence in solution using fluorophore-labelled 
probes.
101
 By functionalising the magnetic capture nanoparticle with DNA instead of antibodies, 
the bio-barcode sensing approach can be applied towards DNA detection. The sensitivity of this 
approach allows for target DNA detection with a LOD of 0.5 aM, which approximately equates to 
just 10 copies of DNA per 30 µL sample.
102
 The bio-barcode amplification approach also exploited 
the versatility of nanoparticles through the simultaneous use of magnetic capture nanoparticles with 













1.2.3  Label Aggregation 
Another approach to label amplification can be demonstrated by an analyte’s ability to affect a 
large number of labels in a collective fashion, as opposed to amplifying the label post an 
analyte‒probe recognition event as seen in replication or multiplication strategies. Rather than 
having one reporter molecule being made responsible for the production of the signal with 
amplification efforts being made to increase the number of these molecules per analyte, it is the 
strategy of label aggregation to harness all the reporter molecules available to create the signal and 
by changing the physical properties of a collective signal in the presence of the analyte, significant 
amplification can be achieved. This type of collective response to minor changes in conditions is 
analogous to colourimetric pH indicators where a slight increase or decrease in acidity is enough to 
shift the equilibrium of the system, which can result in a dramatic colour change. In a similar 
manner, the optical properties of gold nanoparticles are known to be dependent upon the distance 
between each nanoparticle, which is attributed to the surface plasmon resonance (SPR) of gold.
105
 
Manipulation of this physical property phenomenon for label aggregation within a sensing 






Scheme 1.15 Gold nanoparticle label aggregation for colourimetric DNA detection. 
 
 In this approach, ≈13 nm gold nanoparticles were constructed and derivatised with 
mercaptoalkylated probe oligonucleotides to afford a nanoparticle-containing solution with a 
characteristic red colour since the distance between particles is significantly greater than the 
particles themselves. In the presence of target oligonucleotides, hybridisation at both ends of the 
target causes significant aggregation of the nanoparticles and the subsequent decrease in 
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interparticle distance results in a colour change to blue. This simple DNA detection and label 
amplification method was found to be surprisingly selective as a single base-pair mismatch could 
be distinguished from the complementary target. Sensitivity was also high allowing for a LOD of 
≈10 fM of oligonucleotide to be easily detected. 
 
 
Scheme 1.16 Gold nanoparticle label deaggregation for colourimetric lead detection. 
 
 In a similar but opposite approach, Liu and Lu utilised the deaggregation of gold 
nanoparticles towards colourimetric lead ion detection (Scheme 1.16).
107
 In this setup, an 
oligonucleotide probe was used to aggregate gold nanoparticles together through hybridisation at 
both ends. In the presence of lead, inert DNAzymes are activated which results in cleavage of the 
oligonucleotide substrate serving as the linkage between the nanoparticles. The dissociation of the 
nanoparticles results in an easily-visualised colour change from blue to red. Since DNAzymes can 
be synthesised to be very selective for particular cofactors,
108
 this method was shown to be highly 
selective for lead in the presence of a host of other metal ions. The label aggregation provided by 
this methodology provided excellent sensitivity with a LOD of 100 nM lead concentration shown 
to be detectable by the unaided eye. 
 Label multiplication methods such as CARD and the ABC approach both suffer from a 
lack of versatility as there are only a limited number of labels available for amplification. 
Nanostructures compensate for this as their versatile nature has made them popular label 
amplification tools within biosensing. However, they are often cumbersome to prepare and suffer 
from high backgrounds due to oversensitivity from non-specific adsorption. The use of controlled 
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aggregation for label amplification is a simple yet effective strategy for amplification within 
sensing and typically has the benefit of a colour change which can be easily visualised. Despite 
having examples exhibiting powerful amplification, label amplification techniques are often 
analyte-specific and are restricted to the specific type of diagnostic assay they are designed for in 
order to achieve successful amplification. 
 
1.3  Signal Amplification 
Signal amplification is the process whereby the signal generated from an analyte‒probe recognition 
event is amplified by an external amplifier. Signal amplification is the most popular amplification 
method employed in sensing as it is often the easiest amplification methodology to design and 
implement, as amplification does not involve amplifying the target or the label. Due to the high 
number of examples, signal amplification approaches can be divided into four distinct areas based 
on the mechanism of amplification: single-catalyst, double-catalyst, autoinductive and autocatalytic 
(Figure 1.2). As one would expect, the reaction profiles displayed by these signal amplification 
mechanisms are markedly different (Figure 1.3). However, it is not a case of which one provides 
the biggest or fastest signal, as dependent upon the application, one type of signal amplification 
may prove more suitable than another. 
 
 




Figure 1.3 Typical signal amplification profiles observed for the different signal amplification mechanisms. 
 
 Initial developments towards implementing signal amplification within diagnostic assays 
were focused upon using a single amplifier such as an enzyme or a catalyst, which provides a linear 
increase in signal over time. A natural succession from this led to the successful combination of 
two consecutive signal amplifiers to achieve dual-enzyme, dual-catalyst or even hybrid 
enzyme‒catalyst amplification cascades, which often display quadratic-type amplification profiles. 
The constant strive to attain even greater assay sensitivity has led to the development of complex 
auto-amplification strategies, such as autoinductive and autocatalytic signal amplification, where 
the signal-amplified products themselves can increase the rate of signal production. Autoinductive 
signal amplification is a system whereby the products can indirectly accelerate the rate of a 
kinetically meaningful step of the signal amplification mechanism whereas autocatalytic signal 
amplification is the process whereby the products themselves directly serve as catalysts for their 
own production.
109
 As a result; both auto-amplification types exhibit sigmoidal amplification 
profiles with autocatalysis demonstrating exponential signal amplification. Again, choosing the 
appropriate signal amplification protocol for a diagnostic assay is dependent upon a number of 
factors including, but not limited to, the type of analyte being detected, the medium the 
amplification is being performed in, the length of time after analyte recognition that a signal is 
required and the readout method used. For example, an assay requiring the lowest LOD possible 
would look to elect an autocatalytic signal amplification method whereas an assay requiring greater 


























1.3.1  Single-Catalyst Signal Amplification 
Signal amplification methodologies typically use enzymes or synthetic catalysts as amplifiers due 
to their ability to generate multiple product molecules without themselves being chemically altered. 
By designing a detection system whereby the enzyme or catalyst indicate the presence of the target 
and product formation results in a change in physical property, then catalyst or enzyme activity, 
and therefore the target, can be easily detected.
110 
As such, early signal amplification 
methodologies focused on the selective activation of the amplifier in the presence of the target 
analyte. Typically, this is achieved either through intrasteric or allosteric activation. Intrasteric 
activation involves direct competition between the analyte and an inhibitor for the catalyst or 
enzyme active site and allosteric activation involves structural alteration of amplifier conformation 
which results only from recognition of the analyte at a site on the amplifier, other than the active 
site.
111
 Examples of both allosteric and intrasteric activation of enzymes, as well as allosteric and 
intrasteric activation of synthetic catalysts have all been successfully demonstrated for the detection 
of a wide variety of analytes. 
 
 
Scheme 1.17 Intrasteric enzyme activation through steric repulsion for signal-amplified protein detection. 
 
 The very high turnover rate of enzymes under physiological conditions have made them 
popular signal amplifiers within sensing methodologies and varying enzyme activation methods 
have been employed to enable selective analyte detection. Intrasteric activation of enzymes is one 
particular method of activation and works through initial blocking of the active site of the enzyme 
with an inhibitor which restricts enzyme activity. Removal of the inhibitor by an analyte-
recognition event restores enzyme activity which can be detected by the addition of an appropriate 
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enzyme substrate. A very recent development by Tan et al. provides a perfect example where the 
activity of human carbonic anhydrase (HCA) is intrasterically regulated through a strongly bound 
benzenesulfonamide inhibitor which is labelled with a protein-specific tag (Scheme 1.17).
112
 In the 
presence of the target protein, a binding event with the tag occurs which plucks the inhibitor out of 
the HCA active site in order to minimise steric interactions between the protein and the enzyme. 
Enzyme activity is thus restored and can be measured by fluorescence through hydrolysis of non-
fluorescent substrate, fluorescein diacetate (FLDA) 10. The use of an enzyme for signal 
amplification was found to increase fluorescence signals 70-fold. This versatile approach was 




Scheme 1.18 Protein detection via intrasteric enzyme activation through electrostatic interactions. 
 
 Another method towards intrasteric enzyme activation for protein detection has been 
demonstrated by Rotello et al. who developed a procedure known as enzyme-amplified array 
sensing (EAAS) (Scheme 1.18).
113
 In this method gold nanoparticles deliberately developed to 
possess a high cationic surface charge,
114
 electrostatically bind to enzymes such as β-galactosidase 
(β-gal) that have a high anionic surface charge, and inhibit enzyme activity without denaturing the 
enzyme.
115
 In the presence of specific proteins, the nanoparticles blocking the active site of the 
enzyme are removed, which restores enzyme activity. The addition of pro-fluorogenic substrate, 4-
methylumbelliferyl-β-D-galactopyranoside (4-MUG) 12, allows for protein detection via 
fluorescence. The amplification provided by the enzyme delivers a highly sensitive detection assay 
able to differentiate target proteins at 1 nM concentrations. The versatility of using enzymes as 
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amplifiers under physiological conditions is also demonstrated as using an alternative enzyme 
substrate enabled a colourimetric biosensor for bacterial infections to be developed.
116
 Furthermore, 
this electrostatic nanoparticle approach to protein detection can be used in conjunction with 
fluorescent conjugated polymers, vide infra, to develop ‘chemical nose’ sensors capable of 





Scheme 1.19 DNA detection via allosteric enzyme activation through intrasteric enzyme regulation. 
 
 Enzymes have also been used in a number of amplified nucleic acid detection 
methodologies due their ease of conjugation to DNA as well as rapid signal production.
118
 One of 
the first examples of such a system was described by Ghadiri et al. who developed a modified 
protease enzyme where its phosphoramidate inhibitor was covalently bound to itself through a 
single-stranded DNA probe (Scheme 1.19).
119
 Once constructed, the modified enzyme was 
rendered inactive since the flexibility of the DNA probe allowed for the inhibitor to loop around 
and bind to the active site of the enzyme. In the presence of target DNA, hybridisation occurs 
forming a highly favourable rigid DNA duplex and in the process, physically removes the inhibitor 
from the active site of the enzyme. Enzyme activity is therefore restored and hydrolysis of a non-
fluorescent substrate to a fluorescent product enables simple enzyme-amplified DNA detection via 
fluorescence. Both the sensitivity and selectivity of the concept was validated as a 10 pM 
concentration of DNA could be detected within 3 minutes and no discernible signal was observed 
in the presence of non-complementary DNA. Additionally, this approach is not limited to the use of 
proteases for signal amplification as the enzyme thrombin has also been conjugated to an 
inhibitor‒DNA probe for fluorescent DNA detection.120 The excellent control of enzyme activity 
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demonstrated through allosteric regulation allows for molecular logic gates to be developed, 
operated by different DNA sequences.
121
 
 Enzyme and inhibitor do not necessarily have to be covalently bound at either end of the 
same single-stranded DNA probe in order to achieve successful intrasteric enzyme activation as 
Merkx et al. have very recently demonstrated (Scheme 1.20).
122
 In this approach, β-lactamase and a 
β-lactamase inhibitory protein (BLIP) were attached to separate strands of DNA that were 
complementary to that of the probe strand. Through a strong hybridisation interaction and the 
flexibility of the single-stranded probe strand, enzyme and inhibitor are brought together restricting 
substrate turnover. In the presence of target DNA, hybridisation with the probe strands causes 
significant structural rigidity and physically pulls the inhibitory protein from the enzyme active site 
and away from one another, thus restoring enzyme activity. Again, this can be measured by 
fluorescence through the introduction of a non-fluorescent enzyme substrate to afford the 
fluorescent product. This modular approach to intrasteric enzyme activation for sensitive DNA 
detection could detect down to 2 fmol of target single-stranded DNA. 
 
 
Scheme 1.20 Mechanical intrasteric enzyme activation for DNA detection. 
 
 Enzyme activity can also be regulated through selective control of specific allosteric 
factors. In principle, allosteric activation involves target analyte recognition at an allosteric binding 
site which, in turn, causes a structural conformation that activates the catalyst. The excellent 
versatility of being able to regulate enzyme activity through allosteric activation, rather than 
intrasteric activation, has seen this method used extensively for signal amplification within 
biosensors for molecular diagnosis.
123
 Allosteric enzyme activation methods can vary 
tremendously, but generally either occurs through manipulation of enzyme cofactors or through 
modification of the enzyme structure. Enzymes are usually dependent upon cofactors, such as small 
organic molecules,
124
 or metal ions,
125
 for high catalytic activity. Therefore, a popular allosteric 
 
26 
enzyme activation method for sensing is to release enzyme cofactors selectively through an 
analyte‒probe interaction at an allosteric binding site to consequently up-regulate enzyme activity. 
 
 
Scheme 1.21 Fluorescent DNA detection via allosteric organic cofactor release and consequential down-
regulation of enzyme activity. 
 
 Through the manipulation of flavin, a small organic molecule cofactor, Décout et al. have 
also developed an allosteric enzyme activation method for fluorescent DNA detection (Scheme 
1.21).
126
 Modifying flavin with a single-stranded DNA probe was shown not to significantly 
interfere with its ability to act as a cofactor, thus enzyme activity remained on consuming 
fluorescent substrate, nicotinamide adenine dinucleotide (NAD
+
). In the presence of target DNA, 
the rigid DNA double helix formed as a result physically removes the cofactor from the allosteric 
site of the enzyme, which down-regulates enzyme activity. As such, NAD
+
 does not get consumed 
by the enzyme which means fluorescence remains on. This approach to DNA detection is reported 
to detect a 50 nM concentration of target DNA after a 2 hour reaction time. Although no 
optimisation was performed to try to increase the sensitivity of this method, inherent drawbacks to 




 A similar approach has been demonstrated by Yan et al. who use molecular tweezers for 
enzyme-amplified DNA detection (Scheme 1.22).
127
 Molecular tweezers are synthetic molecular 
receptors with two interaction sites bridged by a hinged spacer.
128
 For the detection of DNA, the 
allosteric site in this example was constructed of single-stranded DNA complementary to the target, 
whilst enzyme and cofactor were attached to either end of the tweezer arms. In the absence of any 
target DNA, the tweezers are closed bringing enzyme and cofactor together and activating enzyme 
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activity. However, in the presence of target DNA, a rigid double helix is formed within the 
tweezers which prizes enzyme and cofactor apart, deactivating enzyme activity. By coupling 
enzyme activity with the production of blue dye resazurin 13, which produces a greater signal than 
using NAD
+




Scheme 1.22 Molecular tweezer approach to colourimetric DNA detection via allosteric enzyme activation. 
 
 Metal ion cofactor release has also been exploited for allosteric enzyme activation for 
sensing and has been demonstrated effectively by Graf and Krämer for fluorescent DNA detection 
(Scheme 1.23).
129
 In the presence of Zn
2+
, single-stranded DNA, complementary to that of the 
target, modified at each end with a terpyridine moiety forms a stable cyclic structure.
130
 Upon the 
addition of target single-stranded DNA, a conformational change occurs to accommodate the 
formation of the more favourable DNA double helix and bis-chelation to the metal ion is disrupted. 
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The inactive apoenzyme of carbonic anhydrase (CA) then binds to the released metal to form the 
active holoenzyme. Enzyme activity, which indicates the presence of DNA, can be detected by the 
deacetylation of FLDA 10 to give the fluorescent product fluorescein 11. Despite this elegant 
approach towards allosteric enzyme activation, a significant background reaction by the apoenzyme 
limits the sensitivity of the assay to target DNA concentrations of only 0.1 µM. This high 
background reaction observed with CA was considerably reduced by replacing the enzyme with a 
zinc-dependent aldolase which, via a signal transduction mechanism, results in the consumption of 
UV-active substrate NAD
+





Scheme 1.23 Fluorescent DNA detection via allosteric metal ion cofactor release and consequential up-
regulation of enzyme activity. 
 
 Although many enzymes require cofactors, releasing them in response to certain analytes 
still remains a substantial challenge. This approach towards allosteric enzyme activation for signal 
amplification relies on having a high affinity between the cofactor and enzyme as well as a low 
background rate of the apoenzyme in the absence of the cofactor. However, as shown previously, 
these criteria can be difficult to fulfill. Despite the advantages of using enzymes as amplifiers 
within sensing methodologies such as their high turnover number, they are expensive, can be 
difficult to manipulate without denaturising and they are unable to be used under non-physiological 
conditions. Because of this, synthetic catalysts have gained increased interest as amplifiers within 
sensing as they can be easier to manipulate, have a higher tolerance to changes in conditions and 
have application to the detection of a wider range of analytes. Similarly to enzyme activation, most 
catalytic signal amplification methodologies use either intrasteric or allosteric strategies for 




Scheme 1.24 Fluorescent DNA detection via allosteric metal ion release and catalyst activation 
 
 Intrasteric activation of catalysts for sensing involves target recognition at the catalyst 
active site. In principle, catalyst activity can be significantly reduced by physically blocking the 
catalyst active site with functionalised molecules. If these molecules are functionalised with 
analyte-responsive groups, then only in the presence of the analyte should the selective removal of 
the catalyst inhibitor occur, which would reveal the catalyst active site and restore catalytic activity. 
Simply coupling catalytic activity with signal production leads to a successful analyte detection 
assay with catalytic amplification. Following their initial publication on the allosteric activation of 
enzymes for DNA detection, Krämer et al. adapted the same probe, and therefore the same analyte 
recognition procedure, for a synthetic catalyst-amplified method for DNA detection (Scheme 
1.24).
132
 Building upon DNA-templated metal catalysis,
133





which, in the absence of the target, still forms the same stable cyclic structure. In the presence of 
the target single-stranded DNA, the formation of the double helix occurs and in the same manner as 
shown previously, the metal is released into the system. An active catalyst is then formed between 
the released metal and phenanthroline (phen), a ligand capable of accelerating copper-catalysed 
reactions. Non-fluorescent dichlorofluorescein (DCF) 16 is then oxidised by the active Cu·phen 
catalyst to give the fluorescent product dichlorodihydrofluorescein (DCFH) 17. The low turnover 
rate of the active catalyst however limits DNA detection to a concentration of 5 nM. 
 Prins et al. were also able to utilise intrasteric regulation of a synthetic catalyst for a 
colourimetric enzyme detection assay (Scheme 1.25).
134
 In this example, gold nanoparticles, 
covered with triazacyclononane (TACN) ligands capable of binding Zn
2+
, were prepared and the 
resulting cationic complexes were shown to effectively catalyse transphosphorylation reactions.
135 
However, this catalytic activity could be switched off through the binding of oligoanions, such as 
peptides, to the catalyst through electrostatic interactions, which physically block the active site of 
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the catalyst. When the target protease enzyme was added, cleavage of the peptides occurred which 
reduces the effectiveness of the binding between blocker and nanoparticle. Destabilisation reveals 
the catalyst active sites and catalyses the dephosphorylation of substrate 18, which is accompanied 
by the production of yellow reporter molecule p-nitrophenol (PNP) 19. The benefits of this system 




 complexes towards 
the substrate and a colourimetric detection system. Also, the catalyst-amplified enzyme detection 
assay was shown to be highly sensitive, capable of detecting protease subtilisin A at a 
concentration of 66 nM after an hour reaction time. 
 
 
Scheme 1.25 Intrasteric activation of a synthetic catalyst for catalyst-amplified colourimetric enzyme. 
 
 Intrasteric catalyst regulation through the use of analyte-responsive probe molecules has 
some inherent difficulties associated with it since the catalyst inhibitor requires strong enough 
binding to prevent a high background reaction but not strong enough to prevent an efficient turn on 
of catalytic activity in response to the analyte. As such, signal amplification by allosteric catalysis 
(SAAC) has by far become the most popular catalytic signal amplification strategy used for 
sensing.
136
 Primarily, this is due to the vast number of supramolecular receptors used for analyte 
detection and also the large number of synthetic catalysts used for amplification that can be easily 
coupled together for an amplified detection system.
137
 Consequently, a significant number of 
signalling techniques based upon supramolecular systems have been developed for sensitive DNA, 
protein and small molecule detection.
138
 Additionally, the binding affinities between different 
metal‒ligand complexes are well-known allowing for ligand exchange to become a prominent 




Scheme 1.26 Allosteric catalyst activation for FRET-based detection of lead ions. 
 
 Anslyn et al. were the first to exploit this ligand exchange for SAAC allowing for the 
detection of lead ions (Scheme 1.26).
139
 In this approach, a Cu
2+
 complex with 
tetramethylethylenediamine (TMEDA) was synthesised and shown to be an inactive catalyst within 
a cycloaddition reaction.
 




, were found to competitively 
coordinate with TMEDA and consequently release Cu
2+
 into the system. In the presence of L-
ascorbate, Cu
2+
 is reduced to Cu
+
, the active catalyst within the Huisgen cycloaddition reaction.
140
 
By using FRET pair pyrene-derived alkyne 20 and coumarin-based azide 21 as the reactants, target 
metal ion concentration could be measured directly by fluorescence through the resulting triazole 
product 22. Although being the seminal publication in the field, this approach to catalytic signal 
amplification is not without limitations. The analyte in question has to have orthogonal reactivity to 
the reaction conditions to not cause unwanted side-reactions. For example, Hg
2+
 was shown not to 
activate the cycloaddition reaction, but instead oxidised the reducing agent. Ligand exchange was 
also found to be slow, limiting the amount of active catalyst available relative to the concentration 
of analyte. Since the catalytic amplification is a bimolecular reaction, under the dilute assay 
conditions the reaction was deemed incomplete even after 18 hours, which further shows the 
inefficiencies in this particular catalytic system. Additionally, a high concentration of the analyte 
was found to interfere with the amplification reagents, potentially due to the formation of metal 
acetylides. 
 In an ensuing publication, the authors sought to overcome some of these limitations, by 
choosing to use a more efficient palladium catalyst as the catalytic signal amplifier (Scheme 
1.27).
141
 The ligand exchange strategy, which allows analyte detection through allosteric 
regulation, was improved by replacing the relatively unselective TMEDA ligand with a 
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polyazacyclam (PAC), which provided better selectivity for Cu
2+
 over other metals. Also, by 
designing a catalytic signal amplification methodology around a palladium catalyst, an 
intramolecular Pd
0
-catalysed Heck reaction could be used, which provides increased ease of 
operation and the formation of a fluorescent product.
142
 In this strategy, a Pd·PAC complex was 
synthesised that was shown to be inactive towards the Heck reaction. When the metal ion analyte is 
present, in this case Cu
2+
, ligand exchange occurs since Cu
2+ 





 into the system which is immediately reduced to the active Pd
0
 by a phosphine 
ligand. The resulting active catalyst is able to turn non-fluorescent aryl iodide 22 into fluorescent 
indole 24 allowing for catalyst activity and therefore analyte concentration to be detected via 
fluorescence. Increasing catalytic activity improved the catalytic signal amplification as a 
detectable fluorescent signal was provided from a 30 nM concentration of Cu
2+
. Despite this, a 90 
minute reaction time was required and the ligand exchange methodology for analyte detection was 






 all delivered false positive results. Better 






 could be achieved by using a PAC with a 
bigger ring size to accommodate for the increase in ionic radius.
143 
Better sensitivity was also 
achieved through the production of a coumarin-derived product since the presence of an electron-
withdrawing ester not only increases the rate of Heck coupling but the product also has an 
increased quantum yield than that of indole 24. 
 
 
Scheme 1.27 Allosteric catalyst activation for the fluorescent detection of copper ions. 
 
 The use of PACs for analyte recognition is a major drawback for this methodology since 
analyte detection is limited to only metal ions. Also, ligand exchange is slow, reversible and as 
shown previously, unselective. To extend the application of this catalytic signal amplification 
methodology beyond the detection of metal ions, the group replaced the PAC with a dithiol for the 
fluorescent detection of carbonyl-containing small organic molecules (Scheme 1.28).
144
 In this 
approach, target compounds containing carbonyl functionality, such as a ketone or aldehyde, 
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condense with the analyte-recognising dithiol to give a dithiolane, which has a considerably lower 
binding affinity towards metals than the free thiol. As a result, Pd
2+
 ions are released into the 
system and are reduced by phosphine ligands present in the assay mixture, generating the active 
catalyst for a Sonogashira cross-coupling reaction.
145
 The coupling of phenylacetylene 25 with 9-
bromo-10-(phenylethynyl)anthracene 26 produces the commonly used fluorophore 9,10-
bis(phenylethynyl)anthracene (BPEA) 27, therefore allowing analyte detection to be easily detected 
through fluorescence. Despite the catalytic signal amplification, significant drawbacks with using 
the Sonogashira cross-coupling reaction for catalytic signal amplification is its intolerance of water 
and some of the reaction components cause undesired quenching of anthracene fluorescence. 
However, the initial work published by the Anslyn group proved the concept of SAAC and has 
paved the way for this design to be adapted within other signal amplification methodologies that 
utilise allosteric control of metal ions for catalyst activation. 
 
 
Scheme 1.28 Allosteric catalyst activation for the fluorescent detection of small, carbonyl-containing organic 
molecules. 
 
 One such methodology was described by Ritter and König who developed a signal 
transduction and signal amplification protocol using photo-activated catalysis.
146
 In this procedure, 
a flavin derivative is used as a synthetic photoreceptor while the copper-catalysed Huisgen 
cycloaddition reaction is used for signal amplification (Scheme 1.29). Specifically, the stimulation 
of riboflavin tetraacetate 28 by a photon gives its strongly-oxidising excited state which, in the 
presence of an electron donor, undergoes photoreduction to afford strongly-reducing dihydroflavin 




, thus providing the active 
catalyst for the cycloaddition, resulting in the formation of triazole 32 from azide 30 and alkyne 31. 
Signal detection was measured through the reduction of observed fluorescence since the covalent 
connection between fluorophore and quencher reduces fluorescence emission.
147
 In water, the 
reaction cascade shows light-dependent behaviour as only under irradiation is significant 








 occurs, which removes the active catalyst from the system and stopping the cycloaddition 
reaction. However, it was found that excess continuous irradiation leads to the formation of 
undesired by-products. Other problems associated with the assay include requiring oxygen-free 
conditions to prevent formation of flavin hydroperoxides and a slow background reaction in the 




 by triethylamine in solution. 
However, the principle of transforming a non-chemical input signal, in this case light, into an 
amplified chemical output signal is superbly illustrated in this example, inspiring other groups to 
develop similar signal transduction and amplification chemical systems. 
 
 
Scheme 1.29 Light-activated catalytic signal amplification. 
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 The majority of examples of allosteric catalyst activation previously described have been 
based upon metal‒ligand binding affinities where, analyte recognition leads to coordination 
disruption followed by metal ion release and consequent active catalyst formation. However, this is 
an imperfect approach since analyte recognition is a reversible reaction between the analyte and the 
active catalyst responsible for signal amplification. Also, the formation of the active catalyst is not 
necessarily instantaneous after analyte recognition which leads to long assay times. To overcome 






To achieve this, inorganic macrocycles were constructed via the weak-link approach 
(WLA) consisting of two metal centres and two hemilabile ligands.
149
 The ligands are the key to 
this concept as they are polydentate chelates containing two sets of two differently coordinating 
heteroatoms; one set that strongly binds to the metal centre and one set that weakly binds to the 
metal centre. The dimer that initially forms has all coordinating atoms bound to a metal centre and 
in this ‘closed’ structural conformation, the ligand spacers are forced together. The introduction of 
small, coordinating molecules, that have a higher affinity to the metal than the weakest 
metal‒heteroatom bond, displace the weakly binding heteroatom of the ligand. This then causes a 
structural conformational change to give an ‘open’ complex since the ligand spacers are now pulled 
apart. This precise control over the structural conformation of a macrocycle led to the subsequent 




 To obtain catalytic activity selectively as a result of a structural change in conformation, 
the ligand spacers were replaced with a [Cr·salen]
 3+
 complex proven to catalyse epoxide ring-
opening reactions.
151
 In the absence of the small molecule effectors, the tetrametallic 
supramolecular construct was shown to be in its ‘closed’ conformation and exhibited minimal 
catalytic activity towards the ring-opening of cyclohexene oxide since the catalyst active sites are 
pushed too close together and thus blocking one another, preventing the substrate from reaching the 
catalyst active site. The addition of small molecule effectors Cl
‒
 and CO result in them binding to 
the allosteric Rh
+
 metal centre and causing a structural change in the macrocycle to its ‘open’ 




 metal centres are 
then pulled apart from one another revealing the active sites for the substrate, which consequently 
leads to a 25-fold increase in catalytic activity. In addition, the bimetallic active site of the 
supramolecular catalyst was shown to have an increased rate of reaction over its monomeric 
counterpart, which explains the low background rate observed when the catalyst is ‘closed’.153 
Since the epoxide ring-opening reaction is not attributed with a change in physical property, signal 
amplification via this approach to allosterically-regulated supramolecular catalysis could not be 
used for sensing purposes. 
 Towards this end however, the group sought to change the catalyst responsible for signal 
amplification to a [Zn·salen]
 2+
 complex capable of catalysing the acylation of 4-pyridyl carbinol 32 
(Scheme 1.30).
154
 As a consequence of the acylation, the pH of the reaction medium is lowered 
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since acetic acid is formed as a by-product and as such, signal production was achieved through a 
pH-responsive fluorophore 37 allowing for analyte detection to be determined using 
fluorescence.
155
 Under an atmosphere of carbon monoxide, an 800 nM concentration of Cl
‒ 
ions 
could be distinguished from the background reaction after 6 hours. Since the supramolecular 
catalyst is modular by design, alternative metals can be used at the allosteric site of the 
supramolecular catalyst yet still maintain the same mode of activation and the same catalytic 
reaction for amplification. This can therefore expand the application of the signal amplification 
procedure towards the detection of different analytes.
156 
 It is thought that increased control and a 
reduction in background catalytic activity could be achieved through a triple-layer catalyst where 
the middle layer holds the active catalyst and the top and bottom layers physically block the 
catalyst active sites when the supramolecular structure is ‘closed’.157 Currently, the addition of the 
small molecule allosteric effectors can induce a structural change in the supramolecular structure to 
its ‘open’ conformer and restore catalytic activity to polymerise ε-caprolactone, 158 but has yet to be 
applied towards a sensing methodology. 
 




1.3.2  Double-Catalyst Signal Amplification 
In principle, the addition of an extra catalytic cycle to a single-catalyst signal amplification 
procedure should accelerate the rate of signal production over time and in turn, would lead to a 
signal increase orders of magnitude higher than that of just doubling the number of catalysts of a 
single-catalyst system. However, in comparison to the number of single-catalyst signal 
amplification procedures described, the use of two sequentially-activated catalysts for signal 
amplification is a considerably less explored area. This could be, in part, due to the difficulty in 
finding catalyst combinations whereby products resulting from the first catalytic cycle are able to 
act as catalyst activators for the second catalytic cycle. In addition, to afford sufficient assay 
sensitivity, the background reaction of the second catalyst must be minimal, if not zero, to 
minimise false positive results. Initially, signal amplification protocols utilising a two catalyst 
cascade were developed as a result of applying a single catalytic amplification procedure towards 
the detection of a target that itself also displays catalytic activity. 
 
 
Scheme 1.31 Double-catalyst signal amplification approach to the FRET-based detection of enteropeptidase. 
 
 The first example of a double catalyst signal amplification strategy for a sensing 
application was demonstrated by Zuchner et al. for protease detection using FRET (Scheme 
1.31).
159
 Sensitive protease detection is of paramount importance as abnormal protease activity has 
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been associated with a variety of diseases, one of which includes cancer.
160
 As such, there has been 
huge demand for the development of highly sensitive protease assays and methods to achieve high 
sensitivity have been through the use of enzyme cascades for signal amplification.
161
 
 In this particular example, an initial optimisation of a FRET-based detection assay was 
performed on trypsin, a digestive enzyme that selectively cleaves peptides at the carboxyl side of 
amino acids lysine or arginine.
162
 Of the trypsin substrates synthesised and tested, peptide 39 was 
found to be optimal as it showed a >97% quenching efficiency in the absence of the enzyme and 
after trypsin was introduced, maximum fluorescence was obtained in 15 minutes, achieving a LOD 
of 0.1 fmol. With the second catalytic cycle of the amplification methodology optimised, the next 
objective was to selectively activate it.  
 To do this, the group chose serine protease enteropeptidase, the intestinal enzyme 
responsible for activating multiple digestive enzymes in response to food ingestion,
163
 and whose 
congenital deficiency can lead to severe intestinal malabsorption.
164
 Its primary mode of action is to 
catalyse the activation of trypsin from the inactive zymogen, trypsinogen.
165
 As such, trypsin was 
replaced with trypsinogen and exposed to enteropeptidase to determine if the enteropeptidase could 
catalyse the activation of the second catalytic signal amplification. Indeed, in the presence of 
enteropeptidase, a fluorescent signal was obtained which was attributed to the in situ conversion of 
trypsinogen to trypsin and consequent consumption of pro-fluorescent substrate 39. This double-
catalytic signal amplification methodology achieved a LOD of 0.01 fmol for enteropeptidase after 
an assay time of 3 hours and demonstrated an excellent dynamic range showing a linear 
signal‒concentration correlation over two orders of magnitude. 
 The high sensitivity and selectivity obtained for this dual-enzyme signal amplification 
approach has inspired others to do the same by developing inactive zymogens as enzyme 
precursors that can be activated by a clinically-relevant enzyme to produce a detectable signal. One 
such example can be provided by Yoo et al. who engineered β-lactamase zymogens for 
amplification and determination of protease activity (Scheme 1.32).
166
 In this approach, an inactive 
β-lactamase zymogen was constructed using intrasteric inhibitor BLIP attached to the enzyme 
through a peptide linkage. In the presence of the protease, the peptide linkage is cleaved and 
intrasteric activation of β-lactamase occurs as BLIP is removed from the active site. β-Lactamase 
activity, and therefore protease activity, was measured by the change in absorbance from β-
lactamase substrate, 7-(2-thienylacetamido)-3-((3-carboxy-4-nitrophenyl)thiomethyl)-
cephalosporonic acid (CENTA) 42 to hydrolysed product 43.
167
 To prevent the BLIP from 
remaining bound to the β-lactamase after protease-catalysed amide hydrolysis, which would reduce 
the potential positive output signal, a number of β-lactamase mutants were synthesised and tested 
within the assay. Through this optimisation, a β-lactamase mutant with a lower binding affinity to 
BLIP was able to deliver a 68-fold signal increase from the background reaction. This mutant was 
then utilised as the signal-amplifying enzyme within a dual-enzyme signal amplification strategy 
for the detection of matrix metalloproteinase-2 (MMP2), a protease that plays a significant role 
within cancer progression,
168




Scheme 1.32 Double-catalyst signal amplification for an absorbance-based protease detection assay. 
 
 Another approach to enzyme-triggered enzyme activation has been through the use of split-
protein systems. Split proteins are two protein fragments that do not exhibit any catalytic activity 
separately but can come together to form an active enzyme.
169
 By physically preventing the split-
proteins from coming together through an enzyme-cleavable intrasteric inhibitor, an enzyme-
amplified enzyme detection assay can be achieved. This tactic was exemplified by Ghosh et al. 
who utilised the split-protein system of the enzyme firefly luciferase (FLuc) for protease detection 
(Scheme 1.33).
170
 To prevent the split-proteins from coming together, one of the split-proteins was 
appended with a structure comprised of two interlocking α-helices known as a coiled-coil.171–172 In 
the presence of the target protease, the peptide linkage between the protein and the coiled-coil is 
cleaved allowing the two protein halves to reassemble to form the active FLuc. Once activated, 
FLuc is able to catalyse the bioluminescent oxygenation of 44, allowing protease activity to be 
determined via luminescence. Through this dual-enzyme amplification cascade, a 1000-fold 
increase in the signal-to-noise ratio could be obtained for the detection of tobacco etch virus (TEV) 
protease. The modularity of this method has allowed other split-protein type enzymes, such as β-
lactamase, to be used as the enzyme amplifier and this signal amplification method has also been 
applied to the detection of caspases by simply changing the enzyme-cleavable linkage between the 





Scheme 1.33 Double-catalyst signal amplification for a bioluminescent protease detection assay. 
 
 Utilising enzyme cascades for signal amplification relies on the ability to structurally 
modify enzymes to restrict enzyme activity without denaturisation yet in the presence of the target, 
enzyme activity must be easily restored. Although a number of examples have been demonstrated, 
this still remains a significant challenge. A way of incorporating enzyme cascades for signal 
amplification without needing structural modification of enzymes is to use solid-supported enzyme 
substrates, as enzyme activity can be introduced and removed through physical addition and 
aspiration steps. Inspired by assays where catalyst activity can be measured through 
immunoassays,
174–175
 Garner and Janda developed a catalytic assay using an enzyme-linked click-
chemistry assay (cat-ELCCA) for the fluorescent detection of ghrelin O-acyltransferase (GOAT) 
(Scheme 1.34).
176
 In this approach, a biotin-labelled peptide enzyme substrate is captured on a 
streptavidin-coated solid surface. In the presence of the target enzyme, a selective O-acyl transfer 
occurs where a serine residue is esterified with an n-octynoyl group. The resulting alkynylated 
product is then labelled with HRP via a click reaction, which is able to provide signal amplification 
through catalytic production of fluorescent compound resorufin 14 from HRP-substrate amplex red 
47. Through this unique double-enzyme signal amplification approach, a greater than 7-fold 
fluorescence enhancement was observed. Since GOAT is involved in the acylation of the gastric 
peptide hormone ghrelin,
177
 this signal amplification methodology was subsequently used in the 






Scheme 1.34 Catalytic assay using enzyme-linked click-chemistry assay (cat-ELCCA) for the fluorescent 
detection of ghrelin O-acyltransferase (GOAT). 
 
 However, double catalyst signal amplification is not just limited to the use of enzymes for 
amplification. One example of the use of deoxyribozymes as a catalytic amplifier can be provided 
by Mao et al. who utilise a double catalyst signal amplification methodology for colourimetric 
DNA detection (Scheme 1.35).
179
 Deoxyribozymes, also known as DNA enzymes or DNAzymes, 
are catalytic domains comprised of DNA rather than amino acids and are therefore considered to be 
more stable than traditional protein-based enzymes.
180
 In this amplification approach, target DNA 
is detected using a complementary DNA probe that is also a circular template for RCA, which 
codes for the linear production of DNAzymes. Therefore, the target DNA acts as a primer for RCA 
and once hybridised, initiates the production of repeating units of DNA that form multiple DNA 
peroxidases after complexation to hemin. The DNA peroxidases can then catalyse the oxidation of 
2,2’-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) 48 to afford colourimetric product 
49. This procedure showed an excellent dynamic range where DNA detection covers 
concentrations over four orders of magnitude and delivered a LOD of 1 pM. However, problems 
associated with using RCA as the initial amplification procedure include strict amplification 
durations as any reaction time longer than optimal, results in extensive tangling of the DNAzyme 
chains. Not only this, but the concentration of the circular RCA template is also important as a high 
enough concentration is required to ensure efficient binding to the target, yet too high a 
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concentration leads to unwanted binding of the template to the amplified DNA product thus 
preventing further amplification and folding of the DNA into the DNAzyme. A similar DNAzyme 
cascade has since been described by Tan et al. that replaces RCA with an alternative DNAzyme to 





Scheme 1.35 Rolling circle amplification and DNAzyme catalytic cascade for colourimetric DNA detection. 
 
 
A similar strategy has been described by Aoyama et al. who use ribosomal catalytic 
production, or translation, of protein-based enzymes for the double-catalytic chemiluminescent 
detection of human immunodeficiency virus (HIV) RNA.
182
 For successful RNA detection, the 
group utilise the molecular beacon approach,
183
 where in the absence of the target, the RNA probe 
intramolecularly binds to itself to adopt a hairpin-like conformation which cannot activate the 
catalytic amplification cascade. When in the presence of the target oligodeoxynucleotide (ODN), 
the resulting double-stranded duplex prevents the probe from adopting the hairpin-like 
conformation from occurring, thus revealing the riboregulator which is the specific sequence of the 
probe that activates translation. Once activated, the catalytic production of luciferase enzymes 
begins which are able to produce a chemiluminescent output signal. By using the molecular beacon 
probe, excellent selectivity was achieved and due to the double-catalyst signal amplification, good 
sensitivity was also obtained with a target ODN concentration of 50 fmol being detectable. 
However, because of the size of the target‒probe duplex in comparison to the riboregulator 
sequence, inefficient allosteric activation of the transcription enzyme was observed, leading to a 




Scheme 1.36 Double-catalyst amplification cascade combined with EATR to obtain a triple-catalyst cascade 
for the visible detection of nucleic acids. 
 
 To address this, the group combined their double-catalyst signal amplification 
methodology with EATR to create a triple-catalyst cascade (Scheme 1.36).
184
 In this advancement, 
the duplex formed as a result of target‒probe hybridisation is cleaved by a ribonuclease which not 
only releases the riboregulator, thus making allosteric activation irreversible, but also recycles the 
target ODN. This both improves allosteric translation enzyme activation and allows the target ODN 
to react further with more probes. The extra catalytic cycle of the amplification cascade enhances 
both sensitivity and selectivity, obtaining a target ODN concentration LOD of 9 fmol. In addition, 
the riboregulator sequence can be altered to activate catalytic production of β-gal enzymes which 
enables the visible detection of nucleic acid sequences through conversion of o-nitrophenol-β-D-
galactopyranoside (ONPG) 50 to o-nitrophenol (ONP) 51. 
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 The majority of double-catalyst signal amplification methodologies described to date 
involve the manipulation of enzyme cascades rather than the use of synthetic catalysis. This is 
primarily due to the well-known number and variety of enzyme cascades used in nature for a 
number of purposes. This leads to the easy transition from biosignalling to signal amplification 
within a sensing methodology by coupling the final enzyme with a colour or fluorescent 
production. Although selectivities and sensitivities are high, adjusting enzyme cascades towards the 
signal amplification of different analytes, especially when detection is required in non-aqueous 
solvents, can be difficult. As such, there is still demand for the easily-adaptable synthetic double-
catalyst cascades for the sensitive detection of small organic molecules. Furthermore, hybrid 
systems that can utilise the efficiency of enzymes under physiological conditions along with the 
control and robustness offered by synthetic catalysts could offer excellent versatility within an 
amplification sensing methodology. 
 
1.3.3  Autoinductive Signal Amplification 
Autoinduction is the process whereby the reactants or products of a reaction can directly or 
indirectly affect the rate of the reaction, whether it is either in a positive or negative way. This 
process is typically associated with metabolic enzymes in the body whereby an active 
pharmaceutical ingredient (API) can induce or up-regulate an enzyme involved in its own 
metabolism.
185
 By designing a system whereby the products of a reaction can induce or up-regulate 
the rate of its own production, then this would provide significant signal amplification if applied to 
a sensing methodology. Towards this end, Sella and Shabat designed the concept of the dendritic 
chain reaction (DCR) (Scheme 1.37).
186
 
 Dendrimers themselves are uniform molecular trees made up of highly-branched, repeating 
units, often with reactive functionality on the end groups, which are attached to a central core.
187
 
Because of their unique supra- and macromolecular properties, dendrimers have found application 
within multiple fields such as medicine, catalysis and in particular, sensing.
188
 The concept of 
constructing dendrimers comprised of repeating units capable of undergoing elimination 
mechanisms initially allowed dendrimers to be shown to selectively release their cargo in response 
to a specific stimulus such as, drug compounds under reductive conditions,
189
 coloured compounds 
when exposed to palladium,
190
 and fluorescent compounds in response to light.
191
 The spontaneous 
disassembly, or self-immolation, of dendrimers in response to a specific stimulus has provided a 
distinctive molecular amplification approach to sensing since one analyte can trigger the 
disassembly of a dendrimer with multiple reporter end groups.
192
 However, dendritic amplification 
only multiplies the initial input molecule by the number of end-groups attached to the dendrimer 
core. For example, in a sensing methodology for the detection of the explosive triacetone 
triperoxide, a dendrimer with three reporter molecules was shown to provide three times the signal 
compared with a non-dendritic reporter.
193
 In order to provide amplification more akin to a catalyst 
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or an enzyme in which signal amplification increases over time, DCR was designed to take 
advantage of the multivalent capabilities of dendrimers by attaching signal transducers as well as 
reporter molecules to the central core. Once released, the signal transducers could be manipulated 
into inducing further dendrimer disassembly, therefore leading to an autoinductive signal 
amplification mechanism being in effect. 
 
 
Scheme 1.37 Amplification concept of the dendritic chain reaction (DCR). 
 
 The successful achievement of an autoinductive signal amplification methodology through 
the use of dendrimers was through the clever design of dendron 52, which consists of a p-
nitroaniline reporter molecule, two molecules of choline to relay the signal and a phenylboronic 
acid used for analyte recognition (Figure 1.4). In the presence of hydrogen peroxide, aryl boronic 
acids are known to undergo oxidation to their corresponding phenolates,
194
 via a Baeyer‒Villiger-
type mechanism,
195
 analogous to the Dakin oxidation.
196
 This functional group transformation had 






Figure 1.4 Structure of dendron 52; responsive to the signal propagating molecule, hydrogen peroxide. 
 
 
Scheme 1.38 Breakdown mechanism of dendron 51 initiated by hydrogen peroxide. 
 
 In DCR, phenolate 52 produced as a result of the oxidation is unstable under the mild 
alkaline assay conditions and undergoes multiple quinone methide eliminations,
198
 followed by 
entropically-favourable decarboxylation to release colourimetric reporter 54 and two equivalents of 
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choline 56 to propagate the signal (Scheme 1.38). This is performed by the enzyme choline oxidase 
(COx), which twice oxidises choline to afford trimethylglycine 59 and in the process, generates two 
equivalents of hydrogen peroxide capable of initialising the breakdown of more molecules of 
dendrons 52 (Scheme 1.39). The requirement of COx for signal propagation is especially apparent 
at low concentrations of hydrogen peroxide, as a >50-fold signal enhancement is observed in 
comparison to a system without COx. The exponential production of hydrogen peroxide and 
subsequent exponential decay of all dendrons 52 leads to rapid signal production with full 
conversion observed after 50 minutes. The DCR was then applied to the colourimetric detection of 
penicillin-G-amidase (PGA), through the use of a choline-releasing probe, and showed a significant 
signal increase in comparison to a classic probe-based approach, allowing for PGA concentrations 
of 0.1 µgmL
−1
 to be detected. 
 
 
Scheme 1.39 Signal propagation in DCR: enzyme-catalysed hydrogen peroxide formation. 
 
 One of the major benefits of using DCR as a signal amplification technique is its 
modularity. For example, by changing the boronic acid trigger with a silyl-protected phenol enables 
an autoinductive exponential signal amplification procedure for the sensitive detection of fluoride 
ions.
199
 Additionally, the enzyme amplifier could be replaced with other enzymes capable of 
producing hydrogen peroxide, such as alcohol oxidase (AOx).
200
 Despite its wide application, a 
major weakness of DCR, like many exponential signal amplification methodologies, is the high 
background rate observed in the absence of the trigger, which arises from undesired hydrolytic 
cleavage of the carbonate linkages.
201
 Another difficulty lies in the synthesis of the dendrimers as a 




Scheme 1.40 Two-component dendritic chain reaction (2CDCR). 
 
 To address these issues, the group developed a two-component dendritic chain reaction 
(2CDCR) where one reagent 60 contains the trigger unit responsible for analyte detection and 





 Through this two-component methodology, the unwanted background signal was 
suppressed as hydrolysis of 60 does not directly lead to signal production. Also, by separating 
analyte detection and signal production into different compounds, a mix-and-match approach to 
sensing can be applied to allow DCR signal amplification to be applied to a fluorescence detection 
assay. Alternative enzyme amplifiers have also been incorporated into 2CDCR as a number of 
glucose-containing dendritic amplifier components were tested using glucose oxidase (GOx) as the 
enzyme amplifier.
203
 Additionally, the use of a quinone-based detection component allowed for the 
2CDCR to be applied to the detection of thiols.
204
 Autoinductive signal amplification can also be 
achieved in the absence of the enzyme amplifier by utilising the hydroquinone–quinone oxidation 










 An example of a two-component autoinductive signal amplification protocol used in 
combination with target amplification for increased sensitivity was described by Baker and Phillips 
for the colourimetric detection of palladium (Scheme 1.41).
207
 To achieve this autoinductive signal 
amplification methodology, the first component 64 of the two was equipped with an allyl 
carbamate trigger, for selective palladium detection, and two fluoride leaving groups as the 
amplified signal relay. In the presence of palladium therefore, catalytic deallylation and 
decarboxylation occurs to give 4-(difluoromethyl)aniline which undergoes a double 1,6-elimination 
to produce two fluoride ions. The second component 65, a colourimetric probe for fluoride 
detection itself,
208
 was equipped with a silyl protecting group, sensitive to the fluoride relay signal, 
along with another two equivalents of fluoride to further amplify the signal. After initial breakdown 
of 64 in response to the analyte, silyl deprotection of 65 occurs due to the generated fluoride and 
intermediate phenolate 66 also undergoes a 1,6-elimination and decarboxylation to afford another 
equivalent of aniline 67, capable of eliminating further to afford another two equivalents of 
fluoride. Colourimetric detection occurs following elimination of 67 as the compound 4-
aminobenzaldehyde 68 produced as the elimination by-product is yellow. This two-component 
autoinductive signal amplification strategy in combination with an analyte that exhibits target 




 The reagents used to within this assay are thermally-stable and inexpensive and the colour 
produced can be seen with the naked eye enabling this methodology to be used in resource-limited 
environments. However, reaction times are slow with >24 hour assay times required to detect 
palladium concentrations close to the LOD. Also, due to the slow hydrolysis of 65, an amplified 
background reaction limits assay sensitivity, although the introduction of allylic ethers as 
elimination linkers have shown promise in minimising background reactions yet maintaining signal 
propogation.
210
 The modularity of the small molecule autoinductive signal amplification approach 
has enabled an extension of compound 65 to be developed for fluorescent fluoride detection.
211 
 The ability of a signal amplification protocol to generate products that not only provides a 
detectable signal but can also increase the rate at which the signal is produced, has allowed 
previously inaccessible detection limits to be achieved. Inspired by DCR, the majority of 
autoinductive signal amplification approaches currently described revolve around small molecule-
based systems which allow for thermally-stable, inexpensive reagents to be used for analyte 
detection, signal amplification and signal production in a simple manner. Current challenges 
involve improving reaction times to allow for these signal amplification methodologies to be 
applied within the POC setting. In addition, suppression of the high background rates associated 




1.3.4  Autocatalytic Signal Amplification 
Autocatalysis is the process whereby the product of a reaction is able to catalyse the production of 
itself.
212
 This fascinating phenomenon has been intensively studied for the past forty years since 
autocatalysis may have played a significant role in the origins of life.
213–214
 Early synthetic 
examples of autocatalysis involved the self-replication of small oligonucleotides where the product 





 has also been applied to the self-replication of peptides,
220
 as well as 
small molecules.
221 
Metal-catalysed autocatalysis was first described by Soai et al. where the 
alcohol formed as the product was able to act as a ligand within a zinc-catalysed alkyl addition to 
aldehydes, promoting the formation of more of itself.
222
 Since the reaction can be performed 
asymmetrically, this reaction can be applied to selectively amplify one enantiomer over another and 
therefore increase the enantiometric excess of a near racemic mixture.
223–226
 This powerful 
asymmetric amplification method has even been used to discriminate between carbon-12/carbon-13  
chirality,
227
 which has huge implications for determining the origins of homochirality.
228–229 
 Although considerable effort has been made towards enantioselective amplification using 
autocatalysis,
230
 the application of autocatalysis towards a signal amplification methodology has 
been comparatively less explored. To date, only two autocatalytic signal amplification 
methodologies for sensing have been published and both are advancements upon signal 
amplification concepts already described herein. The first of the two was developed by Yoon and 
Mirkin who manipulated their supramolecular catalysts to be activated by the product allowing for 




 In a previous example, supramolecular constructs based upon the WLA were shown to 
rearrange selectively in the presence of the chloride analyte to reveal a bimetallic active site for a 
Lewis acid-catalysed acylation reaction. Since the by-product of this acylation is acetic acid, the 
authors hypothesised that an autocatalytic variant of SAAC could be achievable if the produced 
acetate anion could bind to the allosteric site of the pre-catalyst and also induce ligand 
rearrangement. Thus, in the presence of tetrabutylammonium acetate (TBAA), used as the model 
analyte, and under a carbon monoxide atmosphere, catalytic activity was shown to be switched on 
through the production of fluorescence. Initially, a minor amount of the catalysts are activated 
leading to slow product formation. However, as more acetate is produced, an increase in catalyst 
activation is observed leading to an acceleration of catalytic activity until the reaction reaches its 
saturation point when full consumption of the substrate occurs. This is confirmed by a study of the 
reaction kinetics; the conversion–time graphs display sigmoidal curves characteristic of 
autocatalytic product generation which starts with a slow induction period followed by an 
exponential increase before reaching a plateau.
232
 Similarly to PCR, analyte concentration 
correlates with the time taken to reach exponential signal amplification. Importantly for 
autocatalytic signal amplification protocols, almost no conversion was observed in the absence of 
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acetate. Although variations at the allosteric site of the catalyst amplifier and the use of alternative 
pH-responsive reporters for different readouts would allow this autocatalytic signal amplification 
protocol to be used within multiple applications, the current procedure described appears to be 
limited towards only acetate detection. 
 
 
Scheme 1.42 Supramolecular autocatalytic signal amplification for fluorescent acetate detection. 
 
 A more flexible approach to autocatalytic signal amplification was provided by Phillips et 
al., who described an autocatalytic variant of their two-component autoinductive signal 
amplification procedure for colourimetric palladium detection (Scheme 1.43).
233
 To achieve 
autocatalysis, signal amplification reagent 72 was designed, inspired by amine proliferation 
compounds used within photolithography,
234
 with a 9-fluorenylmethoxycarbonyl (Fmoc) reporter 
moiety and a piperidine unit which were connected via an aniline linker. Analyte-responsive 
reagent 70 was equipped with an allyl carbamate trigger for selective palladium detection adjoined 
with a signal propagating piperidine group via an electron-rich aniline, which facilitates elimination 
upon analyte recognition.
235
 In the presence of palladium, deallylation and elimination of 70 occurs 
releasing the piperidine catalyst. Since palladium also exhibits target catalysis, multiple equivalents 
of piperidine can be released per molecule of palladium thereby increasing assay sensitivity. After 
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release, piperidine acts as a catalytic base, deprotonating 72 to release another equivalent of 
piperidine and the dibenzofulvene chromophore 73. Proton transfer then occurs regenerating the 
original catalytic base and creating another catalyst. This cycle repeats until full consumption of 
signal amplification reagent 72 occurs and full conversion is obtained.  
 
 
Scheme 1.43 Small molecule autocatalytic signal amplification for colourimetric palladium detection. 
 
 A piperidine catalytic loading of 0.1 mol% was shown to initiate full breakdown of 72 over 
18 hours and exhibited a sigmoidal reaction profile over this time period which indicates that an 
autocatalytic mechanism was in effect. This two-component small molecule approach to 
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autocatalytic signal amplification was capable of reaching a LOD of 12 ppm for palladium and 
variations of 2 ppm in palladium concentration could be easily distinguished. Despite >1000-fold 
signal amplification, the long induction time required for low analyte concentrations prevents this 
methodology from being employed for POC diagnostics. However, this methodology could see use 
within areas such as stimuli-responsive materials where high amplification is required but a 
specific timeframe in which this occurs is less important.
236 
 Autocatalytic signal amplification has the potential to fulfil the needs of diagnostic assays 
which suffer from a lack of sensitivity and is capable of detecting analyte concentrations 
unreachable by other signal amplification methods. The development of such protocols is still in its 
infancy with only two examples successfully demonstrated to date. They have however, shown that 
autocatalytic signal amplification is achievable through completely different methods and should 
inspire the next influx of amplification approaches to match, if not better, current detection limits. 
Future efforts should also be aimed at providing autocatalytic signal amplification towards 
detection of biological samples allowing them to be incorporated within medical diagnostic 
applications. Furthermore, the time taken to induce exponential amplification should be 
dramatically shortened to enable autocatalytic signal amplification to be applied to the POC setting. 
 
1.4  Receptor Amplification 
Within a detection assay, signal production typically occurs after the result of an analyte‒probe 
recognition event. Increasing the number of analyte receptors upon the probe would therefore lead 
to an increase in the probability of an analyte‒probe recognition event occurring and therefore 
faster signal production. This concept is perfectly exemplified by Amir and Shabat who were able 
to increase the number of analyte-responsive triggers on a dendrimer in order to achieve an 
amplified signal response (Figure 1.5).
237
 In this example, three dendrimer derivatives were 
synthesised containing one, two or four enzyme responsive triggers connected to a single reporter 
molecule. Since the removal of just a single trigger is capable of releasing the reporter molecule, 
the dendrimer with the most receptors should deliver the fastest response. Indeed, in the presence 
of the enzyme target, dendrimer 76 with two enzyme triggers was shown to eliminate twice as fast 
as dendrimer 75 containing only one enzyme trigger. However, due to slow elimination kinetics 
associated with the increased number of eliminations required, dendrimer 77 with four enzyme 
triggers attached to the reporter molecule was actually shown to produce a considerably slower 
signal. Still, this dendritic approach to receptor amplification was successfully coupled to a 
dendritic signal amplifier to significantly reduce the time-to-result yet still provide an amplified 
signal for the detection of PGA.
238
 It is on this basic principle that the majority of receptor 
amplification methodologies are based upon.  
 Similarly, but conceptually opposite, to label amplification, receptor amplification 
methodologies utilise the multivalent characteristics of a range of molecular structures to 
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sufficiently amplify the number of receptors adjoined to the signal producer. This has allowed 
structures such as polymers, micelles and hydrogels to all being successfully employed as receptor 
amplifiers within sensing methodologies. 
 
 
Figure 1.5 Concept of receiver amplification and the structures of dendrimers 75, 76 and 77. 
 
 
1.4.1  Polymers 
Prior to the introduction of self-immolative dendrimers, the development of conjugated polymers 
was fundamental to enabling receiver amplification as this allows communication between 
repeating units of the polymer.
239
 Functionalising the conjugated polymers, known as “molecular 
wires”, with analyte-responsive receptors generates a single compound with multiple linked 
receptors. However, it was the use of fluorescent conjugated polymers developed by Swager et al. 







Scheme 1.44 The molecular wire approach to receptor amplification. 
 
 
Scheme 1.45 The molecular wire approach for the fluorescence detection of PQ. 
 
 In a seminal publication, Zhou and Swager described the use of cyclophane receptors 
attached to a polyphenylacetylene backbone for the fluorescent detection of paraquat (PQ) (Scheme 
1.45).
241
 A strongly fluorescent molecular wire was synthesised through palladium-catalysed cross 
coupling of 4-iodophenylacetylene monomers equipped with  bis(p-phenylene)-34-crown-10 
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(BPP), an excellent binder of PQ.
242
 In the presence of the analyte 78, PQ was shown to 
dramatically quench the fluorescence of the conjugated polymer in comparison to the monomer. In 
fact, a 65-fold increase in quenching was observed through the molecular wire approach, which 
was attributed to energy migration transmitted throughout the polymer. In other words, a single 
analyte binding to a single receptor is able to exhort fluorescence quenching over the entire 
polymer. At high molecular weight polymers though, a marked decrease in sensitivity is observed 
due to the length of the polymer being longer than the diffusion length of excitation. Attempts to 
increase the diffusion length of excitation by enhancing the delocalisation throughout the polymer 
backbone in order to improve sensitivity were unsuccessful.
243
 Increased sensitivity can be 
achieved however through deposition of the molecular wires into thin films as energy migration 
can then occur between individual polymers.
244
 
 The concept of receiver amplification employed by this method has allowed amplification 
to be applied to the large array of simple analyte receptor systems previously developed, enabling 
lower LODs to be obtained through these conjugated polymer-based chemical sensors.
245
 The 
considerable number of polymerisation techniques, as well as the number of analyte receptors 
available, has meant that the amplified detection of small ions, explosives and biomolecules can be 
achieved using fluorescent conjugated polymers.
246
 Not only this, but modification of the polymer 
backbone has allowed for colorimetric derivatives of receiver-amplified polymer-based detection 









 Typically, conjugated polymers display fluorescence and it is in the presence of the analyte 
that fluorescence is quenched. In contrast, Leclerc et al. demonstrated the use of conjugated-
polymers for signal-amplified switch-on fluorescent nucleic acid detection (Scheme 1.46).
248
 In this 
invention, a cationic, water soluble, thiophene-derived conjugated polymer,
249
 and an anionic, 
complementary strand of probe DNA initially come together through electrostatic interactions. The 
complexes then aggregate together because of their poor solubility in aqueous media and due to the 
close proximity of the polymers, as well as polymer stiffening, fluorescence quenching is 
observed.
250
 In the presence of target DNA, hybridisation preferentially occurs with the probe DNA 
and a stable triplex is formed where the conjugated polymer is wrapped around the DNA double 
helix, bound to the anionic phosphate backbone. The resulting uniform, helical structure of the 
conjugated polymer, along with the triplex being more soluble in water, leads to dequenching and a 
switch on of fluorescence. This technique was shown to be surprisingly selective as well as 
sensitive since a two base pair mismatch can be easily discriminated and a LOD of 2.4 aM after an 
assay time of 1 hour can be achieved. Labelling the probe DNA with a fluorophore whose optimal 
absorption wavelength is identical to the emission wavelength of the conjugated polymer can 
provide FRET enhancement within the detection methodology.
251
 This not only improves 
selectively since a single base pair mismatch could be distinguished, but also improves sensitivity 
as a LOD corresponding to 3 zM could be achieved after just a 5 minute assay time. This increase 
in sensitivity is attributed to additional fluorescence signal amplification (FSA),
252
 as one 




1.4.2  Encapsulated Reagents 
The concept of encapsulation to segregate reaction reagents and slowly release them in response to 
product formation for reaction rate acceleration is a well-known method of providing chemical 
amplification.
254–255
 Manipulating this premise towards a sensing methodology requires 
modification of the capsule to release its contents selectively in the presence of the analyte and a 
change in physical property must accompany content release in order for effective analyte 
detection.  





 has enabled the development of ‘switch-on’ fluorescent sensing methodologies 
utilising polymeric assemblies and supramolecular structures that display stimuli-responsive 
fluorescence emission characteristics.
258
 In a prime example of this, Matile et al. described the use 
of synthetic supramolecular pores within vesicles for the fluorescent detection of enzyme activity 
(Scheme 1.47).
259
 Artificial rigid-rod molecules capable of self-assembling into β-barrels,260 were 
constructed and then filled with anionic enzyme substrate adenosine triphosphate (ATP) 80, which 
can bind to the cationic inner wall of the barrel through electrostatic interactions. The blocked 
barrels were then slipped into the lipid bilayer of a vesicle containing a high concentration of 5-
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carboxyfluorescein 79 and as such, were non-fluorescent. Since a large number of synthetic pores, 
or analyte receptors, are present per vesicle and only one is needed to be unblocked to release its 
cargo then significant receptor amplification is demonstrated by this approach. In the presence of 
the analyte, a nonspecific adenosine triphosphatase (ATPase) enzyme,
261
 dephosphorylation of 
ATP to adenosine monophatase (AMP) 81 occurs. Due to the decrease in size and the reduced 
number of anionic binding sites, AMP is unable to sufficiently block the barrel and is expelled. 
Once the barrel is unblocked, this allows the release of the trapped molecules within the vesicle 
through the synthetic pores and into the reaction medium. Consequently, dilution of 5-
carboxyfluorescein 79 prevents self-quenching leading to the observed turn-on of fluorescence. 
 
 
Scheme 1.47 Fluorometric detection of enzyme activity with synthetic supramolecular pores. 
 
 The versatility of this amplification methodology was also shown as it was easily adapted 
to the detection of other enzymes, such as aldolases and phosphatases, through the use of the 
appropriate unmodified enzyme substrates as pore blockers. However, the advantage of not 
requiring labelled enzyme substrates is highly dependent on the enzyme substrate showing high 
affinity for the pores and the enzyme product having a significantly lower affinity. In particular, to 
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enable vesicle receptor amplification for the fluorescent detection of ATP, an analyte detection 
method without synthetic pores had to be used.
262
 Despite this, the rigid-rod approach for the 
development of synthetic, multifunctional pores capable of responding to changes in pH, 
concentration and voltage,
263
 has enabled a variety of different analytes to be detected using 





Scheme 1.48 Receptor amplification through self-assembling probes for the 
19
F NMR detection of enzyme 
activity. 
 
 Similarly to self-quenching fluorophores, the phenomenon of molecular signal changes at 
high label concentrations also occurs with self-assembling fluorine-containing compounds when 
using 
19
F nuclear magnetic resonance (NMR) as the detection method. Developed by Hamachi et 
al., a detailed study was conducted into the different combinations of monomers that could be 
obtained through modification of the fluorine-containing tail group, the linker and the analyte-
responsive head group and the effect this would have upon self-assembly.
265
 The successful 
formation of spherical, self-assembled nanoprobes, with the fluorine-containing tail-groups on the 
inside, was determined by a switch-off of the 
19
F NMR signal. Since the outside of the nanoprobe is 
covered with the analyte-responsive head groups and modification or removal of just one could 
disrupt aggregate formation, then considerable receptor amplification can be achieved. 
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 To adapt this observation towards a sensing methodology, the group used nitrobenzene 
head groups for the 
19
F NMR detection of the enzyme nitroreductase (NTR) (Scheme 1.48).
266
 In 
this approach, enzyme-catalysed reduction of the nitro group upon probe 82 to the corresponding 
aniline 83 generates an unstable intermediate that undergoes 1,6-elimination to afford reporter 




NMR signal is observed. Importantly, due to the designed elimination procedure, a shift in the 
19
F 
NMR signal is also observed which confirms the detection of enzyme activity via the proposed 
mechanism as opposed to nanoprobe disaggregation occurring through other means. The 
adaptability of this technique was also demonstrated as by changing the head group to a specific 
peptide chain, the amplified 
19
F NMR detection of cancer biomarker MMP2 could be achieved. 
The nanoprobes also exhibit excellent biocompatibility and this method has been demonstrated for 
both cell surface,
267





Scheme 1.49 Structure of both the size-selective gate and the hinge, and their use in the construction of pH-
controlled, enzyme-encapsulated, mesoporous silica nanoparticles. 
 
 Stimuli-responsive release of encapsulated reagents,
269
 has enormous application to a 
number of biomedical applications such as drug delivery and self-healing materials.
270
 As such, a 
considerable number of analyte-triggered reagent release methodologies are not necessarily 
designed for sensing purposes.
271–272
 Recently, advances have been made from encapsulated 
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reagents to encapsulated enzymes in an effort to provide further amplification as well as to achieve 
programmed enzymatic reactions.
273
 From a sensing perspective, one particular contribution of note 






Scheme 1.50 Size-selective, pH-controlled, enzyme-encapsulated mesoporous silica nanoparticles for the 




 In this method, size-selective pH-controlled silica nanoparticles were constructed 
containing porcine liver esterase (PLE) and capped with a star-like gate through imine hinges 
(Scheme 1.49).
275
 The gate allows the coexistence of the enzyme and enzyme substrate in the same 
media yet prevents their interaction through size-exclusion. System activation occurs in the 
presence of the analyte, 4-acetoxycinnamaldehyde (ACA) 85, which is small enough to fit through 
the gate and is subsequently hydrolysed by the enzyme (Scheme 1.50).
276
 The acid produced as a 
result of enzyme hydrolysis is then capable of catalysing the hydrolysis of the imine hinges holding 
the gate in place. Once all the linkages are broken, the gate is removed from the nanoparticle which 
therefore allows interaction between the enzyme and pro-fluorescent enzyme substrate, 5-
carboxyfluorescein diacetate (CFDA) 87. Enzyme-catalysed hydrolysis of enzyme substrate CFDA 
not only allows enzyme activity to be measured by fluorescence but also produces further 
equivalents of acid, which leads to further gate removal and therefore an increased rate of 
fluorescence production. Although the system demonstrated autoinductive amplification, reaction 
times were long owing to the slow turnover rate of the enzyme. Also, this methodology is limited 
to the detection of acylated compounds that are small enough to fit through the gaps in the gate. 
Despite this, background rates are negligible showing that enzyme activity can be effectively 
controlled using size-selectivity and this methodology could have wider application within 





1.4.3  Hydrogels 
Hydrogels are hydrophilic polymer networks that can absorb up to 99% of their own weight in 
water without dissolution.
278
 They possess the ability to contain a large number of analyte receptors 
either physically encased within the polymer matrix or covalently bound to the polymer and can 
induce a considerable physical response in the presence of specific stimuli.
279
 This, along with their 
high biocompatibility,
280
 has seen the inclusion of hydrogels within a number of sensing 
applications such as temperature and pH monitoring,
281
 as well as for the detection of biologically-
related material.
282
 Typically, the physical response elicited is either through swelling or shrinkage 





 However, these methods require sophisticated instrumentation to afford an 
accurate readout and as a result, there has been efforts made to induce complete disintegration of 
the hydrogel in response to an analyte allowing for naked eye detection. Furthermore, by 
accompanying full dissolution of the hydrogel with a colour change, then an unambiguous positive 
result can be easily determined by eye. One such methodology was developed by Tan et al., who 







Scheme 1.51 An aptamer-bound, enzyme-encapsulated hydrogel for colourimetric cocaine detection. 
 
 In this procedure, amylase enzyme amplifiers were trapped within a cross-linked polymer 
hydrogel that was dependent on DNA aptamers, that are selective for cocaine, for structural 
support.
286
 In the presence of the analyte, competitive binding for the aptamers occur leading to 
hydrogel destabilisation and then inevitable dissolution of the hydrogel with concomitant release of 
amylase enzymes. Thus, the enzyme-catalysed breakdown of amylose is initiated and when the 
assay medium is stained with iodine, the characteristic blue colour associated by the presence of 
amylose does not appear.
287
 The combined receiver amplification of the hydrogel and the signal 
amplification delivered by the enzyme enabled cocaine detection to less than 20 ng with the naked 
eye within 10 minutes. Due to the use of DNA aptamers for analyte detection high selectivity for 
cocaine over structurally similar compounds such as benzoylecgonine (BE) and ecgonine methyl 
ester (EME) was also observed. Enzyme trapping, compared with some enzyme conjugation 
methods, is extremely mild yet effective as no loss of enzyme activity was seen between trapping 
and activation. Also, no undesired substrate breakdown was seen in the absence of the analyte since 
the hydrogel and the enzyme substrate are both polymers. As glucose 89 is produced as a result of 
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the enzyme-catalysed breakdown of amylose, cocaine detection can also be measured 





Scheme 1.52 DCR-enhanced, chemically-reactive supramolecular hydrogel for the visual detection of uric 
acid. 
 
 Supramolecular hydrogels, hydrogels constructed solely on the self-assembly of small 
molecule hydrogelators rather than through chemical cross-linking or polymerisation, are becoming 
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increasingly popular because in addition to being able to support biomaterial within the hydrophilic 
gel, hydrophobic molecules such as fluorophores can also be supported within the supramolecular 
framework itself.
289
 As such, a considerable number of supramolecular hydrogels have been used 
for a number of fluorescent chemosensors that respond to molecular recognition and enzyme 
activity.
290
 Of particular note is the supramolecular hydrogel-based sensing techniques developed 







 However, continuing the endeavour for analyte detection 
without instrumentation, the group very recently successfully coupled their chemically reactive 
supramolecular hydrogel with a DCR-type amplification procedure for the naked-eye detection of 
uric acid in human plasma (Scheme 1.52).
294
 
 In this protocol, supramolecular hydrogels designed to be selective towards hydrogen 
peroxide, were constructed containing three components; analyte selective enzyme urate oxidase 
(UOx), signal transducing self-immolative compound 92, and signal amplifying enzyme sarcosine 
oxidase (SOx). Despite the high number of encapsulated reagents, the hydrogels were shown to be 
physically stable. In the presence of uric acid 90, a biomarker for gout,
295
 UOx catalyses its 
oxidation to 5-hydroxyisourate 91 producing hydrogen peroxide as a byproduct, which can go on to 
oxidise signal transducing reagent 92 to its corresponding phenol 93. This intermediate is unstable 
under the assay conditions and eliminates to produce two equivalents of sarcosine 94. Signal 
amplifying enzyme SOx then catalyses the oxidative demethylation of sarcosine 94 to glycine 95 
producing more molecules of hydrogen peroxide in the process. This can go on to react with more 
equivalents of 92 or react with phenylboronic acid residues upon the hydrogel framework. 
Oxidation and subsequent elimination of these residues is enough to destabilise the matrix and 
cause collapse of the hydrogel, a physical effect visible by eye. This system was capable of 
detecting 80 μgmL−1, the threshold level of hyperuricemia, with the naked eye following a 3 hour 
incubation. The sensitivity was attributed to the amplification provided by DCR, allowing for a 5-
fold decrease in analyte concentration that could be detected via this method. In addition, by 
swapping SOx with GOx, the detection method was easily adapted towards the detection of 
glucose. This mix-and-match approach using different enzymes allows the system to provide logic-
gate output responses from different biological substance input signals.
296 
 
1.5  Conclusion 
Molecular amplification in sensing can now be achieved through a considerable variety of different 
approaches; whether focussed on target, label, signal or receptor amplification. The selection of 
which amplification strategy to choose is not necessarily a case of which one provides the greatest 
amplification but more a matter of which one is most suitable as part of a particular detection assay. 
This is dependent on the analyte being detected, the medium the analyte is being detected from, the 
medium the amplification is taking place in and the desired readout signal. Factors such as the 
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required selectivity and sensitivity, as well as time and cost, also play an important role in selecting 
the most suitable amplification method.  
 Analyte detection methods are constantly evolving. Reversible affinity-based analyte 
recognition has made way to irreversible reaction-based analyte recognition in order to improve 
sensitivity.
297
 In addition; simple indicator-based approaches to sensing are now being made 
obsolete by easy-to-perform, amplified detection assays. Recently, single-amplifier techniques have 
been elaborated with multiple amplifiers in a bid to achieve even greater sensitivity. Current efforts 
are being made not only towards the inclusion of multiple amplifiers but also the incorporation of 
different amplification approaches, such as target and signal amplification within the same 
detection assay. However, the strive to obtain lower and lower detection limits by more and more 
powerful amplification methods can lead to over-complication and problems with false-positive 
results from accidental activation. This is particularly true with regards to the attractive exponential 
amplification displayed by autocatalytic methods. Therefore, analyte selectivity is becoming 
increasingly important not just sensitivity. 
 Future amplification methodologies will always aim for a detection limit of a single 
molecule within a complex mixture with the naked eye. This is not the only goal within sensing 
though as complex diseases, such as cancer, require the successful detection of a panel of 
biomarkers prior to diagnosis, not just one. Therefore, the ability for amplification methodologies 
to demonstrate multiplexed detection without interference is highly desirable. General reagent-
based amplification strategies are also in high demand as the ability to choose an appropriate 
reagent for a specific analyte with a particular readout where amplification is guaranteed will prove 
to be very adventitious within clinical diagnosis. Previously, it has been highlighted that the best 
results are obtained in systems that rely on cascades of amplification events and that most 
amplification protocols rely on hybrid systems. Current objectives within sensing should therefore 
be to develop amplification cascades that utilise both biological and synthetic components for 
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2.0  Introduction 
2.0.1  Atlas Genetics Ltd. 
The work described within this thesis was conducted under the sponsorship of University of Bath 
spin-out company, Atlas Genetics Ltd. (“Atlas”). Atlas is a medical diagnostics company focused 
on decentralised, near-patient and point-of-care (POC) testing.
299
 In order to achieve rapid disease 
diagnosis for POC testing, Atlas have been in the process of developing and commercialising the 
ultra-rapid io™ diagnostic platform. The io™ platform comprises of a small, inexpensive desktop 
instrument capable of reading test-specific disposable cartridges that combine to provide an 
accurate test result in around 30 minutes (Figure 2.1). This aims to give clinicians and other 
healthcare professionals a fully-automated device that enables disease diagnosis without the need 
for central laboratory testing and the associated long test-to-diagnosis time. Actionable test results 
that are provided whilst patients are still present are essential for the effective treatment and control 
of diseases where infection rates are escalating. As a result, Atlas have been initially targeting 
sexually transmitted infections (STIs), as an estimated one million people acquire a curable 
bacterial STI every day,
300
 and hospital acquired infections (HAIs), which are the cause of almost 









2.0.2  Previous Work 
Atlas’ current proprietary technology involves the biomolecular recognition of target bacterial 
deoxyribonucleic acid (DNA) in combination with electrochemical endpoint detection.
302
 The main 
advantages of developing an electrochemical biosensor include the specificity, speed, portability 
and low cost in comparison with optical detection techniques such as colourimetry and 
fluorescence.
303
 In addition, samples do not need to be purified or transparent prior to detection and 
the instrument does not require complex calibration to maintain accuracy. Miniaturisation has also 





Scheme 2.1 Exonuclease-assisted double-stranded DNA cleavage for electrochemical signal amplification. 
 
 In collaboration with Atlas, previous work undertaken in the Frost group involved the 
development of an amplified electrochemical biosensor for DNA detection. This was demonstrated 
through the enzymatic digestion of ferrocene-labelled oligonucleotides (Scheme 2.1). Principally, 
the redox-labelled complementary probe is too large to diffuse to the electrode and as such, a low 
background current in the absence of the target strand is observed. Upon hybridisation to the target, 
the resulting DNA duplex is digested by a nuclease enzyme which splits the oligonucleotide into 
smaller fragments, allowing release of the redox label. The selective digestion of the probe–target 
complex is accompanied by a large increase in current, demonstrating excellent sensitivity for 
DNA detection by this method. This has been successfully achieved with both ferrocene-labelled 
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single-stranded DNA using an endonuclease enzyme,
305
 as well as with ferrocene-labelled double-
stranded DNA using an exonuclease enzyme.
306
 Additional work has focussed on providing further 
amplification through label dimerisation to double the number of redox labels per probe, as well as 
the development of redox labels with discrete oxidation potentials for multiplex electrochemical 
DNA detection.
307
 So far, through functionalisation of the cyclopentadienyl rings upon the 
ferrocene as well as a study into the hydrophobicity effect of the linker between the ferrocene and 
the oligonucleotide,
308
 a successful pentaplex has been demonstrated allowing for four nucleic acid-
based STIs along with an internal control to be detected in just one voltage sweep (Figure 2.2). Not 
only this, but the combined autonomous amplification procedures allow the system to obtain a 
LOD of 25 elementary bodies (EBs), or 3 copies of DNA, per sample in just 25 minutes.
309 
The 
research accomplished during this collaboration is now undergoing integration into the Atlas io™ 
platform which will enable fully-automatable, sensitive, multiplex electrochemical DNA detection 




Figure 2.2 Representative pentaplex for the simultaneous electrochemical DNA of four bacterial infections 





2.0.3  Project Aims 
To complement the existing DNA detection methodology, a sensitive and selective method for 
electrochemical protein detection that could be utilised within a POC device was required. This 
would allow for diseases such as syphilis and the human immunodeficiency virus (HIV), both of 
which have seen sharp increases in recent observed infection rates, to be accurately and rapidly 
detected.
310
 Also, this would allow for the rapid detection of troponin, a protein biomarker for 




 A successful detection assay is dependent upon two key aspects; high selectivity and high 
sensitivity. High selectivity is required so the assay only delivers a positive signal in the presence 
of the desired biomarker and due to the complexity of a biological mixture, poor selectivity can 
easily occur thus leading to false positives. High sensitivity is required to deliver a detectable signal 
when only a low concentration of the biomarker is present, thus eliminating the possibility of false 
negatives, and therefore a missed diagnosis, from occurring. For the successful detection of 







 However, for simplicity, as well as for both high selectivity and 
sensitivity, the method of choice for this project was the immunoassay.
315
 Therefore, the primary 
objective for this project was to develop an immunoassay with electrochemical endpoint detection 
tailored for use within a POC device.  
 
2.1  Electrochemical Immunoassays 
2.1.1  Background to Immunoassays 
The term immunoassay broadly covers any diagnostic assay that uses antibodies as analytical 
reagents to bind to antigens in a sample solution and produces a detectable signal as a result of this 
interaction that is proportional to the concentration of the antigen.
316
 Historically, the first labelled 
immunoassays were immunoradiometric assays (IRMA) where antibodies were tagged with 
radioactive labels which enabled antigen concentration to be determined by radiation.
317
 However, 
due to the obvious safety concern of laboratory personnel being exposed to radiation, along with 
the need for special facilities, expensive counting equipment and the disposal of radioactive waste, 
a safer, inexpensive alternative to radiolabels was sought. The successful coupling of antibodies to 
enzymes without denaturising either component enabled enzymes to be that alternative.
318
 
Inevitably, the development of enzyme immunoassays (EIA),
319
 and the solid-phase derivative 
enzyme linked immunosorbent assays (ELISA),
320
 were reported shortly after this discovery and 
quickly replaced IRMAs. Since then, EIAs and ELISAs have both been integrated within 
automated systems and are routinely used within central medical laboratories around the world for 




 For non-purified or unprocessed samples, ELISAs are typically more suitable than EIAs as 
washing steps within the protocol will lead to a lower chance of false positives occurring. 
However, many types of ELISA formats exist and different enzymes can be used as the enzyme 
label for signal production.
322
 Direct ELISA involves antigen adsorption onto the solid phase prior 
to antibody–enzyme labelling but as this is an ill-defined process which depends heavily on the 
antigen, it is often not the most sensitive type.
323
 Competitive EIAs are rapid and simple to perform 
but since they utilise restricted antigen and enzyme concentrations, these benefits are lost when 
executed on solid-phase as any desorption or denaturisation has a significant impact on these 
concentrations which leads to signal variability and irreproducibility.
324
 Indirect or ‘sandwich’ 
ELISAs are often the most selective format as they utilise two antibodies; one absorbed onto the 
solid-phase for antigen capture and another conjugated to an enzyme for antigen labelling (Scheme 
2.2).
325
 Although they require extra steps during the protocol, sandwich ELISAs are the standard 
choice of ELISA format for medical diagnostics purposes due to the unrivalled selectivity it offers. 
 
 
Scheme 2.2 Typical construction of a sandwich ELISA. 
 
 Although many enzymes can be successfully conjugated to antibodies, typically only three 
are used with ELISAs; horseradish peroxidase (HRP), β-D-galactosidase (β-gal) and alkaline 
phosphatase (ALP).
326
 This is due the purity, specificity and sensitivity of the enzyme, as well as 
the ease of conjugation and the efficacy and stability of the corresponding enzyme–antibody 
conjugate. HRP is inexpensive, is readily available and importantly, has a high turnover rate.
327
 
Also, there are a considerable number of chromogenic substrates that have been developed for HRP 
activity detection which makes it a popular choice within ELISAs that are monitored through 
spectroscopic means. Comparatively fewer electrochemical substrates for HRP exist as they tend to 
undergo electro-oxidation or autooxidation in the absence of the enzyme, which leads to high 
backgrounds and potential false positive results.
328
 In addition to the substrate, HRP requires 
hydrogen peroxide to facilitate oxidation which would add another layer of complexity for 
integration within an automated system. β-gal is also readily available, inexpensive and easily 
conjugated to antibodies but has a significantly slower turnover rate in comparison to HRP.
329
 
Although sensitive chromogenic and fluorogenic substrates have been developed for β-gal 
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detection, far fewer electrochemical substrates exist.
330
 Of the ones that do, they are often derived 
from highly conjugated organic compounds which, despite having accessible oxidation potentials, 
are poorly soluble in aqueous media and contribute extensively to electrode fouling, limiting assay 
sensitivity. ALP has similar attributes to HRP in that it has a very high turnover rate, is readily 
available and easily conjugated but it is comparatively expensive however.
331
 There are also a 
range of colourimetric, fluorometric and electrochemical substrates that have been developed for 
ALP making it an ideal choice as the enzyme label within an electrochemical ELISA.  
 
2.1.2  Electrochemical Substrates for Alkaline Phosphatase 
Once it had been decided that electrochemical biomarker detection was going to be achieved 
through an ALP-labelled sandwich ELISA, an investigation into previously developed 
electrochemical substrates for ALP was launched (Figure 2.3). One of the first, and one of the 
simplest compounds developed as a substrate for electrochemical ALP detection was phenyl 
phosphate 96 (Scheme 2.3).
332
 In the presence of ALP, dephosphorylation of 96 occurs to give 
phenolate 97 which is oxidised at 670 mV vs. Ag/AgCl. The LOD for this detection system was 5 
nmolL
−1
. Despite none of the other assay components being electroactive individually, as a 
mixture, a large background current was observed at the high potential required for phenol 
oxidation and as such, 97 had to be separated from the assay mixture by reverse phase liquid 
chromatography (LC) prior to electrochemical detection. 
 
 
Scheme 2.3 Electrochemical detection of ALP using phenyl phosphate 96 as substrate. 
 
 In order to lower the oxidation potential of the hydrolysed product and therefore reduce the 
high background and remove the need for product separation, electron rich aryl derivatives of 
phenyl phosphate 96 such as 4-aminophenyl phosphate 98,
333
 4-hydroxyphenol phosphate 99,
334
 
and α-naphthol phosphate 100,335 have all been used as electrochemical ALP substrates with the 
latter often proving to be the most stable and the most sensitive. Reactivity is compromised 
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however, since electron-rich phenyl phosphates are less reactive towards hydrolysis. In order to 
increase reactivity, phenyl phosphates with electron-withdrawing groups such as p-nitrophenyl 
phosphate 101,
336
 and p-cyanophenyl phosphate 102,
337
 have also been employed as 
electrochemical substrates for ALP. However, the electrochemical oxidation of phenols generates 
phenoxy radicals, which are known to undergo radical polymerisation,
338
 the main contributor to 
electrode fouling and leads to subsequent loss of electrochemical sensitivity. To help alleviate this, 
3-indoxyl phosphate 103 has also used as an ALP substrate since the product is substantially more 
stable after oxidation.
339
 Despite this, aerobic dimerisation of the enzyme product is required to 
generate the electroactive species and once formed, the dimer is insoluble in water which again 
leads to electrode fouling. Hydroquinone diphosphate 104 has been developed as an alternative that 
has been shown not to produce electrode fouling in electrochemical immunoassays.
340
 In addition, 
the hydroquinone product has a two-electron oxidation at the electrode that produces a significantly 
larger amperometric response than phenol or α-naphthol. The use of hydroquinone diphosphate 104 
has been limited however since it requires two enzyme-catalysed dephosphorylations before the 
electroactive species is generated and the substrate is also not commercially available. 
 
 
Figure 2.3 Structures of commonly-used organic substrates for electrochemical ALP detection. 
 
 One substrate that is commercially available, is L-ascorbic acid 2-phosphate (AA2P) 105 
which is a mono-phosphate whose product, ascorbic acid (AA), also has a favourable two-electron 
oxidation at the electrode and a low oxidation potential of 400 mV vs. Ag/AgCl.
341
 It has also been 
shown to be a far superior substrate in comparison to the previous substrates and subsequently, 
AA2P 105 has been adopted as the industry standard ALP substrate for electrochemical 
detection.
342
 Despite this, AA has a broad oxidation potential range as the electrons given at the 
electrode are inequivalent. Also, AA requires acidic media to deliver optimal current which 
conflicts with the optimum pH for ALP activity.
343
 To increase AA sensitivity, and electrochemical 
immunoassays in general, substantial effort has gone into immunosensor fabrication and electrode 
modification.
344
 However, many of these approaches are inapplicable towards integration within a 
POC test since they are expensive and cannot be easily mass-produced. Therefore, in order to 
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improve electrochemical immunoassays for application with POC testing, further research needs to 
be performed regarding electrochemical enzyme substrates. 
 
 
Figure 2.4 Structures of ferrocene-derived substrates for electrochemical ALP detection. 
 
 When designing any electrochemical labels or substrates for biological detection methods, 
ferrocene is one of the first electroactive species that is considered due to its facile oxidation 
potential, good stability in aqueous media and compatibility with biological components, as well as 
being easily derivatised.
345
 Despite these excellent attributes, the number of ferrocene-derived 
substrates for ALP described in the literature to date are limited to just three (Figure 2.4).
346
 The 
first, 4-ferrocenamidophenyl phosphate 106 developed by Bannister et al., had an oxidation 
potential identical to that of the phenol product at 180 mV vs. a saturated calomel electrode (SCE) 
and successful ALP detection was reliant on the phenol product exhibiting a higher peak current 
than the starting material.
347
 Nevertheless, an ALP concentration of 1.2 pmolL
−1
 could still be 
detected via this method. It was noted therein that in order to obtain further enzymatic 
amplification, future electrochemical enzyme substrates should be designed so that the product 
should have a significantly lower oxidation potential than the substrate and that this difference 
should be approximately 100 to 200 mV so that the oxidation potentials of both substrate and 
product are electrochemically distinguishable. 
 The second structurally similar compound, 4-ferrocenamido-4,6-dimethylphenyl phosphate 
107, was developed by Degrand et al. as its corresponding phenol product could be separated from 
107 by the use of polymer-coated glassy carbon electrode even though they possess the same 
oxidation potential of 350 mV vs. SCE.
348
 The increase in hydrophobicity is required as this 
provided an acceptable separation in comparison with 106 which couldn’t be easily separated from 
the product using the polymer and therefore led to a high background current.
349
 An ALP LOD of 
2.8 pmolL
−1
 could be achieved by the use of these modified electrodes but due to accumulation of 
the product within the polymer, the electrodes could only be used once. The third and simplest 
derivative, 2-(ferrocenyl)ethyl phosphate 108, was also developed by Limoges and Degrand as a 
substrate that would allow the polymer-modified electrodes to be re-used.
350
 108 and its 
corresponding alcohol product 2-(ferrocenyl)ethanol again have the same oxidation potential, 300 
mV vs. Ag/AgCl, but could still be efficiently separated by the polymer and was capable of being 
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reused several times via cathodic stripping voltammetry without a noticeable drop in sensitivity 
being observed, with an LOD of this substrate being approximately 2 pmolL
−1
. Despite the good 
sensitivity, having to use modified electrodes can be expensive and small changes in polymer 
thickness can result in fluctuations in sensitivity; factors typically avoided for mass-produced POC 
tests. To avoid the use of modified electrodes, an electrochemical system whereby substrate and 
product have distinguishable oxidation potentials, known as ratiometric sensing, would be highly 
advantageous. 
 
2.1.3 Ratiometric Detection for Point-of-Care Sensing 
 
 
Scheme 2.4 Ratiometric electrochemical DNA detection using gold electrodes modified with a molecular 
beacon probe labelled at both ends with electroactive tags with unique oxidation potentials. 
 
Despite the vast array of electrochemical biosensors published to date,
351
 very few have been 
integrated within POC devices for a number of reasons, such as reproducibility, robustness and 
reliability. This is primarily due to problems associated with miniaturisation where variations in 
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electrode surface area and reagent concentrations are unavoidable yet small changes in either, can 
lead to a significant change in current. Typically, each new electrode is required to undergo a 
number of background scans after being installed into a device and the signal produced resulting 
from an assay would be referenced against this calibration. However, this is a time-consuming 
method and obviously inapplicable to the POC setting. Since signal intensities can vary 
dramatically to small differences within the sensing environment such as temperature, pH and 
polarity, as well as instrument and probe variation, then accurate, quantitative sensing can be 
difficult to achieve, especially when these differences are amplified within a POC device. To 





Scheme 2.5 Ratiometric electrochemical detection of aldolase activity where ferrocene-derived enzyme 
substrate 109 and product 111 have unique oxidation potentials. 
 
 With the plethora of organic fluorophores currently available, it is no surprise that the 
majority of ratiometric sensing platforms are based upon fluorescence detection.
353
 Until only very 
recently, there were no examples whatsoever of ratiometric sensing being performed 
electrochemically. The first ratiometric electrochemical DNA sensing method was initially 
developed by Ellington et al. (Scheme 2.4),
354
 where surface-bound oligonucleotide-derived 
molecular beacons,
355
 were labelled at both ends with electroactive moieties, typically ferrocene 
(Fc) and methylene blue (MB), that have unique oxidation potentials. In the presence of target 
DNA, a decrease in current for one label is observed while the other label exhibits a constant 
current. This in-built internal control allows the electrochemical detection to be a lot more robust, 
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reproducible and reliable. It is no wonder that these benefits have quickly been exploited towards 
other ratiometric electrochemical DNA detection systems,
356





 and small molecule,
361
 sensing strategies. 
 The only example of enzyme activity being measured through ratiometric electrochemical 
sensing was described by Shabat et al. (Scheme 2.5).
362
 In this development, ferrocene carbamate 
109 was synthesised and exposed to an aldolase antibody. In the presence of the aldoase, substrate 
109 undergoes a retro-aldol and a retro-Michael elimination followed by decarboxylation of 
intermediate 110 to achieve aminoferrocene 111. Substrate 109 and product 111 were found to 
have a difference in oxidation potentials of approximately 150 mV and as such, were 
distinguishable via differential pulse voltammetry (DPV). This example was used as the primary 
inspiration for designing a ferrocene-derivative that could be applied to the ratiometric 
electrochemical detection of alkaline phosphate. 
 
2.3  Ratiometric Electrochemical Enzyme-Linked Immunosorbent Assay 
2.3.1  Enzyme Substrate Design and Synthesis 
 
 
Scheme 2.6 Designed structure of ALP substrate 112 and the proposed elimination mechanism to yield 




In order to achieve the ratiometric electrochemical detection of alkaline phosphatase activity, 
ferrocene phosphate 112 was designed (Scheme 2.6). It was proposed that in the presence of ALP, 
enzyme-catalysed dephosphorylation of 112 would first occur. The intermediate phenolate 113 
would then be unstable under the basic conditions preferred by the enzyme and would undergo 1,6-
elimination followed by decarboxylation to release aminoferrocene 111. Retrosynthetic analysis of 
112 (Scheme 2.7) revealed two key intermediates; ferrocenylisocyanate 115 and benzyl alcohol 
116. Ferrocenylisocyanate 115 could be installed via a Curtius rearrangement of ferrocenoyl azide 
117, which in turn could be obtained through a simple functional group interconversion from 
commercially available ferrocenecarboxylic acid 118. Since the synthesis of ferrocenylisocyanate 
115 is known, the starting point for the investigation was to be the synthesis of the benzyl alcohol. 
 
 
Scheme 2.7 Retrosynthetic analysis of ALP substrate 112. 
 
 Prior to the investigation, there was only one previous example of a benzyl alcohol with a 
bis-protected phosphate in the para position 116, where the protecting groups could be removed 
under mild conditions.
363
 Therefore, the investigation began with the synthesis of that specific 
benzyl alcohol 124 where the phosphate is protected with two 2-(trimethylsilyl)ethyl (TMSE) 
groups (Scheme 2.8). Attempts to reproduce the synthesis of 124 from commercially available 2-





unsuccessful. This is thought to be due to selectivity issues between the phenol and the benzyl 
alcohol, as well as instability of the protecting groups under purification by silica gel 
chromatography, known to induce a Peterson elimination of TMSE groups.
365
 In the absence of 
alternatives, further retrosynthetic analysis of the benzyl alcohol was performed (Scheme 2.9). 
 
 
Scheme 2.8 Attempted synthetic route towards bis(TMSE)-protected phosphate 124. 
 
 Selectivity issues could be prevented through masking the alcohol as an aldehyde 125 and 
the phosphorylated phenol could be simply achieved by combining commercially available 4-
hydroxybenzaldehyde 126 with a protected phosphorochloridate. Again, options were limited as 
the only commercially available phosphorochloridate with protecting groups that could be removed 
under mild conditions was bis(2,2,2-trichloroethyl (TCE)) phosphorochloridate 127. Lacking in 
other choices, phenol 126 and chlorophosphate 127 were reacted together in the presence of base 
and progress was monitored by thin layer chromatography (TLC) analysis (Scheme 2.10). Despite 
full consumption of the starting material and the appearance of a new product being observed 
within 2 hours, only starting material was recovered after silica gel column chromatography. This 
is attributed to the electron-withdrawing nature of the aldehyde, in combination with the mildly 
acidic conditions of the silica, activating the phosphate towards undesired hydrolysis upon 
purification. As an alternative method of purification, recrystallisation of crude 128 was attempted 
and successfully achieved from hot ether, albeit achieving only 7% yield. Methods to improve on 
this yield through the use of different solvents and solvent mixtures were unsuccessful. 
Nevertheless, with benzaldehyde 128 in hand it was taken forward to the next step. 
 
 




Scheme 2.10 Synthesis of 4-formylphenyl bis(TCE) phosphate 128. 
 
 
Scheme 2.11 Synthesis of 4-(hydroxymethyl)phenyl bis(TCE) phosphate 129. 
 
 Typically, reduction of benzaldehydes to benzyl alcohols is achieved using sodium 
borohydride in methanol.
366
 However, under these standard conditions; the desired product was 
only obtained in poor yield (Scheme 2.11). This was thought to be due to the solvent, as methanol 
could be a strong enough nucleophile to inflict an SN2 reaction upon the phosphate, especially 
considering the good leaving group ability of an electron-deficient phenol. Disappointed with 2% 
overall yield for the two steps, it was decided to take the reaction mixture forward from the 
phosphorylation step crude, since TLC analysis previously revealed full conversion from starting 
material to product, and perform the reduction using a different solvent (Scheme 2.12). Thus, 
telescoping the two reaction procedures and using tetrahydrofuran (THF) as reaction solvent for the 
reduction delivered benzyl alcohol 129 in a much improved isolated yield over the two steps. In 
addition, the procedure could be performed on a 4 mmol scale allowing for >1 g of benzyl alcohol 
129 to be achieved in a single operation.  
 
 
Scheme 2.12 Telescoped synthesis of 4-(hydroxymethyl)phenyl bis(TCE) phosphate 130. 
 
 With the desired benzyl alcohol in hand, the next objective was to couple it with 
ferrocenoyl azide 117. Ferrocenoyl azide was synthesised in a straightforward manner from 
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commercially available ferrocenecarboxylic acid 118 employing a literature procedure (Scheme 
2.13).
367
 A suspension of 118 was transformed into ferrocenoyl chloride 130 using oxalyl chloride, 
followed by exposure of crude 130 to sodium azide under Schotten–Baumann conditions,368‒369 to 
afford ferrocenoyl azide 117 in good yield. With carbonyl azide 117 in hand, it was then necessary 
to couple it with benzyl alcohol 129 via ferrocenyl isocyanate 115 (Scheme 2.14). Thus, 117 was 
heated to reflux in a sealed vessel to induce a thermal Curtius rearrangement,
370
 to obtain 
isocyanate 115, which was reacted with benzyl alcohol 129 in situ to afford the desired ferrocene 
carbamate 131 in moderate yield over the reaction sequence. 
 
 
Scheme 2.13 Synthesis of ferrocenoyl azide 117. 
 
 
Scheme 2.14 Synthesis of 4-((bis((TCE)oxy)phosphoryl)oxy)benzyl ferrocenylcarbamate 131. 
 
 Deprotection of the TCE protecting groups is typically achieved using zinc or a zinc–
copper couple where metal insertion between the carbon–chlorine bond facilitates β-elimination. 
Therefore, bis(TCE)-protected phosphate 131 was exposed to standard deprotection conditions of 
zinc powder in pyridine (Scheme 2.15).
371
 However, although the desired phosphoric acid 132 was 
observed by crude 
31
P NMR, isolation of the product from the excess reactants proved impossible. 





Scheme 2.15 Attempted deprotection of bis(TCE) phosphate 131. 
 
 Having exhausted all of the commercial sources of phosphorochloridates, retrosynthetic 
analysis revealed that they can be obtained from the corresponding protected phosphites (Scheme 
2.7). Although many are commercially available, only dibenzyl phosphite 133 possessed easily 
removable protecting groups and was subsequently used as the starting material for the synthesis of 
dibenzyl phosphorochloridate 134. Phosphites are known to be easily transformed to their 
corresponding phosphorochloridates through simple treatment with N-chlorosuccinimide (NCS) in 
high yield.
372
 Due to the high reactivity and instability during purification of phosphorochloridates, 
it was decided to react 134 immediately once synthesised with phenol 126 in order to prevent loss 
of yield. Also, since it has already been discovered that 4-formylphenyl phosphates are unstable to 
silica gel column chromatography, it was also decided to reduce the crude aldehyde 135 product 
once formed. Thus, in a highly telescoped procedure, dibenzyl phosphorochloridate 134 was 
synthesised through electrophilic chlorination of commercially available dibenzyl phosphite 133 
with NCS and was subsequently used to phosphorylate 4-hydroxybenzaldehyde 126 (Scheme 
2.16). The dibenzyl (4-formylphenyl) phosphate 135 formed was then reduced with sodium 
borohydride to furnish the desired dibenzyl (4-(hydroxymethyl)phenyl) phosphate 136 in good 
overall yield over the three steps. With 136 in hand, it was reacted with ferrocenoyl azide 117 via 
the Curtius rearrangement to form the desired dibenzyl-protected ferrocene phosphate 137 in 
moderate yield (Scheme 2.17). 
 
 




Scheme 2.17 Synthesis of dibenzyl (4-(hydroxymethyl)phenyl) phosphate 136. 
 
 Benzyl ether deprotection is typically achieved through hydrogenolysis catalysed by a 
heterogeneous metal source such as palladium on carbon.
373
 As such, dibenzyl-protected phosphate 
136 was subjected to standard hydrogenolysis conditions of catalytic palladium on carbon in a 
protic solvent under an atmosphere of hydrogen (Scheme 2.18). Although full consumption of 
starting material was seen, the desired deprotected phosphoric acid 132 was not observed. Instead, 
aminoferrocene 111 was isolated as the major product due to the concurrent hydrogenation of the 
benzyl linker. Since the linker is unstable towards the deprotection conditions, an orthogonal 
protecting group was required. 
 
 
Scheme 2.18 Attempted deprotection dibenzyl phosphate 136. 
 
 With no other phosphites bearing two protecting groups remaining that were commercially 
available, it was necessary to synthesise them. Retrosynthetic analysis showed that they can be 
easily obtained through the reaction of phosphorous trichloride with two equivalents of an alcohol 
(Scheme 2.7).
374
 Thus, the synthesis of hydrogen phosphites bearing two functional groups that 
could be removed under mild conditions were attempted. The intermediate phosphites are known to 
be synthesised in high yield and in good chemical purity and are often taken forward crude to the 
next step.
375
 As such, the procedure for constructing the phosphites was attached to the beginning 
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of the already highly telescoped procedure for the synthesis of the 4-(hydroxymethyl)phenyl 
phosphates (Scheme 2.19). 
 
 
Scheme 2.19 Synthetic route to obtain protected (4-(hydroxymethyl)phenyl) phosphates bearing orthogonal 
protecting groups. 
 
 Firstly, tert-butyl alcohol was employed as the alcohol since phosphates bearing tert-butyl 
groups can be removed in strong, dry acid.
376
 However, the desired dibutyl-protected phosphate 
was not observed via this method as the bulky tert-butyl groups sterically prevent an SN2 reaction 
at the phosphorous centre of 141 from occurring during the phenol phosphorylation step. Secondly, 
3-hydroxypropionitrile was used as the alcohol as cyanoethyl groups can be removed from 
phosphates through simple treatment with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).
377
 However, 
once again the desired bis-cyanoethyl-protected phosphate was not observed due to the high water 
solubility of the intermediate phosphite 139 and as such, was unable to be extracted. Thirdly, allyl 
alcohol was tried as the protecting group-containing alcohol as palladium-catalysed phosphate 
deallylation can be easily performed under acidic conditions.
378
 Pleasingly, the desired diallyl-
protected phosphate 149 was obtained from this highly telescoped procedure, albeit in poor yield. 
By changing the solvent and the base used in the phosphite synthesis to facilitate an easier 
extraction, the isolated yield was trebled over the four steps. In addition, the introduction of a 
hydroxide workup after the aldehyde reduction removes any unreacted 4-hydroxybenzylalcohol 
120, which greatly simplifies purification since co-elution of 120 with product 149 was 
unavoidable. The procedure could also be scaled up to 50 mmol scale to allow 4 grams of diallyl 




Scheme 2.19 Synthesis of 4-((bis(allyloxy)phosphoryl)oxy)benzyl ferrocenylcarbamate. 
 
 With another bis-protected 4-(hydroxymethyl)phenyl phosphate in hand, 149 was reacted 
with ferrocenoyl azide 117 in an identical manner as previous and the desired ferrocenylcarbamate 
150 was obtained cleanly in good yield (Scheme 2.19). Next, 150 was exposed to a number of 
palladium-catalysed deallylation procedures which were analysed by 
31
P NMR (Table 2.1). 
 
 
Pd Source Hydride Source 
31
P NMR Conversion (%) 
a 
10 mol% Pd(PPh3)4 2 eq. Et3SiH, 2 eq. AcOH >99% 
10 mol% Pd(PPh3)4 10 eq. TEA, 15 eq. HCOOH >99% 
10 mol% Pd nanoparticles 10 eq. TEA, 15 eq. HCOOH 0% 
10 mol% Pd EnCat
®
 10 eq. TEA, 15 eq. HCOOH decomp. 
10 mol% Pd/C 10 eq. TEA, 15 eq. HCOOH decomp. 
10 mol% Pd/silica 10 eq. TEA, 15 eq. HCOOH ~30% 
b 
polymer-bound Pd(PPh3)4 10 eq. TEA, 15 eq. HCOOH >99% 
polymer-bound Pd(PPh3)4 2 eq. 
n
Bu3SnH decomp. 
polymer-bound Pd(PPh3)4 10 eq. NH4OOCH 0% 
a estimated using relative peak heights. b mono-deprotected phosphate.
 
Table 2.1 Palladium-catalysed deprotection of bis(allyl)-protected ferrocenylcarbamate 150. 
 
 Initially, literature conditions using catalytic tetrakis(triphenylphosphine) palladium with 
triethylsilane as the reducing agent afforded complete conversion of starting material 150 to 
product 132.
379
 However, problems with isolation of phosphoric acid 132 from the catalyst as well 
as silyl by-products prompted a cleaner alternative. Fortunately, replacing the silane with transfer 
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hydrogenation conditions of triethylamine (TEA) and formic acid also delivered complete 
conversion.
380
 Removing the catalyst from the product though still proved problematic so therefore, 
a range of heterogeneous palladium catalysts were screened which would enable catalyst removal 
to be achieved simply by filtration. The use of palladium nanoparticles just returned starting 
material, while encapsulated palladium and palladium on carbon both led to decomposition of 150, 
possibly due to hydrogenolysis of the benzyl linker. Palladium on silica showed improved 
reactivity as small conversion to the mono-deallylated product was observed. Gratifyingly, 
polymer-supported tetrakis(triphenylphosphine) palladium delivered quantitative conversion and 
was easily removed by simple gravity filtration. Efforts to enable a simpler purification through the 
use of different hydride sources such as tributyltin hydride,
381
 and ammonium formate,
382
 only 
decomposed or returned starting material respectively.  
 
 
Scheme 2.20 Optimised synthesis of 4-(((ferrocenylcarbamoyl)oxy)methyl)phenyl phosphate 112. 
 
 Unable to purify phosphoric acid 132 through silica gel column chromatography without 
decomposition, the phosphate salt 112 was prepared to allow purification through alternative 
means. Thus, treatment of crude 132 with twelve equivalents of 1M sodium hydroxide provided 
112, along with ten equivalents of sodium formate (Scheme 2.20). Although methods for the 
attempted recrystallisation of 112 proved unsuccessful, purification of 112 could be achieved via 
preparative reverse phase C18-silica gel column chromatography. Furthermore, the catalytic loading 
of the polymer-bound palladium could be reduced to 1 mol% yet still achieve quantitative 
31
P NMR 
conversion for the deprotection despite the reaction time needing to be extended to 16 hours. With 
the designed ratiometric substrate now successfully synthesised and isolated, it was necessary to 
establish whether 112 would act as an appropriate substrate for ALP. 
 
2.3.2 Mechanistic, Electrochemical and Stability Studies 
In order to determine if designed substrate 112 could be hydrolysed by ALP, it was decided that 
enzyme and substrate should simply be combined in a buffered solution and any interaction 
between the two components could be monitored by 
31
P NMR. Due to the seemingly different 
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magnetic environments of the substrate compared with the released phosphate, it was thought that 
the peak shifts of the two would be distinguishable on a 
31
P NMR spectrum. When a 20 mM 
solution of 112 was exposed to 10 UmL
−1
 of ALP, a single peak at 2.7 ppm was observed after 12 
minutes which differed from the peak position of 0.1 ppm for 112. However, to confirm that the 
appearance of the new peak coincides with the disappearance of the substrate peak, ALP 
concentration was reduced to 2 UmL
−1
 which would allow the reaction to be monitored in greater 
detail (Figure 2.5). Over time, the peak corresponding with the 112 slowly disappears and the peak 
corresponding with the released phosphate appears at the same rate. In a background experiment 
where a solution of 112 is monitored by 
31
P NMR over time in the absence of the enzyme, no 
released phosphate peak is observed confirming that dephosphorylation of 112 occurs selectively in 
the presence of the enzyme. Due to the requirement for a protic buffer, other reaction products such 
as quinone methide, its water-trapped derivative 4-hydroxybenzyl alcohol 120, or aminoferrocene 
111 could not be detected by 
1
H NMR. An attempt to scale up the reaction and extract 111 from the 
buffer in order to confirm its release from the linker in the presence of ALP was unsuccessful. 
 
 
Figure 2.5 Stacked 
31





Scheme 2.21 Synthesis of aminoferrocene 111 from ferrocenoyl azide 117 via ferrocenylcarbamate 151. 
 
 
Figure 2.6 Differential pulse voltammogram of a 1 mM solution of aminoferrocene 111 in pH 9 Tris buffer. 
 
 To identify whether aminoferrocene 111 was being released from the linker subsequent to 
enzyme-catalysed dephosphorylation, an authentic sample of 111 was to be synthesised and its 
oxidation potential compared with that of the reaction between 112 and ALP. Thus, 
aminoferrocene 111 was synthesised in good yield according to a literature procedure and its 
spectroscopic data was shown to be identical with that of literature precedent (Scheme 2.21).
383
 
With aminoferrocene successfully synthesised, separate solutions of ALP substrate 112 and ALP 
product 111 in pH 9 Tris buffer, an optimal buffer for ALP activity,
384
 were made up and subjected 
to electrochemical analysis. Using differential pulse voltammetry (DPV), a 1 mM solution of 
aminoferrocene 111 was found to have an oxidation potential of −130 mV vs. Ag/AgCl (Figure 
2.6), whereas ALP substrate 112 was found to have an oxidation potential of 85 mV vs. Ag/AgCl 



















Potential vs. Ag/AgCl (mV) 
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that both should be electrochemically distinguishable and in order to determine this, an equimolar 
solution of 111 and 112 was exposed to electrochemical analysis (Figure 2.8). 
 
 
Figure 2.7 Differential pulse voltammogram of a 1 mM solution of ALP substrate 112 in pH 9 Tris buffer. 
 
 As desired, both substrate and product were distinguishable electrochemically and as such, 
allows for reaction conversions to be obtained through peak integration in a similar manner that 
organic reaction conversions can be calculated through peak integration of 
1
H NMR spectra. Thus, 
at any given time point, the enzyme-catalysed conversion of 112 to 111 can be calculated by the 
following equation: 
                
    
            
       
To test this and to confirm whether aminoferrocene 111 is released as a result of ALP acting upon 
the substrate, a 1 mM solution of 112 was treated with 1000 UL
−1
 of ALP and stirred for 30 
minutes, which is the acceptable waiting period for a POC diagnostic test result (Scheme 2.22).
385
 
After this time, a sample was taken and analysed electrochemically. Pleasingly, quantitative 
conversion of substrate to product was observed as only one peak at −130 mV corresponding to 
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absence of the enzyme showed no conversion after 30 minutes as only one peak at 85 mV 
corresponding to substrate 112 was seen on the voltammogram. 
 
 
Figure 2.8 Differential pulse voltammogram of a solution containing 0.5 mM of 111 and 0.5 mM of 112 in 
pH 9 Tris buffer. 
 
 
Scheme 2.22 Electrochemically-determined conversion of a 1 mM solution of enzyme substrate 112 to 
enzyme product 111 in the presence, and absence, of ALP. 
 
 Although no conversion was seen without the enzyme, it was necessary to perform stability 
studies upon substrate 112 as unwanted hydrolytic degradation could occur and lead towards false 
positive results. Two stability studies were performed; one solid in a screw-top vial and one in 



















Potential vs. Ag/AgCl (mV) 
 
92 
the solid enzyme substrate had exhibited a colour change from orange to brown but only showed 
30% degradation to aminoferrocene as determined electrochemically. This is assumed to be due to 
adventitious hydrolysis of the substrate by atmospheric moisture and as such, subsequent storage of 
112 has been in a desiccator to maintain compound purity. In solution, substrate 112 showed 
excellent stability at high concentrations in buffer with minimal degradation observed after 5 
weeks. However, at more dilute concentrations, degradation is more apparent as full degradation of 
the substrate is seen within 3 weeks. As a result, subsequent ALP detection assays were performed 
using a solution of 112 made from a stock 10 mM concentration that was freshly prepared every 
week. 
 
Storage Time Concentration of 112 
  1 mM 0.1 mM 0.01 mM
 
21 days 0.5% 17% 100% 
35 days 1% 48% 100% 
 
Table 2.2 Degradation of 112 at various concentrations in pH 9 Tris buffer at room temperature. 
 
 Having achieved the selective ratiometric electrochemical detection of ALP and 
established that enzyme detection occurs through the proposed mechanism also in addition to 
substrate stability, the next objective was to optimise the detection assay in order to attain the 
lowest LOD possible. 
 
2.3.3 Optimisation of the Enzyme Detection Assay 
Pleased with obtaining quantitative conversion in the presence of ALP after 30 minutes, the 
reaction was repeated and monitored over time to determine the efficiency of the assay (Figure 
2.9). In addition, the concentration of enzyme was gradually lowered to identify the detection limit 
of the current conditions. It was discovered that at the high concentration of ALP of 1000 UL
−1
, 
quantitative conversion was actually achieved within 6 minutes. Enzyme concentrations of 250 
UL
−1
 or higher, also delivered quantitative conversion within the 30 minute timeframe. Under these 
assay conditions, no conversion was seen in the absence of the enzyme and as such, a LOD of 5 
UL
−1
 could be obtained.  
 An investigation into how the rate of reaction changes with enzyme substrate 
concentration, known as Michaelis‒Menten analysis,386‒387 was next to be performed. To do this, a 
standard enzyme concentration of 100 UL
−1
 was chosen to identify any increase or decrease in rate 
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was observed with increases or decreases in substrate concentration. Substrate concentrations either 
side of 1 mM were made and tested against the standard ALP concentration and the reaction was 
again monitored over time (Figure 2.10). Increasing the substrate concentration from 1 mM does 
not significantly improve the rate of reaction as at this concentration of enzyme, all molecules of 
enzyme are in the form of the enzyme‒substrate complex and is therefore approaching the 
maximum rate, Vmax. However, decreasing the substrate concentration led to an increase in 
conversion and concentrations lower than 0.25 mM delivered quantitative conversion within 30 
minutes. Lowering the concentration further to 0.05 mM allowed for 100 UL
−1
 of ALP to give full 
conversion within just 9 minutes. Unfortunately, due to the rapid conversion observed and 
infrequent sampling, initial rates cannot be calculated and as such, the maximum rate Vmax and the 
Michaelis constant KM, for ALP could not be obtained via this method. Substrate concentrations 
lower than 0.05 mM were unable to give a strong enough signal to enable conversion to be 
calculated. Although there was minimal difference in rate between 0.05 mM and 0.5 mM substrate 
concentration, a concentration of 0.5 mM was the concentration taken forward and used in 
subsequent assays due to the significant increase in the observed current as well as improved 




Figure 2.9 ALP-catalysed conversion of enzyme substrate 112 to enzyme product 111 in the presence of 






Figure 2.10 ALP-catalysed conversion of enzyme substrate 112 to enzyme product 111 at different substrate 




Figure 2.11 ALP-catalysed conversion of enzyme substrate 112 to enzyme product 111 in the presence of 





Figure 2.12 Amperometric response from aminoferrocene 111 at −130 mV over time in the presence of 
different concentrations of ALP at 37 °C. Error bars indicate standard deviation (n = 3). The LOD is 
calculated as 3 × the standard deviation from the mean background. 
 
 Typically, the optimal working temperature for mammalian enzymes such as ALP is 37 °C 
and as a result, the next improvement to the assay was to increase the temperature.
388
  Accordingly, 
the ALP detection assays were repeated with the optimised substrate concentration at 37 °C (Figure 
2.11). The desired increase in sensitivity was indeed observed as ALP concentrations of 50 UL
−1
 
and higher were able to deliver quantitative conversions within the 30 minute assay duration. The 
increase in temperature also allowed an ALP concentration of 1 UL
−1
 to be distinguished from the 
background rate. However, in order to calculate an accurate LOD, the average background current 
needs to be determined and compared to the current obtained for the enzyme product under 
different concentrations of ALP. Therefore, the raw current of aminoferrocene 111 at −130 mV 
obtained for the assays ran with enzyme concentrations of 50 UL
−1
 and lower was plotted against 
time (Figure 2.12). 
 The fluctuations in current due to a culmination of problems associated with POC sensing 
such as sampling and electrode errors are immediately apparent when using solely current as the 
output signal. This reinforces the increase in accuracy that can be attained by using ratiometric 
sensing as the detection method. Fortunately, the observed background current is sufficiently low 
and consistently low as demonstrated by the tight error bars. This enables an ALP concentration of 
5 UL
−1
 to be easily distinguished from the background when using substrate 112 and product 111 
as an amperometric detection system. A plot of the current response of 111 against the log of the 
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enzyme concentration allows for a LOD for ALP to be calculated at 0.3 pM after a 27 minute 
incubation period at 37 °C (Figure 2.13). 
 
 
Figure 2.13 A plot of the amperometric response obtained from aminoferrocene 111 at −130 mV after 27 
minutes at 37 °C vs. the log10 of the ALP concentration. R
2
 = 0.98.  
 
 
2.3.4 Application of the Enzyme Substrate towards Immunosorbent Assays 
With the concentration of the substrate and the temperature of the assay optimised, the next goal 
was to apply the substrate to a solid-supported immunoassay. Prior to this however, the substrate 
was tested with an ALP‒conjugate in order to determine whether structural modification of the 
enzyme would significantly disrupt enzyme activity. In addition, the considerable size of the 
protein could hinder the approach of the substrate, which may also contribute to a decrease in 
turnover number. To test this potential problem, the streptavidin‒ALP conjugate was chosen as 
streptavidin can be utilised to tag ALP to biotin-labelled antibodies via the highly favourable 
streptavidin‒biotin binding. This could be useful information with regard to a successful 
immunoassay design that could be incorporated onto a cartridge in the future. As such, a 0.5 mM 
solution of ferrocene-derived ALP substrate 112 was exposed to varying concentrations of 
streptavidin‒ALP at 37 °C (Figure 2.14). 
 Pleasingly, protein‒enzyme conjugation did not lead to a significant decrease in enzyme 
activity towards substrate 112 as positive conversions were observed. Protein‒enzyme 
concentrations higher than 25 mgL
−1
 delivered quantitative electrochemical conversions in 30 
minutes. Again, in the absence of the protein‒enzyme conjugate, no electrochemical conversion 
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was observed. This allowed for a protein‒enzyme detection limit to be in the micromolar range as 
0.5 mgL
−1




Figure 2.14 ALP-catalysed conversion of enzyme substrate 112 to enzyme product 111 in the presence of 




Scheme 2.23 Construction of the ALP-labelled sandwich ELISA for electrochemical CRP detection. 
 
 Since determining that enzyme conjugation does not prevent substrate turnover, the next 
test was to apply substrate 112 towards an immunosorbent assay for ratiometric electrochemical 
protein detection. A commercial ELISA kit for the detection of C-reactive protein (CRP) that uses 
ALP as the enzyme label was chosen as a model immunoassay. CRP is a plasma protein that is 
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produced by the body as a response to inflammation and because of this, it has been used 
extensively as a diagnostic biomarker primarily for the detection of inflammation but it can also be 
used to indicate impending major cardiovascular events such as coronary heart disease.
389
 The 
sandwich ELISA was constructed according to the manufacturer’s procedure (Scheme 2.23) using 





Figure 2.15 Electrochemical conversion obtained for different concentrations of CRP with ALP substrate 



























Figure 2.16 Current obtained for different concentrations of CRP with either ALP substrate 112 or AA2P 
105 at 37 °C. 
 
 Gratifyingly, positive conversions were observed for most CRP concentrations tested and 
no conversion was seen in the absence of CRP which demonstrates the low susceptibility of 
ratiometric sensing towards false positive results. Quantitative conversions were unable to be 
attained using an ALP-labelled ELISA in comparison to the tests composed with the free enzyme 
as this is thought to be due to the lack of mechanical stirring and the enzyme label being surface-
bound. However, the use of the ratiometric electrochemical detection method was shown to have 
excellent reproducibility as shown by the tight error bars which indicate the standard deviation 




























Figure 2.17 Voltammogram overlays of electrochemical CRP ELISAs using substrate AA2P 105. Oxidation 
potential for product AA 152 is typically between 350 and 500 mV. Spikes observed at 0 mV is due to the 
oxidation of the silver reference electrode. 
 
 To compare ALP substrate 112 with a commonly-used substrate, the ELISAs were 
repeated but this time electrochemical detection was achieved using either 112 or commercially 
available substrate AA2P 105 as the enzyme substrate (Figure 2.16). In addition, the temperature of 
the incubation with the enzyme substrate was increased to 37 °C to increase enzyme activity and 
therefore improve the current response for the products of both substrates. Similar current 
responses were observed for both substrates at low concentrations of CRP but at higher 
concentrations, substrate 112 was capable of delivering a significantly higher current than AA2P 
105. Despite the similar current responses, the Gaussian peak observed for the product of substrate 
112 imparts a greater confidence in the output signal in comparison to the broad hump observed for 
AA 152, the product of AA2P 105, whose absolute oxidation potential can vary considerably 
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reliability and improved accuracy for inclusion within an electrochemical POC device over a 
‘switch on’ detection method. 
 
2.4 Conclusion 
2.4.1 Project Summary 
Towards implementation within a commercial point-of-care biosensor for rapid and sensitive 
protein detection, a novel electrochemical substrate for the ratiometric detection of the enzyme 
alkaline phosphatase was designed. Through a highly telescoped procedure, the substrate was 
successfully synthesised in just 3 steps in 14% overall yield. Once synthesised, the substrate was 
shown to be stable indefinitely as a pure solid stored in a desiccator and also demonstrated 
satisfactory stability as a concentrated solution in alkaline buffer. The substrate was shown to have 
a significantly different oxidation potential from that of the product which enables ALP detection 
to be ratiometric. Through 
31
P NMR experiments, ALP was shown to act upon the substrate and 
using electrochemical analysis, the desired product was detected at the electrode demonstrating its 
release from the desired elimination of the dephosphorylated intermediate. 
 An optimisation of the ratiometric ALP detection assay revealed an optimal substrate 
concentration of 0.5 mM that delivered both quantitative conversion and a large current response 
within 30 minutes. Increasing the temperature of the detection assay also improved the rate of 
conversion allowing for a LOD of 0.3 pM ALP concentration to be detected within this timeframe. 
Protein-conjugated enzymes were shown not to affect reaction conversion as a streptavidin–ALP 
conjugate also demonstrated high activity allowing for less than 1 mgL
−1
 of the enzyme conjugate 
to be detected. 
 Since ALP is often used as the enzyme label within enzyme-linked immunosorbent assays, 
the substrate was also applied to the ratiometric electrochemical detection of proteins via an 
ELISA. Moderate conversions were obtained for the detection of model analyte C-reactive protein, 
but more importantly, conversions were highly reproducible owing to the ratiometric detection 
method. In comparison to L-ascorbic acid 2-phosphate (AA2P), a commonly-used switch-on 
substrate for ALP, the developed substrate delivered similar current responses when applied to the 
electrochemical detection of CRP. However, because of its ratiometric detection method, the 
developed substrate offers significant improvements over AA2P such as greater confidence in 
absolute oxidation potential as well as reproducibility. As such, the substrate described herein is 
considerably better suited for application as an electrochemical ELISA substrate within a rapid 




2.4.1 Future Work 
Including the substrate developed herein, only two substrates for ratiometric electrochemical 
enzyme detection have been described to date; one for catalytic antibodies that demonstrates 
aldolase activity and the one herein for alkaline phosphatase. To increase the number of hydrolytic 
enzymes that can be detected through ratiometric electrochemical detection, and therefore expand 
the repertoire of potential point-of-care biosensors, other ferrocene-derived substrates that contain 
alternative enzyme-cleavable functional groups could be developed. For example, substrates 
containing sulfate 153, amide 154, acetate 155 or sugar moieties 156, would enable the ratiometric 
electrochemical detection of sulfatase, protease, esterase or glycosylase enzymes respectively, via 
the same elimination mechanism (Figure 2.18). 
 
 
Figure 2.18 The design of different ferrocene-derived substrates for the potential ratiometric electrochemical 
detection of alternative enzymes. 
 
 Additionally, the use of traditional alcohol protecting groups such as allyl 157 or silyl 158 
groups as the analyte-responsive trigger could extend this methodology towards the ratiometric 
electrochemical detection of palladium or fluoride respectively, both of which being of diagnostic 
interest (Figure 2.19). Furthermore, masked phenols such as phenylboronic acid 159 could also be 
used as the trigger moiety for the ratiometric electrochemical detection of hydrogen peroxide. By 
extension, this could allow for the indirect detection of hydrogen peroxide-producing enzymes such 
as glucose oxidase, and therefore the possibility for the diagnosis of diabetes, through this method. 
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Inversely, hydrogen peroxide consuming enzymes such as horseradish peroxidase could also be 
detected with this probe enabling a reverse protein detection strategy to be achieved using more 
popular HRP-labelled ELISAs (Figure 2.20). 
 
 
Figure 2.19 The design of different ferrocene-derived probes for the potential ratiometric electrochemical 
detection of palladium or fluoride. 
 
 
Figure 2.20 The design of a boronic acid-containing ferrocene-derived probe for the direct ratiometric 





Enzyme-Triggered Catalytic Signal Amplification
390‒391 
3.0 Introduction 
3.0.1 Signal-Amplified Enzyme-Linked Immunosorbent Assays 
In order to improve the sensitivity of a diagnostic assay, some degree of amplification is absolutely 
essential. Although enzyme-linked immunosorbent assays (ELISAs) contain inherent amplification 
from the enzyme, efforts have been directed at replacing the enzyme with alternatives that either 
have a higher turnover rate or can provide increased amplification through other means. 
Considerable success has been achieved by replacing the enzyme label with nucleic acid labels, 
which has allowed nucleic acid amplification techniques such as the polymerase chain reaction 
(PCR) and rolling circle amplification (RCA) to be used for signal amplification purposes. 
Typically, detection limits are improved up to 10000-fold by this method. Despite achieving these 
excellent sensitivities, the amplification procedure is complex in comparison to a standard ELISA 





Scheme 3.1 Gold nanoparticle-labelled sandwich immunoassay for the electrochemical detection of PSA. 
 
 Alternatively, nanoparticles possessing useful characteristics such as catalytic activity and 





 For example, Yang et al. described the use of gold nanoparticles as the 
immunoassay label within an electrochemical immunoassay for sensitive protein detection (Scheme 
3.1).
395
 First, capture antibodies were immobilised onto a ferrocene-coated indium tin oxide (ITO) 
electrode via a streptavidin‒biotin linkage. In the presence of the target, prostate specific antigen 
(PSA), a standard sandwich immunoassay is formed with the antibody-coated gold nanoparticles. 
The gold nanoparticles were then demonstrated to catalyse the reduction of p-nitrophenol (PNP) 18 
to p-aminophenol 160, which can be detected at a facile oxidation potential due to the ferrocene-
modified electrodes. Further amplification is provided through redox cycling as the oxidised 
quinone product 161 can be reduced by the reducing agent present.
396
 Together; a competitive 
detection limit of 1 fgmL
−1
 for PSA was obtained. Similar electrochemical immunoassays that use 





Scheme 3.2 Copper oxide nanoparticle-labelled sandwich immunoassay for colourimetric HIV antigen 
detection. 
 
 Nanoparticles have also been used as antibody labels to provide a colourimetric detection 
method within immunoassays. One example specifically was described by Jiang et al., who used 
copper oxide nanoparticle labels to catalyse the aggregation of gold nanoparticles for the detection 
of human immunodeficiency virus (HIV) antigens (Scheme 3.2).
398
 Here, a direct immunoassay 
was constructed where the antigen was adsorbed onto the surface of the microtitre well and 
identified with a primary antibody. This complex was then labelled with a secondary antibody 
tagged with copper oxide nanoparticles. In the presence of the nanoparticles, and therefore the 
analyte, the introduction of a strong, acidic solution to the assay dissolves the copper nanoparticles, 
releasing Cu
2+
 ions into the system. Once released, the Cu
2+
 ions can catalyse the Huisgen 
cycloaddition reaction between two sets of gold nanoparticles; one set covered with terminal 
alkynes and the other covered with alkyl azides. After a significant number of gold nanoparticles 
have been knitted together, the aggregation causes the colour of the solution to change from red to 
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blue. In the absence of the antigen, the copper catalyst is not produced and the gold nanoparticles 
remain separate keeping the detection solution red. Although not explicitly stated, the LOD 
obtained for this detection method was said to rival that of a traditional fluorescence ELISA. 
 
 
Scheme 3.3 Plasmonic ELISA for the colourimetric detection of disease biomarkers with the naked eye. 
 
 Rather than replacing the enzyme, recent efforts to increase the sensitivity ELISAs have 
been aimed towards the application of additional amplifiers. Of particular note, de la Rica and 
Stevens developed a plasmonic ELISA for the visual detection of disease biomarkers (Scheme 
3.2).
399
 In this example, a traditional sandwich ELISA labelled with catalase, an enzyme that 
catalyses the breakdown of hydrogen peroxide, was constructed. In the presence of the target, and 
therefore the enzyme, hydrogen peroxide is broken down to water and molecular oxygen which 
allows the solution containing Au
3+
 ions to form ill-defined nanoparticles that aggregate together 
leading to a blue colour to be developed. In the absence of the target, hydrogen peroxide remains in 
solution and reduces the Au
3+
 ions in the solution to Au
0
. This leads to the formation of regular, 
spherical nanoparticles that do not aggregate together and causes a red colour to be developed. This 
example of gold nanoparticle label amplification in conjunction with enzyme signal amplification 
allowed for a limit of detection (LOD) of 1 agmL
−1
 for the detection of PSA and enabled the visual 
detection of HIV antigens at concentrations that were undetectable by a traditional nucleic acid-
based test. This has since given rise to the development of a number of biodiagnostic tests that 
utilise plasmonic nanomaterials for both amplification and signal production.
400
 However, it has 
been identified that successful and accurate signal production is highly dependent on a freshly 
prepared and precise concentration of hydrogen peroxide.
401
 Because of this and the poor stability 




3.0.2 Project Aims 
Although there have been several disclosures regarding amplification techniques aimed towards 
improving the sensitivity of ELISAs, few utilise electrochemical endpoint detection and those that 
do,
93,395
 are too impractical to be integrated into a POC device. Continuing on from the substrate 
development for the ratiometric electrochemical detection of alkaline phosphatase (ALP)-labelled 
ELISAs, the next objective was to design a signal amplification protocol for ALP that utilised the 
same endpoint detection method. This should improve the sensitivity of the ELISA and therefore 
lower the LOD of the system, yet still allow detection to be achieved using ratiometric 
electrochemical analysis.  
 
3.1  Signal-Amplified Ratiometric Electrochemical Enzyme-Linked Immunosorbent 
 Assay 
3.1.1 Signal Amplification Concept 
As previously discussed, a large number of ELISA amplification methodologies are aimed at 
replacing the enzyme label with alternative amplifiers such as nanoparticles that offer either an 
improved turnover rate or an orthogonal detection method that doesn’t require substrate 
development. However, amplifier‒antibody conjugation can be inefficient and signal production 
can be slow and labour intensive. As such, their application within POC sensing is limited. 
Fundamentally, a strategy that replaces the enzyme of an ELISA with another amplifier appears 
counterintuitive and efforts should be made towards building upon the inherent amplification of an 
ELISA. Towards this end, a double-catalyst signal amplification concept for an ELISA was 
designed (Figure 3.1). 
 
 
Figure 3.1 Concept of a double-catalyst signal amplification protocol for increasing ELISA sensitivity in 
comparison with a traditional single-catalyst signal amplification protocol. 
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 Prior to beginning of this project, the idea of a double-catalyst signal amplification 
procedure for an ELISA had only been illustrated in principle.
402
 A number of amplification 
methodologies that utilise either enzyme cycling,
403
 or redox cycling,
404
 as post-enzyme 
amplification procedures have been described and can offer improved LODs. However, accidental 
triggering of these cycling methods can lead to high background signals and the possibility of false 
positive results. The successful demonstration of an enzyme-triggered catalyst activation procedure 
for ELISA signal amplification had remained elusive until, when during the development of this 





Scheme 3.4 Double-catalyst ELISA signal amplification protocol for the colourimetric detection of PSA. 
 
 In this example, a typical sandwich ELISA was constructed aimed towards the detection of 
PSA and using ALP as the enzyme label. In the presence of the enzyme, and therefore the target, 
commercially available ALP substrate L-ascorbic acid 2-phosphate (AA2P) 105 becomes 
hydrolysed to ascorbic acid (AA) 152. AA was then able to reduce a palladate species to the active 
catalytic palladium nanostructures that aggregate upon the surface of non-participating gold 
nanoparticles.
406
 As a peroxidase mimic, the palladium nanostructures can catalyse the hydrogen 
peroxide-mediated oxidation of 3,3’,5,5’-tetramethylbenzidene (TMB) 163 to its corresponding 
blue diimine 164.
407
 Through an extensive screening process, a positive colourimetric signal was 
shown to only be produced by the palladium nano-catalysts which themselves were only created in 
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the presence of ALP, consequently leading to a low background signal. Importantly, the double-
catalyst signal amplification procedure was shown to be significantly more sensitive than a 
traditional single-catalyst ELISA and could deliver an LOD of 0.05 ngmL
−1
 for the detection of 
PSA. However, due to the number of reagents required to acquire a positive signal, the procedure is 
considerably labour-intensive and requires the time-consuming preparation of gold nanoparticles. 
Nevertheless, the powerful concept of enzyme-triggered catalyst activation as a signal 
amplification protocol for improving immunoassay sensitivity had been proven.  
 
3.1.2 Secondary Catalytic Signal Amplification 
At the outset of this investigation, development of the second catalytic amplification step was the 
primary focus as this would be the step responsible for the production of the ratiometric 
electrochemical signal. For the active catalytic species, an organometallic catalyst was initially 
considered since catalytic activity could be regulated through careful control of ligands. However, 
for successful deployment into an electrochemical POC biosensor, the catalyst must fulfil a number 
of criteria, such as; high efficiency, excellent water-tolerance, low toxicity and good reliability. 




Scheme 3.5 Iridium-catalysed transfer hydrogenation of benzaldehyde 165 to benzyl alcohol 167. 
 
 Among the comprehensive number of catalytic organic transformations that occur in 
aqueous media, many involve the use of high pressures, high temperatures or long reaction times 
and were therefore unsuitable.
408
 In contrast, a range of water-soluble iridium-based catalysts have 
recently shown high efficiency within applications such as hydrogen storage,
409
 and water 
oxidation,
410





 and the oxidation of alcohols.
413
 One transformation in particular that possessed the 
desired characteristics to be employed within this signal amplification concept was the iridium-
catalysed transfer hydrogenation reaction.
414‒417
 When applied to the reduction of benzaldehyde 
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165, a transfer hydrogenation iridium–diamine complex 166 has been shown to deliver quantitative 
conversion to benzyl alcohol 167 at a catalytic loading of 0.01 mol% in water within an hour 
(Scheme 3.5).
418
 Also, by increasing the catalytic loading, reaction times could be shortened to just 
5 minutes whilst maintaining quantitative conversions. 
 
 
Scheme 3.6 Literature conditions applied to the iridium-catalysed transfer hydrogenation of 
ferrocenecarboxaldehyde 169 to ferrocenemethanol 170. 
 
 
Figure 3.2 Differential pulse voltammogram of a 1 mM solution of ferrocenecarboxaldehyde 169 in pH 9 
Tris buffer.  
 
 Impressed with the efficiency and low catalytic loading of this process, the investigation 
therefore began with the application of these literature conditions to an electrochemically-active 
aldehyde (Scheme 3.6). Naturally, due to its facile oxidation potential, excellent stability in 
























Potential vs. Ag/AgCl (mV) 
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ferrocenecarboxaldehyde 168 was chosen as the initial electroactive aldehyde. Pleasingly, 
conversion to the desired product, ferrocenemethanol 170, was observed and could be isolated in a 
71% yield.  
 




Figure 3.4 Differential pulse voltammogram of a solution containing 0.5 mM of ferrocenecarboxaldehyde 









































Potential vs. Ag/AgCl 
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 With ferrocenemethanol 170 in hand, it was necessary to perform electrochemical analysis 
on both the starting material 169 and product 170 in order to determine if they were 
electrochemically distinguishable. Using differential pulse voltammetry (DPV), a 1 mM solution of 
ferrocenecarboxaldehyde 169 was found to have an oxidation potential of 450 mV vs. Ag/AgCl 
(Figure 3.2), whereas a 1 mM solution of ferrocenemethanol 170 was found to have an oxidation 
potential of 170 mV vs. Ag/AgCl (Figure 3.3). A difference in oxidation potential of 280 mV 
between starting material and product suggests that both should be electrochemically 
distinguishable and as such, an equimolar solution of 169 and 170 was made up and exposed to 
electrochemical analysis (Figure 3.4). 
 As desired, both starting material and product had sufficiently different oxidation potentials 
that enabled them to be separable on a voltammogram. This therefore allowed for the iridium-
catalysed conversion of aldehyde 169 to alcohol 170 to be obtained through electrochemical 
analysis of the crude reaction mixture. Peak integration of the resulting voltammogram would 
allow accurate reaction conversions to be calculated by the following equation: 
                
    
            
       
 Satisfied that the iridium-catalysed transfer hydrogenation reaction could be employed as 
the secondary catalytic signal amplification cycle, an optimisation of the reaction conditions was 
performed in order to reduce the unfavourably high temperature and long reaction time that would 
be unsuitable for application within a POC device (Scheme 3.7). To achieve this, the catalytic 
loading was initially increased and since the reaction was heterogeneous, a biocompatible organic 
co-solvent was introduced to improve the solubility of the substrate as well as reduce errors 
associated with reaction sampling. Together, this allowed for quantitative isolated yield to be 
obtained at room temperature in just 30 minutes. Additionally, this result was obtained without the 
need to pre-form the catalyst as pre-catalyst and ligand 171 could simply be added separately to 
generate the active catalyst in situ. This could lend extra applicability of this catalytic 
transformation towards signal amplification within a POC setting. 
 
 
Scheme 3.7 Optimised conditions for the iridium-catalysed transfer hydrogenation of 




 It has been shown that varying the substituents upon the aryl ring of the ligand can affect 
the rate of the transfer hydrogenation reaction.
419
 Therefore, a range of ligands with varying 
substituents upon the aromatic ring were synthesised and tested within the transfer hydrogenation 
reaction to determine if any provided an increase in rate over the standard N-tosyl-
(ethylenediamine) 171 ligand. The mono-sulfonamide(ethylenediamine) ligands were synthesised 
from the reaction between ethylenediamine 172 and the corresponding sulfonyl chlorides under 
standard conditions in moderate to good yields (Table 3.1). 
 
 
Product R Yield (%) 
a 
171 4-Me 49% 








177 4-F 21% 
178 4-Br 66% 
179 4-OMe 37% 
180 4-NO2 29% 
181 4-CF3 59% 
a isolated yields.
 
Table 3.1 Preparation of ligands 171, 173‒181. 
 
 With a range of ligands in hand containing substituents with varying steric and electronic 
demand, it was necessary to test them within the iridium-catalysed transfer hydrogenation reaction 
(Table 3.2). To determine either positive or negative effects of the ligand, the reaction was 
performed at half the optimised catalytic loading and was sampled after just 9 minutes. After 
sample dilution, the reaction was analysed by ratiometric electrochemical detection in order to 
calculate the reaction conversion. 
 Typically, electron-poor benzenesulfonamides deliver an accelerated rate when utilised 
within the iridium-catalysed transfer hydrogenation reaction. However, when applied to the 
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reduction of ferrocenecarboxaldehyde 169, both electron-poor benzenesulfonamides, p-nitro 180 
and p-trifluoromethyl 181, did not perform as well as standard p-methyl ligand 171. At the opposite 
end of the Hammett scale, electron-rich benzenesulfonamide p-methoxy ligand 179, also delivered 
poor conversion. However, the mildly electron-rich alkyl-substituted ligands offered best 
conversions with 2,4,6-trimethylbenzenesulfonamide 175 delivering a slightly better conversion 
than the tosyl derivative. As a result, mesityl derivative 175 was taken as the optimal ligand for this 
reaction and was used in all further reactions. Increasing the steric bulk of the ligand was shown to 
severely restrict reaction conversion as 2,4,6-triisopropylbenzenesulfonamide 176 performed little 
better than the background rate. This is thought to be due to either prevention of active catalyst 
formation or blocking the approach of the catalyst substrate. Significantly, in the absence of any 
ligand, minimal conversion was observed thus reinforcing the importance of the ligand with 
regards to obtaining high catalyst turnover frequencies. Therefore, as a method for selective 
catalyst activation, careful control of the ligand could be crucial in achieving a positive conversion 
in the presence of the enzyme yet a negative conversion in its absence. 
 
 
Ligand R Conversion (%) 
a 
none - 1% 
171 4-Me 40% 








177 4-F 39% 
178 4-Br 18% 
179 4-OMe 18% 
180 4-NO2 25% 
181 4-CF3 32% 
a determined by ratiometric electrochemical analysis.
 
Table 3.2 Screen of ligands 171, 173‒181 within the iridium-catalysed transfer hydrogenation reaction. 
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3.1.3 Primary Catalytic Signal Amplification 
To switch on catalytic activity selectively in the presence of an enzyme, a programmed release of 
the ligand was required. In principle, if an enzyme could release the ligand into the system, then the 
iridium-catalysed transfer hydrogenation reaction would undergo ligand acceleration and 
conversion of ferrocenecarboxaldehyde 169 to ferrocenemethanol 170 would be observed by 
electrochemical analysis. On the other hand, if an enzyme was not present, then the ligand would 
not be released into the system and the transfer hydrogenation reaction would not undergo ligand 
acceleration leaving only ferrocenecarboxaldehyde 169 to be observed on the voltammogram. 
Chemical modification of the ligand structure was initially considered as an option to prevent the 
ligand from binding to the metal and increasing its rate within transfer hydrogenation reaction. It 
was presumed that modification of the ligand with an enzyme-cleavable trigger and a linker that 
could undergo a designed elimination, would allow ligand release in the presence of the enzyme. 
Prior to that however, a range of N-methylated ethylenediamines were tested as ligands (Table 3.3), 
along with their N-mesitylsulfonamide derivatives (Scheme 3.8), within the iridium-catalysed 
transfer hydrogenation reaction (Table 3.4). This would determine both how much, and where 
substitution was required in order to prevent a successful metal–ligand binding event and 
subsequent rate acceleration from occurring. 
 
 













 Conversion (%) 
a 
172 H H H H 2% 
182 Me H H H 2% 
186 Me Me H H <1% 
188 Me H Me H 2% 
190 Me Me Me Me 0% 
a determined by ratiometric electrochemical analysis.
 










 Conversion (%) 
a 
175 H H H >99% 
184 Me H H 34% 
185 H H Me 6% 
187 Me H Me 0% 
189 Me Me H 0% 
a determined by ratiometric electrochemical analysis.
 
Table 3.4 Screen of N-methyl mesitylesulfonamido-ethylenediamine ligands within the iridium-catalysed 
transfer hydrogenation reaction. 
 
 Under the optimised conditions, ethylenediamine 172 and its mono- and di-methylated 
derivatives 182, 186 and 188 were all found to be ineffective ligands within the transfer 
hydrogenation reaction. Additionally, and somewhat expectedly, tetramethylethylenediamine 
(TMEDA) 190 was shown to completely inhibit catalyst activity. This highlights the need for a 
sulfonamide-containing ligand in order to achieve high reaction rates. Further confirmation of this 
was shown by the best performing ligand found from the ligand screen as ligand 175 delivered 
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quantitative conversion after 30 minutes. Modifying 175 with a single methyl group at the primary 
amine position, ligand 184, was shown to be enough to hamper the reaction but interestingly, was 
insufficient to shutdown reactivity completely. This was thought to be due to the fact the ligand is 
still equipped with a proton for activation of the substrate carbonyl towards hydride attack as well 
as a sulfonamide for metal insertion. Further methylation at this position, ligand 189, and thus 
disabling proton-assisted activation of the substrate carbonyl, completely inhibits reactivity as no 
conversion was at all observed. Alternatively, additional methylation on the sulfonamide nitrogen, 
ligand 187, and thus preventing metal insertion to form the active catalyst, also leads to a complete 
loss in catalytic activity. However, solely blocking the sulfonamide nitrogen with a methyl group, 














196 Bn <1% 
197 4-MeOBn 2% 
a determined by ratiometric electrochemical analysis.
 
Table 3.5 Screen of N-carbamate N-mesitylesulfonamido-ethylenediamine ligands within the iridium-
catalysed transfer hydrogenation reaction. 
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 Clearly, functionalisation at the primary amine position of mesitylsulfonamide 175 was 
sufficient in hindering ligand acceleration within the transfer hydrogenation reaction. To 
investigate this further, a number of carbamate derivatives of ligand 175 were synthesised since 
these functional groups are more amenable to elimination than a methylene group (Scheme 3.9). 
When tested within the transfer hydrogenation reaction, the carbamate derivatives of ligand 175 
were also found to be ineffective ligands (Table 3.5). Importantly, benzyl carbamates 196 and 197 
delivered negligible conversions which could allow ligand release to potentially be achieved 
through the quinone–methide elimination mechanism. 
 
3.1.4 Enzyme Substrate Design and Synthesis 
 
 




 Consequently, compound 198 was designed armed with a phosphate trigger enabling 
ligand release to be achieved through ALP-catalysed hydrolysis (Scheme 3.10). Enzyme substrate 
198 was subsequently termed a ‘proligand’ since it was designed not to act like a ligand in its 
current form, but could undergo a functional group transformation to create an active ligand. In 
principle, a low background reaction should be seen in the absence of an enzyme as the proligand 
should remain protected as carbamate 198. Yet in the presence of the enzyme, enzyme-catalysed 
hydrolysis of the enzyme substrate would give phenolate 199. 1,6-elimination and subsequent 
decarboxylation should then release ligand 175 into the system and once released, the ligand can 
bind to the iridium pre-catalyst to form active catalyst 200, which would have an increased rate 
within the catalytic transfer hydrogenation reaction. This would lead to a faster turnover of 
ferrocenecarboxaldehyde 169 to ferrocenemethanol 170, which could be monitored through 
ratiometric electrochemical analysis. 
 
 
Scheme 3.11 Retrosynthetic analysis of proligand 198. 
 
 To prove this concept, proligand 198 first had to be synthesised. Retrosynthetic analysis of 
198 revealed that, after phosphate protection, bis-protected compound 201 could simply be 
achieved through coupling of ligand 175 with a bis-protected phosphoryl benzyl alcohol such as 
149 through the use of a carbonyl coupling reagent such as 1,1’-carbonyldiimidazole (CDI) 202 
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(Scheme 3.11). Towards this end, the synthesis of proligand 198 began with the coupling of 
previously synthesised benzyl alcohol 149 to optimal ligand 175 using CDI 202 under standard 
conditions, which afforded carbamate 201 in good yield (Scheme 3.12). The previously optimised 
allyl deprotection conditions were then applied to bis-allyl protected phosphate 201 and were also 
found to be effective for this substrate as full consumption of starting material was observed. 
However, owing to the poor solubility of product 198 in any solvent, purification by preparative 
reverse phase C18-silica gel column chromatography or recrystallisation was unachievable. 
Fortunately, allyl deprotection typically occurs cleanly and owing to the polymer-supported 
catalyst and volatility of the reagents, crude compound 198 could still be obtained in high enough 
purity. Typically, 
31
P NMR was a single peak corresponding to the product and 
1
H NMR shows 
mainly product with sodium formate, arising from deprotonation of leftover formic acid from the 
deprotection step, as the sole minor impurity. Since sodium formate is used as the hydride source in 
the transfer hydrogenation reaction, this impurity was thought not to affect the outcome of any 








Proligand 198 ALP Buffer Yield (%) 
a 
2 mol%  0 UmL
−1
 H2O 4% 
2 mol% 100 UmL
−1
 pH 9 Tris 95% 
0 mol% 100 UmL
−1
 pH 9 Tris 29% 












Table 3.5 Background reactions. 
 
 With proligand 198 in hand, it was necessary to test it as a ligand within the transfer 
hydrogenation reaction (Table 3.5). In the absence of any enzyme, a low yield of 
ferrocenemethanol 170 was obtained showing that, in water, the proligand does not contribute to 
undesired reaction acceleration. Pleasingly, in the presence of ALP in its optimal pH 9 Tris buffer, 
a near quantitative yield of 170 was obtained with proligand 198. To confirm whether conversion 
of ferrocenecarboxaldehyde 169 to ferrocenemethanol 170 was occurring through the proposed 
mechanism, the reaction was repeated in the absence of the proligand. Unfortunately, a 
significantly large background reaction was observed which could be due to either enzyme 
stabilisers or the enzyme itself, or components of the buffer solution. Since ethylenediamine- and 
ethanolamine-like compounds present in both the buffer and as enzyme stabilisers, or bidentate 
amino acid side-chains on the enzyme, could act as ligands themselves within the transfer 
hydrogenation reaction, the assay was repeated in an ALP-compatible buffer that did not contain 
these classes of structures. The change in buffer resulted in a dramatic reduction in the background 
rate as no conversion to ferrocenemethanol 170 whatsoever was observed. This points to 
components in the buffer, most probably tris(hydroxymethyl)aminomethane (Tris) itself, as the 
main culprit for the previously observed high background rate. To ensure the positive reaction 
maintained a high conversion despite the buffer change, the reaction was again repeated but this 
time with the inclusion of proligand 198. Again, a high isolated yield of ferrocenemethanol 170 
was obtained which, with greater certainty, can be attributed to enzyme triggered release of ligand 
175 from the proligand and subsequent ligand-acceleration of the transfer hydrogenation reaction.  
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3.1.5 Mechanistic Studies 
In order to determine that the observed conversion of ferrocenecarboxaldehyde 169 to 
ferrocenemethanol 170 was occurring through the proposed mechanism, a number of mechanistic 
studies were performed. First, to confirm that the proligand can be selectively hydrolysed by ALP, 
a buffered solution of 198 was exposed to ALP and the interaction monitored by 
31
P NMR (Figure 
3.5). Indeed, when a 50 mM buffered solution of 198 was treated with 5 UmL
−1
 of ALP, the peak at 
−0.15 ppm corresponding to proligand 198 slowly decreases over time. Concomitantly, a peak at 
2.25 ppm corresponding to the free phosphate slowly increases over time. A repeat experiment in 
the absence of ALP did not lead to the deconstruction of proligand 198 over the same time period, 
which shows that dephosphorylation occurs only in the presence of ALP. Similarly to previous, the 
protic aqueous buffer required for enzyme activity prohibits the use of 
1
H NMR to identify any 
reaction intermediates, such as quinone methide or 4-hydroxybenzyl alchohol, or product 175. 
Additionally, attempts to isolate and characterise ligand 175 after the reaction was complete to 
confirm its release as a result of dephosphorylation were unsuccessful. For further mechanistic 
elucidation, an orthogonal reaction-monitoring technique was required. 
 
 
Figure 3.5 Stacked 
31




 In order to detect the intermediate phenol and elimination products such as quinone 
methide or 4-hydroxybenzyl alcohol as well as the production of ligand 175 from the reaction of 
proligand 198 with ALP, the reaction was then monitored using direct infusion electrospray 
ionisation ultrahigh resolution time-of-flight mass spectrometry (ESI-UHR-TOF MS). In negative 
ion mode, an initial 3 mM solution of 198 in water was directly injected at rate of 3 μLmin−1 for 10 
minutes and over this time period, only the peak corresponding to the [M−H]− mass ion for 
hydrogen phosphate 204 was observed (Figure 3.6). This confirms the stability of proligand 198 to 
both undesired hydrolysis as well as the ionisation technique used for MS analysis. 
 
 
Figure 3.6 Accumulative averaged mass spectrum acquired over a 10 minute period of proligand 198 in 
water prior to the addition of ALP. 
 
 
Figure 3.7 Accumulative averaged mass spectrum acquired over a 3 minute period of proligand 198 in water 
6 minutes after the addition of ALP. 
 
 
Figure 3.8 Accumulative averaged mass spectrum acquired over a 2 minute period of proligand 198 in water 
29 minutes after the addition of ALP. 
 
 Upon the addition of a buffered solution of ALP, a peak corresponding to the [M−H]− mass 
ion for deprotonated sulfonamide anion 205 becomes immediately apparent (Figure 3.7). This 
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shows that, once proligand 198 undergoes ALP-catalysed dephosphorylation, 1,6-elimination and 
decarboxylation of the intermediate phenolate 199 occurs and ligand 175 was released as desired. 
After a 30 minute reaction period, the peak corresponding to the [M−H]− mass ion for 204 
disappears indicating that full consumption of the enzyme substrate occurs over time as expected 
(Figure 3.8). Additionally, the peak corresponding to the [M−H]− mass ion for 205 increases with 
intensity over time indicating that as proligand 198 was consumed, the concomitant production of 
ligand 175 also occurs. Clarification of this observation can be better provided through a plot of the 
intensities for both [M−H]− mass ion peaks for 204 and 205 over time (Figure 3.9). The peak 
corresponding to the [M−H]− ion for 4-hydroxybenzyl alcohol was not evident under these 
conditions, as loss of the phenolic proton would lead to a 1,6-elimination to release hydroxide and 
the resulting neutral quinone methide would be undetectable by MS in negative ion mode. 
Nevertheless, release of ligand 175 was indeed occurring as a direct result of enzyme-catalysed 
hydrolysis of proligand 198. 
 
 
Figure 3.9 Peak intensities representing proligand 198 and ligand 175 over time after the addition of ALP. 
 
 Having proven that the iridium-catalysed transfer hydrogenation reaction could be 
selectively accelerated through enzyme activity and that this occurs through the programmed 
release of a ligand from a proligand, the next objective was to optimise the enzyme-triggered 




3.1.6. Optimisation of the Enzyme Detection Assay 
Initially, a study into the optimal catalytic loading of the iridium–ligand catalyst 200 was first 
required in order to determine the concentration of proligand 198 needed to deliver efficient 
enzyme-triggered ligand-accelerated catalytic signal amplification. Specifically, identification of 
the lowest catalytic loading that delivered quantitative electrochemical conversion in the shortest 
amount of time was sought. Towards this end, ferrocenecarboxaldehyde 169 was exposed to 
different catalytic loadings of iridium catalyst 200 and the reaction was monitored every 3 minutes 
using ratiometric electrochemical analysis (Figure 3.10). 
 
 
Figure 3.10 Electrochemical conversion of aldehyde 169 to alcohol 170 under different catalytic loadings at 
room temperature. 
 
 At a catalyst loading of 0.5 mol%, only ≈50% electrochemical conversion of 
ferrocenecarboxaldehyde 169 to ferrocenemethanol 170 was observed after 30 minutes at room 
temperature. Doubling the catalyst loading to 1 mol% afforded quantitative electrochemical 
conversion within the same time period. Doubling the catalytic loading again to 2 mol% delivered 
quantitative electrochemical conversion within just 3 minutes. Importantly, in the absence of the 
ligand, <1% conversion was observed after 30 minutes showing the dramatic signal change that can 
be achieved through ligand acceleration. 
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 Encouraged by the efficiency of the iridium-catalysed transfer hydrogenation reaction at 2 
mol%, the next step was to apply this catalytic loading towards the detection of ALP by replacing 
ligand 175 with proligand 198 (Figure 3.11). Pleasingly, in the presence of high concentrations of 
ALP (10 and 100 UmL
−1
), positive conversions were indeed observed over a 30 minute reaction 
time. However, an ALP concentration of 1 UmL 
−1
 could not be confidently discerned from the 
background rate, which had increased slightly through the use of proligand 198. Nevertheless, the 
enzyme-triggered catalytic signal amplification methodology had been successfully demonstrated 
in one pot without the need for protection, separation or manipulation of the reagents, ideal for use 
within an automated POC device.  
 
 
Figure 3.11 Electrochemical conversion of aldehyde 169 to alcohol 170 in the presence of different enzyme 
concentrations at room temperature. 
 
 Of particular interest is the sigmoidal shape of the reaction profiles as this indicates that 
there are two distinct phases to the enzyme-triggered catalytic signal amplification methodology. 
Initially, there is a catalyst activation period where enzyme-triggered ligand release and subsequent 
active catalyst complex formation is effectively rate limiting. Once a sufficient proportion of the 
enzyme substrate has been consumed and a significant number of ligands have been released, then 
the number of active catalysts in the system is increased which leads to the pseudo-exponential rate 
increase. After this, a standard reaction profile is observed where consumption of the starting 
material leads to a plateau in rate. These sigmoidal profiles are indicative of an exponential-type 
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signal amplification mechanism being in effect, as previously reported double catalyst, 




Figure 3.12 Electrochemical conversion of aldehyde 169 to alcohol 170 in the presence of different enzyme 
concentrations at room temperature. 
 
 In order to improve the sensitivity of the assay, iridium precatalyst and proligand 198 
loading was doubled to 2 mol% and 4 mol% respectively, as it was thought that this would increase 
turnover of the aldehyde substrate (Figure 3.12). At an enzyme concentration of 100 UmL
−1
, this 
led to an increase in conversion and a sharper exponential signal increase. However, since a larger 
amount of proligand 198 needs to be hydrolysed to achieve complete catalyst acceleration, a lower 
enzyme concentration of 10 UmL
−1
 was found to be unable to do this and as such, a longer catalyst 
activation period and an associated lower conversion was therefore observed. Additionally, the 
increase in catalytic loading also provided an increase in the undesired background reaction. 
Resultantly, the catalytic loading was returned to 2 mol% and a study into assay temperature was 




Figure 3.13 Electrochemical conversion of aldehyde 169 to alcohol 170 in the presence of different enzyme 
concentrations at 25 °C. 
 
 
Figure 3.14 Electrochemical conversion of aldehyde 169 to alcohol 170 in the presence of different enzyme 
concentrations at 37 °C. 
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 Increasing the temperature to 25 °C enabled quantitative conversions of 
ferrocenecarboxaldehyde 169 to ferrocenemethanol 170 within 30 minutes at enzyme 
concentrations of 10 UmL
−1
 and higher (Figure 3.13). The increase in temperature also allowed for 
an enzyme concentration of 1 UmL
−1
 to be distinguished from the background within the same 
timeframe. Incidentally, the background reaction is also increased due to the rise in temperature 
which prevents an enzyme concentration of less than 0.1 UmL
−1
 from being detected. Increasing 
the reaction temperature further, to 37 °C to coincide with the optimum working temperature of the 
enzyme also delivered an improvement to assay sensitivity as expected (Figure 3.14). Again, 
quantitative conversions were observed at high enzyme concentrations and at 1 UmL
−1
, a much 
greater conversion was obtained. Despite another slight increase in the background reaction, an 
enzyme concentration of 0.1 UmL
−1
 was now distinguishable. 
 
 
Figure 3.15 Electrochemical conversion of aldehyde 169 to alcohol 170 in the presence of an initial enzyme 
concentration of 0.1 UmL
−1
 at 37 °C. After 30 minutes, the assay was spiked with either 2 mol% of ligand 
175 or 100 UmL
−1
 of ALP. Error bars indicate standard deviation (n = 3). 
 
 The proposed mechanism of this enzyme-triggered catalytic signal amplification 
methodology contains a number of potential bottlenecks which could limit the sensitivity of the 
assay. These were identified as enzyme-catalysed hydrolysis of proligand 198, elimination and 
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release of ligand 175 from phenolate intermediate 199, ligand–metal complexation to form active 
catalyst 200 and the iridium-catalysed transfer hydrogenation reaction itself. In order to determine 
which step was rate-limiting, specific spiking experiments were performed (Figure 3.15).  
 To begin with, the assay for the detection of 0.1 UmL
−1
 was performed analogous to 
previous and ran for 30 minutes, with sampling every 3 minutes. After this period, the assay was 
first spiked with ligand 175 to determine if either ligand release or enzyme-catalysed hydrolysis 
was rate limiting. Immediately after the introduction of ligand 175, dramatic rate acceleration was 
observed with quantitative conversion being achieved within 6 minutes after ligand addition. This 
indicated that the iridium pre-catalyst was still available to undergo metal–ligand complexation to 
form active catalyst 200 as rapid transfer hydrogenation was seen after the addition of ligand 175. 
To distinguish between whether enzyme-catalysed hydrolysis of proligand 198 or release of ligand 
175 from intermediate phenolate 200 were rate limiting, the assay was repeated but after 30 
minutes, the assay was spiked with 100 UmL
−1
 of ALP.  Again, as a consequence of the spike, 
significant rate acceleration was observed. This indicates that at low concentrations of ALP, the 
enzyme substrate is not being hydrolysed quick enough to release sufficient amounts of ligand 175. 
Therefore, enzyme-catalysed hydrolysis of proligand 198 was concluded as being the rate-limiting 
step of the enzyme-triggered catalytic signal amplification methodology. 
 
 
Figure 3.16 Electrochemical conversion of aldehyde 169 to alcohol 170 in the presence of different enzyme 
concentrations at 37 °C with an additional 30 minute incubation period. 
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 Armed with this knowledge, further attempts to improve the sensitivity of the signal 
amplification methodology were aimed at increasing the rate of enzyme-catalysed hydrolysis of 
proligand 198. Towards this end, an incubation period, where the enzyme and the enzyme substrate 
were reacted together prior to the addition of the potentially interfering signal amplification 
reagents, was included within the procedure (Figure 3.16). The introduction of an incubation period 
allowed enzyme concentrations of 10 UmL
−1
 or higher to deliver quantitative conversions within 
15 minutes. The sensitivity of the assay was also increased by an order of magnitude as an enzyme 
concentration of 0.01 UmL
−1
 could now be distinguished from the background rate. 
 
 
Figure 3.17 Electrochemical conversion of aldehyde 169 to alcohol 170 in the presence of different enzyme 
concentrations at 37 °C with a 30 minute incubation period at double concentration. 
 
 Looking to increase sensitivity further, the reaction concentration of the incubation period 
was investigated next (Figure 3.17). Doubling the concentration of the incubation delivered higher 
conversions for lower concentrations of ALP. However, the working range of the detection 
methodology becomes limited as quantitative electrochemical conversions were not observed under 
any concentration of ALP. Instead, high ALP concentrations across three orders of magnitude all 
delivered similar conversions of ≈80%. As a result, the concentration of the incubation period was 





Figure 3.18 A plot of the electrochemical conversion of aldehyde 169 to alcohol 170 3 minutes after the 
addition of the signal amplification reagents vs. the log10 of the ALP concentration. R
2
 = 0.99. 
 
 Due to the rapid conversions seen under these conditions, a plot of the conversion obtained 
3 minutes after the addition of the signal amplification reagents against the log of the enzyme 
concentration enabled a LOD for ALP to be calculated at 7.6 pM after a 33 minute total assay time 
at 37 °C (Figure 3.18). The significant background reaction observed with the signal amplification 
methodology means that this detection assay is not as sensitive as the reagent-based detection 
method previously described. However, it does have a bigger dynamic range as enzyme 
concentrations over 5 orders of magnitude can be accurately distinguished compared to 3 orders of 
magnitude seen with the reagent-based approach. 
 
3.1.7 Application of Enzyme-Triggered Catalytic Signal Amplification towards Immunosorbent 
 Assays 
Prior to the application of enzyme-triggered catalytic signal amplification to an enzyme-linked 
immunosorbent assay (ELISA), the amplification methodology was tested with streptavidin-
conjugated ALP. Again, this was to determine if the structural modification of the enzyme would 
prevent enzyme-catalysed hydrolysis of enzyme substrate 198 due to denaturisation or through 
steric hindrance. As such, a 1 mM solution of proligand 198 was incubated with varying 
concentrations of streptavidin–ALP for 30 minutes prior to the addition of the signal amplification 
reagents. After which, conversion of ferrocenecarboxaldehyde 169 to ferrocenemethanol 170 was 
monitored for a further 30 minutes via ratiometric electrochemical analysis (Figure 3.19). 
 Protein–enzyme conjugation did not appear to have a detrimental impact upon ALP-
catalysed hydrolysis of proligand 198 or upon the iridium-catalysed transfer hydrogenation reaction 
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as positive electrochemical conversions were observed. Quantitative conversions were seen at 
streptavidin–ALP concentrations of 10 mgL−1 and higher, whilst a concentration of 0.01 mgL−1 
could easily be distinguished from the background. Enzyme-triggered catalytic signal amplification 
again showed an excellent dynamic range as protein–enzyme concentrations over 4 orders of 
magnitude could be accurately determined. For completion, the assay was performed in the absence 
of proligand 198 to confirm that positive conversion was occurring through the proposed 
mechanism. Without the proligand, conversions lower than the background rate was seen showing 




Figure 3.19 Electrochemical conversions of aldehyde 169 to alcohol 170 in the presence of different enzyme 
conjugate concentrations at 37 °C with a 30 minute incubation period. 
 
 As enzyme conjugation does not interfere with hydrolysis of the enzyme substrate or with 
organometallic catalyst activity, the next goal was to apply enzyme-triggered catalytic signal 
amplification to an immunosorbent assay for signal-amplified ratiometric electrochemical protein 
detection. C-reactive protein (CRP) was chosen once more as the model analyte which could be 
identified through a commercial ELISA kit that utilises ALP as the enzyme label. Again, the 
sandwich ELISA was constructed according to the manufacturer’s procedure and incubated with a 
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1 mM solution of proligand 198 for 30 minutes prior to the addition of the signal amplification 













Figure 3.20 Electrochemical conversions of aldehyde 169 to alcohol 170 in the presence of different CRP 
concentrations at 37 °C after a 30 minute incubation period of proligand 198 with the sandwich complex. 
Error bars indicate standard deviation (n = 3). 
 
 Pleasingly, positive conversions were observed at all concentrations of CRP tested with 
high concentrations able to produce ≈35% conversion after 30 minutes. Interestingly, a CRP 
concentration of 1 μgL−1 delivered a higher average conversion than a CRP concentration of 3 
μgL−1, which does show the potential high sensitivity of the amplification methodology. However, 
the background rate is high enough to limit this sensitivity. Due to the use of a second amplifier, 
any error produced as a result of the first amplification step is amplified by the second, as indicated 
by the large error bars. Therefore, in attempting to achieve greater sensitivity, accuracy and 
reproducibility had been compromised.  
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3.1.8 Background Suppression 
 
 
Scheme 3.13 Retrosynthetic analysis of proligand 206. 
 
In order to improve the signal amplification methodology, efforts were made to reduce the 
unsatisfactorily high background rate. From the results obtained where streptavidin-conjugated 
ALP was being detected (Figure 3.19), it was clear that a combination of both proligand 198 and 
the iridium precatalyst were contributing to the high background rate. Although contrary to the 
conclusions resulting from the ligand derivative screen (Table 3.4), this was considered to be due to 
that at the higher reaction temperatures iridium insertion into the sulfonamide N–H bond could 
occur to form a partially-active catalyst within the transfer hydrogenation reaction. It was thought 
that a structural adjustment of the proligand would prevent this metal insertion from occurring and 
could nullify the background reaction. Towards this end, a second generation proligand, compound 
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206, was designed. By simply moving the phosphate trigger and the benzyl linker attachment from 
the primary amine position to the sulfonamide nitrogen position would remove the acidic 
sulfonamide yet allow the same enzyme-triggered ligand release mechanism to remain in effect. 
Proligand 206 could be synthesised in much a similar way to the proligand 198 albeit with an 
added protection/deprotection step (Scheme 3.13). The amine protecting group was chosen to be an 
allyloxycarbonyl (alloc) group as deprotection of this group should occur in the same synthetic 
procedure as allyl deprotection of the phosphate group. 
 
 
Scheme 3.14 Alloc protection of ligand 175. 
 
 
Scheme 3.15 Attempted synthesis of triallyl protected proligand 207. 
 
 Thus, the synthesis of proligand 206 began with alloc protection of ligand 175 with allyl 
chloroformate 209 which proceeded in good yield (Scheme 3.14). Next, the synthesis of the triallyl 
protected proligand 207 was attempted analogous to previous where benzyl alcohol 149 could be 
coupled to the sulfonamide nitrogen of 208 through the use of carbonyl coupling reagent CDI 202 
(Scheme 3.15). However, due to the poor nucleophilicity of the sulfonamide, the desired product 
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was not observed. To improve the reactivity between the coupling partners, it was decided to 
replace the carbonyl coupling reagent with the much more reactive phosgene, enabling coupling to 
go through the corresponding benzyl chloroformate. In addition, the use of a nucleophilic catalyst 
should greatly improve the electrophilicity of the intermediate chloroformate. 
 
 
Scheme 3.16 Synthesis of triallyl protected proligand 207. 
 
 Indeed, the use of phosgene as the carbonyl coupling reagent and 4-
(dimethylamino)pyridine (DMAP) as the nucleophilic catalyst delivered the desired triallyl 
protected proligand 207 in moderate yield (Scheme 3.16). To obtain proligand 206, deprotection of 
207 was attempted using the standard optimised deallylation conditions (Scheme 3.17). However, 
despite the desired product being observed in the crude 
1
H NMR, compound 198 was also observed 
in the inseparable mixture. This product is presumed to have formed from an intramolecular 
rearrangement through nucleophilic attack of the carbamate by the primary amine subsequent to 






Scheme 3.17 Attempted synthesis of proligand 206. 
 
 
Scheme 3.18 Synthesis of tetraallyl protected proligand 210. 
 
 To avoid the intramolecular rearrangement yet maintain functionalisation at the 
sulfonamide nitrogen, it was decided that attachment of another phosphate trigger and benzyl linker 
at this position would achieve the desired reduced background rate in the transfer hydrogenation 
reaction despite needing two enzyme-catalysed dephosphorylations to release the active ligand. In a 
similar procedure for the synthesis of 207, tetraallyl protected bis-phosphate 210 was synthesised in 
moderate yield from previously prepared 201 (Scheme 3.18). With compound 210 in hand, it was 
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then exposed to the palladium-catalysed deallylation conditions to remove the four allyl protecting 
groups (Scheme 3.19). Initially, this was successfully achieved but the conditions used for 
disodium phosphate salt formation led to decomposition of the product. This was thought to be due 
to the hydroxide acting as a nucleophile and hydrolysing the N-sulfonyl carbamate linkage. 
Repeating the synthesis but using a milder base led to formation of the desired bis-phosphate salt in 
quantitative yield. The addition of an extra phosphate group greatly improved the water solubility 




Scheme 3.19 Synthesis of bis-phosphate proligand 211. 
 
 With bis-phosphate 211 in hand, it was then tested as the proligand within the enzyme-
triggered catalytic signal amplification methodology (Figure 3.21). Initially, unconjugated ALP 
was used as the enzyme trigger to determine the background rate, if any, prior to testing 211 within 
the more procedurally complex ELISA. Pleasingly, in the presence of ALP, rapid conversion of 
ferrocenecarboxaldehyde 169 to ferrocenemethanol 170 was observed through ratiometric 
electrochemical analysis. Despite requiring two ALP-catalysed dephosphorylations of proligand 
211 to release ligand 175, this was shown not to significantly hinder reactivity as quantitative 
conversions were still obtained within 30 minutes. However, in the absence of ALP, a small 
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undesired background reaction was still present with ≈10% conversion being observed after 30 
minutes. This indicates that the background reaction was not necessarily caused by iridium-
insertion into the acidic sulfonamide N–H bond creating a partially-active catalyst. Nevertheless, 
with the improved water solubility of proligand 211 over proligand 198, it was thought that 211 
could still be used as the enzyme substrate within an ELISA and the undesired background reaction 
could be potentially minimised through a careful optimisation. 
 
 
Figure 3.21 Electrochemical conversion of aldehyde 169 to alcohol 170 in the presence of different enzyme 
concentrations at 37 °C using proligand 211 as the enzyme substrate. 
 
 Once again, an ELISA was constructed for the detection of model analyte CRP which was 
tested at the highest concentration available as well as in its absence in order to obtain the detection 
range (Figure 3.22). In the absence of any CRP, a low background was indeed observed with a 
maximum 2% conversion reached over the course of the 30 minute assay. A conversion 
distinguishable from the background was seen in the presence of 100 μgL−1 of CRP but under these 
conditions, the signal amplification methodology barely delivered over 10% conversion. Pleased 
with the low background rate however, ways to improve conversion in the case of a positive 




Figure 3.22 Electrochemical conversions of aldehyde 169 to alcohol 170 in the presence of different CRP 
concentrations at 37 °C after a 30 minute incubation period of proligand 211 with the sandwich complex at 
room temperature. 
 
 One method to improve the signal output was thought to simply increase the catalytic 
loading of the second catalytic amplifier of the signal amplification methodology. As such, the 
overall catalytic loading was increased to 12 mol% and again tested within an ELISA for CRP 
detection (Figure 3.23). The higher catalytic loading does indeed provide higher conversion within 
the methodology as greater than 50% conversion was observed after a 30 minute reaction time. 
However, much more strikingly is that this increase in signal was accompanied by a huge increase 
in background rate with nearly 50% conversion also being seen. 
 From this result it is clear that the background reaction is not caused by complexation of 
the proligand to the metal forming a partially-active catalyst. Instead, the background reaction was 





Figure 3.23 Electrochemical conversions of aldehyde 169 to alcohol 170 in the presence of different CRP 
concentrations at 37 °C with an overall catalytic loading of 12 mol% after a 30 minute incubation period of 
proligand 211 with the sandwich complex at room temperature. 
 
 
3.2 Signal-Amplified Detection of Alkaline Phosphatase with Alternative Signal Readout 
One of the major benefits of the enzyme-triggered catalytic signal amplification methodology 
developed herein, other than the signal amplification itself, is its modularity. For example, if an 
electrochemical enzyme substrate had been previously described, but the readout method required 
for a different application is fluorescence or colourimetric, then an entirely new enzyme substrate 
with those particular attributes would need to be developed. With this methodology however, the 
same enzyme substrate can always be used but the readout method can be easily changed by 
choosing an aldehyde that simply possesses the desired properties. This has an increased benefit 
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since many aldehydes are commercially available and do not require multiple procedures to 
synthesise unlike typical enzyme substrate development. To test this principle, the previously 
optimised conditions for ALP detection were applied to a range of different commercially-available 
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 Table 3.6 Application of enzyme-triggered catalytic signal amplification to different aldehydes for 
alternative signal readout. 
 
 Initially, a number of polyaromatic aldehydes were tried as this would allow enzyme 
detection through the amplification methodology to be achieved by fluorescence. 1-napthyl, 9-
anthracenyl and 1-pyrenyl aldehydes all furnished excellent conversions in the presence of ALP yet 
delivered satisfactorily low conversions in its absence. This shows that the methodology could be 
utilised within an amplified enzyme detection assay with fluorescent signal readout. A number of 
fluorine-containing aromatic aldehydes were next used as the substrate which would enable 
19
F 
NMR to be used as the readout method. Good conversions were also seen with these aldehydes but 
the more electron-withdrawing substrates were prone to high background conversions. This was 
confirmed with the very electron-withdrawing p-nitro substrate where half catalytic loadings were 
required to obtain acceptably low background conversions. Pleasingly, reduction of the nitro group 
itself was not observed. 
 Exploring the electronic demands of the substrate within the transfer hydrogenation 
reaction further, showed that electron-rich aromatic substrates were able to suppress these 
background reactions yet still provide quantitative conversions in the present of the enzyme. 
However, very electron-rich substrates such as vanillin deactivated the aldehyde enough to limit its 
reduction. Interestingly, when a dialdehyde was used as the substrate, the mono-alcohol was found 
to be the major product over the di-alcohol in a 3:1 ratio. The methodology was also found to not 
be limited to aromatic aldehydes as aliphatic substrates also furnished quantitative conversions in 
the presence of the enzyme. In the absence of the enzyme though, the cyclohexyl derivative 
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delivered a complex mixture of products as observed in the crude 
1
H NMR spectrum, with no 
starting material or product being seen. Cinnamaldehydes were also shown to be excellent catalyst 
substrates within the methodology as the 2-methoxy derivative gave good conversion in the 
presence of the enzyme yet poor conversion in its absence. In addition, no reduction of the alkene 
was observed.  
 In the majority of cases, excellent conversions were obtained in the presence of the enzyme 
without needing to re-optimise the assay showing the potential applicability of the amplification 
methodology within detection methods that utilise alternative signal readouts. The excellent 
functional group tolerance could also lend this methodology towards applications other than 
sensing, such as stimuli-responsive materials and molecular computing. However, the iridium pre-
catalyst also exhibits high background conversions with these aldehydes. Despite being able to 
minimise this through reducing the catalytic loading, any background could hinder the 
incorporation of this methodology within other sensing applications.  
 
3.3 Conclusion 
3.3.1 Project Summary 
For the development of a signal-amplified enzyme-linked immunosorbent assay (ELISA) towards 
rapid and ultrasensitive electrochemical protein detection, a novel signal amplification 
methodology was designed and developed for the ratiometric detection of alkaline phosphatase 
(ALP). This methodology utilised a highly efficient iridium catalyst as the second catalytic 
amplifier within a double-catalyst signal amplification strategy, whose activity could be accelerated 
through ligand control. To accelerate catalytic activity selectively in the presence of ALP, an 
enzyme-triggered ligand release protocol was achieved through careful design of a proligand 
enzyme substrate, which bore an enzyme-selective phosphate trigger and benzyl linker attached to 
the ligand. The proligand itself was shown not to accelerate the iridium-catalysed transfer 
hydrogenation reaction but in the presence of ALP, hydrolysis of the proligand and consequent 
elimination of the linker was shown to release the active ligand, capable of accelerating the rate of 
the transfer hydrogenation reaction. The catalytic reaction could be monitored through ratiometric 
electrochemical analysis by using ferrocenecarboxaldehyde as the catalyst substrate since the 
corresponding product, ferrocenemethanol, had a significantly different oxidation potential from 
the starting aldehyde. 
 The enzyme-triggered catalytic signal amplification methodology was shown to go through 
the desired mechanism as 
31
P NMR experiments revealed that hydrolysis of the proligand occurs 
selectively in the presence of ALP and mass spectrometry experiments identified that release of the 
ligand occurs as a direct result of enzyme-catalysed phosphate cleavage. A considerable 
optimisation was then performed to provide both further mechanistic insight as well as to find the 
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limit of detection for ALP activity, which was calculated to be 7.6 pM after a 33 minute assay 
reaction time. However, when applied to protein detection through an ELISA, a significant 
background rate was observed which limited the sensitivity of the assay. Also, the addition of a 
second amplifier to the detection methodology enhances any errors accrued from the first amplifier 
and as such, significant variation in positive results was observed. 
 The high background rate was considered to come from partial activation of the catalyst by 
the proligand in the absence of the enzyme. To prevent this, a second proligand was designed and 
synthesised where a second enzyme trigger and benzyl linker was affixed to another attachment 
point of the proligand. However, despite this modification, the undesired background reaction 
remained leading the conclusion that this was as a result of the iridium pre-catalyst itself being an 
active catalyst within the transfer hydrogenation reaction. Nevertheless, the versatility of the 
enzyme-triggered catalytic amplification methodology was shown through the enzyme-triggered 
catalytic reduction of a range of commercially-available aldehydes. Potentially, this enables 
amplified ALP detection through means other than electrochemistry, such as fluorescence or 
19
F 
NMR, and the methodology could also be incorporated into systems other than sensing, where both 
signal transduction and signal amplification is needed. 
 
3.3.2 Future Work 
To increase the sensitivity and therefore the applicability of the enzyme-triggered catalytic signal 
amplification methodology, minimisation of the high background reaction would be paramount. 
Knowing that the cause of this background was the iridium pre-catalyst, then using a more inert 
pre-catalyst could reduce the background rate. From the ligand optimisation study, 
tetramethylethylenediamine (TMEDA) was shown to completely inhibit the transfer hydrogenation 
reaction and therefore, synthesis of an Ir∙TMEDA complex such as 227 and testing it as the pre-
catalyst within the transfer hydrogenation reaction would be the initial intention (Scheme 3.20). 
 
 
Scheme 3.20 Design of inert iridium complex 227 and its potential application as a precatalyst within the 




 Once the background reaction has been minimised, the signal amplification methodology 
could then be applied to the signal-amplified detection of other analytes. Replacing the phosphate 
trigger of the proligand with other enzyme-cleavable functional groups would enable the amplified 
electrochemical ratiometric detection of other enzymes such as sulfatase, protease, esterase or 
glycosylase (Figure 3.24). Additionally, replacing the trigger with phenol protecting groups such as 
allyl or silyl groups would extend this methodology to the detection of palladium or fluoride 
respectively. Phenylboronic acids could also be used as the trigger moiety allowing for the 
amplified detection of hydrogen peroxide. This would also extend the signal amplification 
methodology towards an inverse horseradish peroxidase (HRP) detection assay as well as protein 
detection through HRP-labelled ELISAs. 
 
 
Figure 3.24 Potential application of enzyme-triggered catalytic signal amplification applied for sensitive 
ratiometric electrochemical detection of alternative enzymes. 
 
 As well as modifying the enzyme or analyte-selective substrate for alternative analyte 
detection, other aspects of the methodology could also be changed such as the catalyst substrate. 
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Although the aldehyde scope was briefly demonstrated, a more thorough optimisation using 
fluorescent or colourimetric substrates would greatly highlight the applicability of this 
methodology within detection assays that require signal readouts other than electrochemistry. 
Furthermore, since this is the first example of enzyme-triggered catalyst activation through ligand 
acceleration, further work should be aimed at other catalyst–ligand systems that could be used as 







4.0  General Information 
4.0.1 Instruments 
Proton, carbon, fluorine and phosphorous nuclear magnetic resonance (NMR) spectra were recorded on 
Bruker 300, 400 or 500 MHz spectrometers or on an Agilent Technologies 500 MHz spectrometer (
1
H NMR 
at 300 or 400 MHz, 
13
C NMR at 75.5 or 101 MHz, 
19
F at 376.5 or 470.5 MHz and 
31
P NMR at 121.5 MHz) at 
298 K unless otherwise stated. Chemical shifts for protons are reported in parts per million downfield from 
Si(CH3)4 and are referenced to residual protium in the deuterated solvent (CHCl3 at 7.26 ppm, C6H6 at 7.16 
ppm, H2O at 4.79 ppm, DMSO at 2.50 ppm).
420
 Chemical shifts for carbons are reported in parts per million 
downfield from Si(CH3)4 and are reference, where available, to the carbon resonances of the deuterated 
solvent (CDCl3 at 77.0 ppm, C6D6 at 128.1 ppm, d6–DMSO at 39.5 ppm).
420
 Chemical shifts for fluorines are 
reported in parts per million downfield from CFCl3. Chemical shifts for phosphorous’ are reported in parts 
per million downfield from 85% H3PO4. NMR data are presented in the following format: chemical shift 
(number of equivalent nuclei by integration, multiplicity [app = apparent, br = broad, d = doublet, dd = 
doublet of doublets, dq = doublet of quartets, dt = doublet of triplets, ddd = doublet of doublet of doublets, 
ddt = doublet of doublet of triplets, m = multiplet, q = quartet, s = singlet, sept = septet, t = triplet], coupling 
constant [in Hz], assignment). Electrospray ionisation ultrahigh resolution time-of-flight mass spectrometry 
(ESI–UHR–TOF–MS) was performed on a Bruker maXis mass spectrometer. Electrospray ionisation high 
resolution time-of-flight mass spectrometry (ESI–HR–TOF–MS) was performed on a Bruker micrOTOF 
spectrometer. Infrared (IR) spectra were recorded on a Perkin–Elmer 1600 FT (Fourier transform) IR 
spectrophotometer, with absorbencies quoted as wavenumber (ν [in cm−1]). Electrochemical analysis was 
performed on a Metrohm Autolab PGSTAT30 potentiostat controlled by a personal computer running 
General Purpose Electrochemical System (GPES) software. Melting points were obtained on a Bibby Sterilin 
SMP10 melting point machine and are uncorrected. Enzyme-linked immunosorbent assays (ELISAs) were 
incubated on a Benchmark Scientific H1000-M Incu-Shaker Mini. pH was measured using a Hanna 
Instruments HI 9321 pH meter and was calibrated prior to use. 
 
4.0.2 Materials 
Analytical thin-layer chromatography (TLC) was performed on aluminium-backed plates coated with 
Alugram
®
 SIL G/UV254 purchased from Macherey–Nagel and visualised with UV light (254 or 365 nm) 
and/or KMnO4, 2,4-DNPH or ninhydrin staining where appropriate. Silica gel column chromatography was 
performed using 60 Å, 200‒400 mesh particle size silica gel purchased from Sigma–Aldrich. Reverse phase 
C18-silica gel column chromatography was carried out using VersaPak
®
 30g C18 cartridges (23 mm × 110 
mm) preloaded with 20‒45 µm spherical C18 bonded silica purchased from Sigma–Aldrich. High sensitivity 
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C-reactive protein (CRP) enzyme-linked immunosorbent assay (ELISA) kits were purchased from Kalon 
Biological Ltd. (Guildford, UK) and stored at 4 °C prior to use. 
 
4.0.3 Chemicals 
All reactions were performed in oven-dried glassware under an atmosphere of nitrogen at room temperature 
(≈18 °C) unless otherwise stated. All water used was purified through a Merck Millipore reverse osmosis 
purification system prior to use. Anhydrous acetonitrile (MeCN), anhydrous dichloromethane (CH2Cl2), 
anhydrous tetrahydrofuran (THF) and anhydrous toluene (PhMe) were dried and degassed by passing 
through anhydrous alumina columns using an Innovative Technology Inc. PS‒400‒7 solvent purification 
system (SPS) and stored under an atmosphere of argon prior to use. Anhydrous N,N-dimethylformamide 
(DMF) was purchased from Sigma–Aldrich and used as received. Hexane refers to high-pressure liquid 
chromatography (HPLC) grade hexane which was purchased from Sigma–Aldrich and used as received. 
Triethylamine (TEA), purchased from Sigma–Aldrich, was dried over KOH pellets and distilled before being 
stored under an atmosphere of nitrogen prior to use.
421
 N-Chlorosuccinimide (NCS), purchased from Sigma–
Aldrich, was rapidly recrystallised from glacial acetic acid and washed well with water before being dried in 
vacuo prior to use.
421
 Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer and ferrocenecarboxylic acid 
were purchased from Alfa Aesar and used as received. Oxalyl chloride was purchased from Fluorochem and 
used as received. NaOH and KOH pellets as well as anhydrous Na2SO4 were purchased from Acros Organics 
and used as received. Sand and MgSO4 were purchased from Fisher Scientific and used as received. Polymer-
bound tetrakis(triphenylphosphine)palladium was purchased from Sigma–Aldrich as a 200‒400 mesh 
polymer, 2% cross-linked with divinylbenzene, labelled with 0.5‒0.9 mmolg−1 palladium and used as 
received. Alkaline phosphatase (ALP) from bovine intestinal mucosa (≥2000 DEA units/mg) was purchased 
from Sigma–Aldrich as a lyophilised powder and stored at 4 °C prior to use. Streptavidin–alkaline 
phosphatase conjugate from streptomyces avidinii (700‒2300 DEA units/mg) was purchased from Sigma–
Aldrich as a lyophilised powder and stored at −20 °C prior to use. All other chemicals were purchased from 
Sigma–Aldrich and used as received. All buffers were freshly prepared according to previously published 





4.1  General Procedures 
4.1.1 Synthetic Procedures 
4.1.1.1 Procedure A 
  
To a stirring solution of ferrocenoyl azide (1 eq.) in anhydrous toluene (3 mL / mmol) under argon was added 
the alcohol (1 eq.). The reaction mixture was then heated to reflux and stirred for 2 hours. The reaction 
mixture was then allowed to cool to room temperature before being concentrated in vacuo to afford the crude 
product. 
 
4.1.1.2 Procedure B 
  
To a stirring solution of the 4-((bis(allyloxy)phosphoryl)oxy)benzyl carbamate (1 eq.) in anhydrous THF (10 
mL / mmol) at 0 °C was added polymer-bound Pd(PPh3)4 (1 mol%) followed by formic acid (15 eq.) and 
anhydrous TEA (10 eq.). The reaction mixture was allowed to warm to room temperature and stirred for 16 
hours. The reaction mixture was then filtered via gravity filtration and the filtrate concentrated in vacuo. The 
residue was then cooled to 0 °C and 1M NaOH(aq.) (12 eq.) was added slowly. The reaction mixture was 
allowed to warm to room temperature and stirred for 1 hour before being concentrated in vacuo to afford the 
crude product. 
 
4.1.1.3 Procedure C 
  
To a stirring solution of ethylenediamine (10 eq.) in anhydrous CH2Cl2 (2.5 mL / mmol) at 0 °C was added 
the sulfonyl chloride (1 eq.) in anhydrous CH2Cl2 (2.5 mL / mmol) dropwise. After complete addition, the 
reaction mixture was allowed to warm to room temperature and stirred for 1 hour. The reaction was then 
quenched with water and the organics separated. The aqueous layer was then extracted twice with CH2Cl2. 
The combined organics were then washed with water, then brine, dried over MgSO4 and concentrated in 
vacuo to afford the crude product. 
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4.1.1.4 Procedure D 
  
To a stirring solution of N-methylethylenediamine (3 eq.) in anhydrous CH2Cl2 (2.5 mL / mmol) at 0 °C was 
added mesitylsulfonyl chloride (1 eq.) in anhydrous CH2Cl2 (2.5 mL / mmol) dropwise. After complete 
addition, the reaction mixture was allowed to warm to room temperature and stirred for 3 hours. The reaction 
was then quenched with water and the organics separated. The aqueous layer was then extracted twice with 
CH2Cl2. The combined organics were then washed with water, then brine, dried over MgSO4 and 
concentrated in vacuo to afford the crude product. 
 
4.1.1.5 Procedure E 
  
To a stirring solution of the ethylenediamine (1 eq.) in anhydrous CH2Cl2 (2.5 mL / mmol) at 0 °C was added 
mesitylsulfonyl chloride (1 eq.) in anhydrous CH2Cl2 (2.5 mL / mmol) dropwise. After complete addition, the 
reaction mixture was allowed to warm to room temperature and stirred for 1 hour. The reaction was then 
quenched with water and the organics separated. The aqueous layer was then extracted twice with CH2Cl2. 
The combined organics were then washed with water, then brine, dried over MgSO4 and concentrated in 
vacuo to afford the crude product. 
 
4.1.1.6 Procedure F 
  
To a stirring solution of 1,1’-carbonyldiimidazole (1.3 eq.) in anhydrous MeCN (7.5 mL / mmol) at room 
temperature was added a solution of the benzyl alcohol (1 eq.) in anhydrous MeCN (7.5 mL / mmol) 
dropwise. After complete addition, the reaction mixture was left to stir for 16 hours before being 
concentrated in vacuo and the residue quenched with water. The aqueous layer was then extracted three times 
with CHCl3. The combined organics were then washed with water, then brine, dried over Na2SO4 and 
concentrated in vacuo. The residue was then taken up in anhydrous THF (15 mL / mmol) and N-(2-
aminoethyl)-2,4,6-trimethylbenzenesulfonamide 175 (1 eq.) was added in one portion. The reaction mixture 
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was then left to stir for 16 hours before being concentrated in vacuo and the residue quenched with water. 
The aqueous layer was then extracted three times with EtOAc. The combined organics were then washed 
twice with water and once with brine before being dried over Na2SO4 and concentrated in vacuo to afford the 
crude product. 
 
4.1.1.7 Procedure G 
  
To a stirring solution of diallyl (4-(hydroxymethyl)phenyl) phosphate (1.1 eq.) in anhydrous toluene (1 mL / 
mmol) was added phosgene solution (≈20% in toluene) (1.1 eq.) dropwise and the reaction was allowed to 
stir at room temperature for 30 minutes before being concentrated in vacuo. The residue was then taken up 
into anhydrous THF (2 mL / mmol) and added dropwise to a stirring solution of the N-(2-aminoethyl)-
sulfonamide (1 eq.), DIPEA (1.5 eq.) and DMAP (10 mol%) in anhydrous THF (3 mL / mmol). The reaction 
mixture was then allowed to stir for 16 hours at room temperature before being quenched with NaHCO3 (sat.) 
and extracted three times with EtOAc. The combined organics were then washed with water, then brine 
before being dried over MgSO4 and concentrated in vacuo to afford the crude product. 
 
4.1.1.8 Procedure H 
  
To a stirring solution of dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (0.25 mol%), 4-((((2-
((2,4,6-trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (0.5 mol%) and 
sodium formate (5 eq.) in pH 9.8 0.05M sodium carbonate buffer (2 mL / mmol) was added alkaline 
phosphatase (25 UmL
−1
) followed by a solution of the aldehyde (1 eq.) in ethanol (2 mL / mmol). The 
reaction mixture was then warmed to 37 °C and stirred for 30 minutes. The reaction was then quenched with 
water and extracted three times with EtOAc. The combined organics were dried over MgSO4 and 




4.1.1.9 Procedure I 
   
To a stirring solution of dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (0.125 mol%), 4-((((2-
((2,4,6-trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (0.25 mol%) and 
sodium formate (5 eq.) in pH 9.8 0.05M sodium carbonate buffer (2 mL / mmol) was added alkaline 
phosphatase (25 UmL
−1
) followed by a solution of the aldehyde (1 eq.) in ethanol (2 mL / mmol). The 
reaction mixture was then warmed to 37 °C and stirred for 30 minutes. The reaction was then quenched with 
water and extracted three times with EtOAc. The combined organics were dried over MgSO4 and 






P NMR Procedures 
4.1.2.1 ALP-catalysed Dephosphorylation of Substrate 112 
  
To 350 μL of a 28.6 mM solution of 112 in pH 9 Tris buffer in a clean, oven-dried Young’s NMR tube was 
added 50 μL of D2O, to achieve successful NMR locking, followed by 100 μL of a 50 UmL
−1
 solution of 
ALP in pH 9 Tris buffer. This achieved a 0.5 mL reaction volume that consisted of a 20 mM concentration of 
112 and a 10 UmL
−1
 concentration of ALP. The tube was then sealed with a screw-top lid and the reaction 
mixture agitated through vertical inversion and reversion of the reaction vessel. The reaction was then 





data acquisition. Approximately every 5 minutes, the reaction vessel was ejected and agitated in the same 
manner as previous, before reinsertion into the NMR machine. To maintain accurate peak position, locking 
and shimming was performed prior to every acquisition. This process was repeated until full consumption of 
the starting material was observed. 
 
4.1.2.1 ALP-catalysed Dephosphorylation of 198 
  
To 350 μL of a 72 mM solution of 198 in pH 9.8 CO3
2−
 buffer in a clean, oven-dried Young’s NMR tube was 
added 50 μL of D2O, to achieve successful NMR locking, followed by 100 μL of a 25 UmL
−1
 solution of 
ALP in pH 9.8 CO3
2−
 buffer. This achieved a 0.5 mL reaction volume that consisted of a 50 mM 
concentration of 198 and a 5 UmL
−1
 concentration of ALP. The tube was then sealed with a screw-top lid and 
the reaction mixture agitated through vertical inversion and reversion of the reaction vessel. The reaction was 





H} data acquisition. Approximately every 10 minutes, the reaction vessel was ejected and agitated in the 
same manner as previous, before reinsertion into the NMR machine. To maintain accurate peak position, 
locking and shimming was performed prior to every acquisition. This process was repeated until full 




4.1.3 Mass Spectrometry Procedure 
  
To 900 μL of a 2.8 mM solution of 198 in water was added 100 μL of a 10 UmL−1 solution of ALP to give a 
1 mL reaction mixture that consisted of a 2.5 mM solution of 198 and a 1 UmL
−1
 solution of ALP. 
Immediately after ALP addition, the reaction mixture was taken up in a micro-syringe and directly infused at 
3 μLmin−1 into an ESI–UHR–TOF mass spectrometer in negative ion mode. Spectra were recorded between 
0‒500 m/z over a reaction timeframe of 30 minutes and accumulative averaged mass spectra were generated 
between specific time points. Additionally, relative peak intensities for 198 at 471.0996 ± 0.002 m/z and for 




4.1.4  Electrochemistry Procedures 
All electrochemical analysis was conducted by direct application of the sample to a screen-printed 
electrochemical cell (GM Nameplate, Seattle) comprising of carbon working and counter electrodes and a 
silver (pseudo Ag/AgCl) reference electrode. All samples were analysed amperometrically using differential 
pulse voltammetry (modulation = 0.04 s, interval = 0.1 s, step potential = 3 mV, modulation amplitude = 
49.95 mV). Peak integrals were obtained through the software’s ‘peak search’ function (automatic search, 
linear baseline). Current was measured either through the software’s ‘peak search’ function (automatic 
search, no baseline) or, when no peaks could be found, through the software’s ‘interpolate’ function where 
the current at a specific voltage could be obtained. 
 
4.1.4.1 Ratiometric Electrochemical Detection of ALP with Substrate 112 
  
1 mL of ALP in pH 9 Tris buffer was charged to a 10 mL screw-top vial containing a magnetic flea and 
warmed to the desired temperature using a multi-vial, aluminium DrySyn
®
 heating block upon a stirrer 
hotplate. 1 mL of 1 mM 112 was then added and the reaction sealed and stirred at 1000 rpm for 30 minutes. 
Every 3 minutes during the reaction, a 25 μL sample was taken and subjected to electrochemical analysis 
(initial voltage = −300 mV, end voltage = 200 mV). 
 
4.1.4.2 Ratiometric Electrochemical Detection of Streptavidin‒ALP with Substrate 112 
  
1 mL of streptavidin‒ALP in pH 9 Tris buffer was charged to a 10 mL screw-top vial containing a magnetic 
flea and warmed 37 °C using a multi-vial, aluminium DrySyn
®
 heating block upon a stirrer hotplate. 1 mL of 
1 mM of 112 was then added and the reaction sealed and stirred at 1000 rpm for 30 minutes. Every 3 minutes 
during the reaction, a 25 μL sample was taken and subjected to electrochemical analysis (initial voltage = 




4.1.4.3 Ratiometric Electrochemical Detection of CRP with Substrate 112 
  
A sandwich ELISA was constructed according to the general procedure (4.1.5) before the addition of 100 μL 
of a 0.5 mM solution of 112 in pH 9 Tris buffer. The microwells were then mixed briefly on a plate shaker 
and incubated at either room temperature or 37 °C for 30 minutes. After this duration, a 25 μL sample was 
taken and subjected to electrochemical analysis (initial voltage = −300 mV, end voltage = 200 mV). 
 
4.1.4.4 Amperometric Electrochemical Detection of CRP with AA2P 105 
  
A sandwich ELISA was constructed according to the general procedure (4.1.5) before the addition of 100 μL 
of a 0.5 mM solution of AA2P 105 in pH 9 Tris buffer. The microwells were then mixed briefly on a plate 
shaker and incubated at 37 °C for 30 minutes. After this duration, a 25 μL sample was taken and subjected to 





4.1.4.5 Ratiometric Electrochemical Detection of ALP with Proligand 198 
  
To a 10 mL screw-top vial charged with a magnetic flea was added 
dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (4 mg, 5 μmol, 1 mol%), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbomyl)oxy)methyl)phenyl phosphate 198 (5 mg, 10 μmol, 2 mol%) 
and sodium formate (170 mg, 2.5 mmol, 5 eq.). 1 mL of 2 × the desired concentration of ALP in pH 9.8 
CO3
2−
 buffer was then added. Immediately thereafter, a 1 mL solution of ferrocenecarboxaldehyde 169 (107 
mg, 0.5 mmol, 1 eq.) was then added in one portion. The reaction was then warmed to the desired 
temperature using a multi-vial, aluminium DrySyn
®
 heating block upon a stirrer hotplate and stirred at 1000 
rpm for 30 minutes. Every 3 minutes during the reaction, a 1 µL sample was taken from the reaction mixture 
and diluted into 999 µL of pH 9.8 CO3
2−
 buffer. After shaking, a 100 µL sample of this solution was diluted 
into 900 µL of pH 9.8 CO3
2−
 buffer to give a 25 µM ferrocene concentration. After shaking again, a 25 µL 
sample of this twice-diluted solution was subjected to electrochemical analysis (initial voltage = −200 mV, 
end voltage = 400 mV). 
 
4.1.4.6 Ratiometric Electrochemical Detection of Streptavidin‒ALP with Proligand 198 
  
To a 10 mL screw-top vial charged with a magnetic flea was added 
dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (4 mg, 5 μmol, 1 mol%), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbomyl)oxy)methyl)phenyl phosphate 198 (5 mg, 10 μmol, 2 mol%) 
and sodium formate (170 mg, 2.5 mmol, 5 eq.). 1 mL of 2 × the desired concentration of streptavidin‒ALP in 
pH 9.8 CO3
2−
 buffer was then added. Immediately thereafter, a 1 mL solution of ferrocenecarboxaldehyde 
169 (107 mg, 0.5 mmol, 1 eq.) was then added in one portion. The reaction was then warmed to the desired 
temperature using a multi-vial, aluminium DrySyn
®
 heating block upon a stirrer hotplate and stirred at 1000 
rpm for 30 minutes. Every 3 minutes during the reaction, a 1 µL sample was taken from the reaction mixture 
and diluted into 999 µL of pH 9.8 CO3
2−
 buffer. After shaking, a 100 µL sample of this solution was diluted 
into 900 µL of pH 9.8 CO3
2−
 buffer to give a 25 µM ferrocene concentration. After shaking again, a 25 µL 
sample of this twice-diluted solution was subjected to electrochemical analysis (initial voltage = −200 mV, 




4.1.4.7 Ratiometric Electrochemical Detection of CRP with Proligand 198 
 
A sandwich ELISA was constructed according to the general procedure (4.1.5) before being washed (filled 
and aspirated with pH 9.8 CO3
2−
 buffer) another four times to remove surfactants in the previous wash 
solution that were found to cause high background signals. 100 μL of a 10 mM solution of 198 in pH 9.8 
CO3
2−
 buffer (0.5 mg, 1 μmol, 2 mol%) was then added. The microwells were then mixed briefly on a plate 
shaker and incubated at 37 °C for 30 minutes. After this duration, the substrate solution was aspirated and 
added to a 1 mL screw-top sample vial charged with a magnetic flea as well as containing 10 μL of a 5 mM 
solution of dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (0.4 mg, 0.5 μmol, 1 mol%), 90 μL of a 
0.56 M solution of ferrocenecarboxaldehyde 169 (11 mg, 0.05 mmol, 1 eq.) and sodium formate (17 mg, 0.25 
mmol, 5 eq.). The reaction was then warmed to 37 °C using a multi-vial, aluminium DrySyn
®
 heating block 
upon a stirrer hotplate and stirred at 1000 rpm for 30 minutes. Every 3 minutes during the reaction, a 1 µL 
sample was taken from the reaction mixture and diluted into 999 µL of pH 9.8 CO3
2−
 buffer to give a 25 µM 
ferrocene concentration. After shaking, a 25 µL sample of this diluted solution was subjected to 
electrochemical analysis (initial voltage = −200 mV, end voltage = 400 mV). 
 
4.1.4.8 Ratiometric Electrochemical Detection of ALP with Proligand 211 
  
To a 10 mL screw-top vial charged with a magnetic flea was added 
dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (4 mg, 5 μmol, 1 mol%), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbomyl)oxy)methyl)phenyl phosphate 211 (8 mg, 10 μmol, 2 mol%) 
and sodium formate (170 mg, 2.5 mmol, 5 eq.). 1 mL of 2 × the desired concentration of ALP in pH 9.8 
CO3
2−
 buffer was then added. Immediately thereafter, a 1 mL solution of ferrocenecarboxaldehyde 169 (107 
mg, 0.5 mmol, 1 eq.) was then added in one portion. The reaction was then warmed to the desired 
temperature using a multi-vial, aluminium DrySyn
®
 heating block upon a stirrer hotplate and stirred at 1000 
rpm for 30 minutes. Every 3 minutes during the reaction, a 1 µL sample was taken from the reaction mixture 
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and diluted into 999 µL of pH 9.8 CO3
2−
 buffer. After shaking, a 100 µL sample of this solution was diluted 
into 900 µL of pH 9.8 CO3
2−
 buffer to give a 25 µM ferrocene concentration. After shaking again, a 25 µL 
sample of this twice-diluted solution was subjected to electrochemical analysis (initial voltage = −200 mV, 
end voltage = 400 mV). 
 
4.1.4.9 Ratiometric Electrochemical Detection of CRP with Proligand 211 
 
A sandwich ELISA was constructed according to the general procedure (4.1.5) before being washed (filled 
and aspirated with pH 9.8 CO3
2−
 buffer) another four times to remove surfactants in the previous wash 
solution that were found to cause high background signals. 100 μL of a 10 mM solution of 211 in pH 9.8 
CO3
2−
 buffer (0.8 mg, 1 μmol, 2 mol%) was then added. The microwells were then mixed briefly on a plate 
shaker and incubated at 37 °C for 30 minutes. After this duration, the substrate solution was aspirated and 
added to a 1 mL screw-top sample vial charged with a magnetic flea as well as containing 10 μL of a 5 mM 
solution of dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (0.4 mg, 0.5 μmol, 1 mol%), 90 μL of a 
0.56 M solution of ferrocenecarboxaldehyde 169 (11 mg, 0.05 mmol, 1 eq.) and sodium formate (17 mg, 0.25 
mmol, 5 eq.). The reaction was then warmed to 37 °C using a multi-vial, aluminium DrySyn
®
 heating block 
upon a stirrer hotplate and stirred at 1000 rpm for 30 minutes. Every 3 minutes during the reaction, a 1 µL 
sample was taken from the reaction mixture and diluted into 999 µL of pH 9.8 CO3
2−
 buffer to give a 25 µM 
ferrocene concentration. After shaking, a 25 µL sample of this diluted solution was subjected to 
electrochemical analysis (initial voltage = −200 mV, end voltage = 400 mV).  
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4.1.5 ELISA Construction for CRP Detection 
  
To a polystyrene microtitre well pre-coated with affinity-purified sheep anti-CRP antibodies, was added 50 
μL of a standard, pre-diluted CRP concentration, mixed briefly on a plate shaker and incubated at room 
temperature for 1 hour. The microwells were then washed (filled and aspirated with a wash solution 
containing buffered saline and a commercial surfactant) four times before 100 μL of a solution containing 
affinity-purified sheep anti-CRP antibodies labelled with ALP, mixed briefly on a plate shaker and incubated 
at room temperature for 1 hour. The microwells were then washed (filled and aspirated with a wash solution 
containing buffered saline and a commercial surfactant) another four times to leave the constructed ALP-
labelled sandwich immunoassay.  
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4.2 Compound Data 
4.2.1 4-Formylphenyl Bis(2,2,2-trichloroethyl) Phosphate 128 
  
To a stirring solution of 4-hydroxybenzaldehyde (0.61g, 5 mmol, 1 eq.) in anhydrous THF (25 mL) at 0 °C 
was added anhydrous TEA (0.7 mL, 5 mmol, 1 eq.) followed by bis(2,2,2-trichloroethyl) 
phosphorochloridate (1.90 g, 5 mmol, 1 eq.). The reaction mixture was stirred at 0 °C for 30 minutes before 
being allowed to warm to room temperature. After stirring for 2 hours, the reaction was concentrated in 
vacuo and the residue quenched with NaHCO3 (sat.) (20 mL). The aqueous layer was then extracted three times 
with CH2Cl2 (20 mL). The combined organics were dried over Na2SO4 and then concentrated in vacuo to 
afford the crude product. Purification by recrystallisation (hot Et2O) gave the title compound as white needles 
(0.17 g, 7%). MP: 77‒79 °C. IR (solid, cm−1); ν 3068 (C–H), 2953 (C–H), 2862 (C–H), 1699 (C=O), 1272 
(P=O), 1046 (P–O), 641 (C–Cl). 1H NMR (300 MHz, CDCl3); δH 9.98 (1H, s, CHO), 7.92 (2H, d, J = 8.4 
Hz, ArH), 7.45 (2H, dd, J = 8.4 Hz, 
4
JH‒P = 0.9 Hz, ArH), 4.74 (2H, dd, J = 12.7, 
3
JH‒P = 7.1 Hz, CH2), 4.70 
(2H, dd, J = 12.7, 
3
JH‒P = 7.1 Hz, CH2). 
13
C NMR (75.5 MHz, CDCl3); δC 190.6 (CHO), 154.3 (d, 
2
JC‒P = 7 
Hz, ArC), 134.2 (ArC), 131.9 (ArC), 121.0 (d, 
3
JC‒P = 5 Hz, ArC), 94.3 (d, 
3
JC‒P = 11 Hz, CCl3), 77.8 (d, 
2













4.2.2 4-(Hydroxymethyl)phenyl Bis(2,2,2-trichloroethyl) Phosphate 129 
  
To a stirring solution of 4-hydroxybenzaldehyde (0.49 g, 4 mmol, 1 eq.) in anhydrous THF (25 mL) at 0 °C 
was added anhydrous TEA (0.56 mL, 4 mmol, 1 eq.), followed by bis(2,2,2-trichloroethyl) 
phosphorochloridate (3.03 g, 8 mmol, 2 eq.). The reaction mixture was stirred at 0 °C for 30 minutes before 
being allowed to warm to room temperature. After stirring at room temperature for 2 hours, the reaction was 
concentrated in vacuo and the residue quenched with NaHCO3 (sat.) (20 mL). The aqueous layer was then 
extracted three times with CH2Cl2 (20 mL). The combined organics were dried over Na2SO4 and 
concentrated in vacuo. The residue was then taken up into THF (30 mL) and cooled to 0 °C. Sodium 
borohydride (0.30 g, 8 mmol, 2 eq.) was then added portion-wise. The reaction was then concentrated in 
vacuo and the residue quenched with NH4Cl (sat.) (30 mL). The aqueous layer was then extracted three times 
with EtOAc (30 mL). The combined organics were dried over Na2SO4 and then concentrated in vacuo to 
afford the crude compound. Purification by silica gel column chromatography (hexane 8:2 EtOAc, Rf = 0.45) 
gave the title compound as a colourless oil (1.02 g, 55%). IR (film, cm
−1); ν 3412 (O–H), 2953 (C–H), 2876 
(C–H), 1282 (P=O), 1025 (P–O), 637 (C–Cl). 1H NMR (300 MHz, CDCl3); δH 7.37 (2H, d, J = 8.1 Hz, 
ArH), 7.26 (2H, d, J = 8.1 Hz, ArH), 4.75‒4.64 (6H, m, CH2), 1.86 (1H, br s, OH). 
13
C NMR (75.5 MHz, 
CDCl3); δC 149.3 (d, 
2
JC‒P = 7 Hz, ArC), 138.9 (d, 
5
JC‒P = 1 Hz, ArC), 128.6 (ArC), 120.4 (d, 
3
JC‒P = 5 Hz, 
ArC), 94.5 (d, 
3
JC‒P = 11 Hz, CCl3), 77.7 (d, 
2




H} NMR (121.5 








4.2.3 Dibenzyl (4-(Hydroxymethyl)phenyl) Phosphate 136 
  
To a stirring solution of NCS (0.67 g, 5 mmol, 1 eq.) in anhydrous toluene (25 mL) under argon at 0 °C was 
added the dibenzyl phosphite (1.1 mL, 5 mmol, 1 eq.) drop-wise. The reaction mixture was allowed to warm 
to room temperature and stirred for 2 hours. The reaction mixture was then filtered via gravity filtration and 
concentrated in vacuo. The residue was then taken up into anhydrous THF (10 mL) and added drop-wise to a 
stirring solution of 4-hydroxybenzaldehyde (0.61 g, 5 mmol, 1 eq.) and anhydrous TEA (0.7 mL, 5 mmol, 1 
eq.) in anhydrous THF (10 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 30 minutes before being 
allowed to warm to room temperature. After stirring at room temperature for 2 hours, the reaction was 
concentrated in vacuo and the residue quenched with NaHCO3 (sat.) (25 mL). The aqueous layer was then 
extracted three times with EtOAc (25 mL). The combined organics were dried over Na2SO4 and concentrated 
in vacuo. The residue was then taken up into THF (45 mL) and cooled to 0 °C. Sodium borohydride (0.38 g, 
10 mmol, 2 eq.) was then added portion-wise. The reaction mixture was then allowed to warm to room 
temperature and stirred for 2 hours. The reaction was then concentrated in vacuo and the residue quenched 
with NH4Cl (sat.) (50 mL). The aqueous layer was then extracted three times with EtOAc (25 mL). The 
combined organics were then dried over Na2SO4 and concentrated in vacuo to afford the crude product. 
Purification by silica gel column chromatography (hexane 1:1 EtOAc, Rf = 0.20) gave the title compound as 
a white solid (1.21 g, 63%). MP: 52‒54 °C. IR (solid, cm−1); ν 3367 (O–H), 3063 (C–H), 3029 (C–H), 2964 
(C–H), 2893 (C–H), 2846 (C–H), 1245 (P=O), 1054 (P–O). 1H NMR (300 MHz, CDCl3); δH 7.22‒7.15 
(10H, m, ArH), 7.13 (2H, d, J = 8.5 Hz, ArH), 6.96 (2H, dd, J = 8.5 Hz, 
4
JH‒P = 1.0 Hz, ArH), 4.96 (4H, d, 
2
JH‒P = 8.4 Hz, ArCH2OP), 4.46 (2H, s, ArCH2OH), 3.25 (1H, br s, OH). 
13
C NMR (75.5 MHz, CDCl3); δC 
149.5 (d, 
2
JC‒P = 7 Hz, ArC), 138.4 (d, 
5
JC‒P = 1 Hz, ArC), 135.3 (d, 
3
JC‒P = 7 Hz, ArC), 128.7 (ArC), 128.6 
(ArC), 128.2 (ArC), 128.2 (ArC), 128.0 (ArC), 70.0 (d, 
2





NMR (121.5 MHz, CDCl3); δP −5.53. HRMS (ESI): calc’d for C21H21NaO5P [M+Na]
+





4.2.4 Diallyl (4-(Hydroxymethyl)phenyl) Phosphate 149 
  
To a stirring solution of phosphorous trichloride (8.7 mL, 100 mmol, 2 eq.) in anhydrous THF (70 mL) at 0 
°C was added a solution of allyl alcohol (13.6 mL, 200 mmol, 4 eq.) and anhydrous TEA (31 mL, 220 mmol, 
4.4 eq.) in anhydrous THF (30 mL) drop-wise. After complete addition, the reaction mixture was allowed to 
warm to room temperature and stirred for 1 hour before being cooled back down to 0 °C. Water (50 mL) was 
then added slowly and the reaction mixture was allowed to warm to room temperature before being stirred 
for 0.5 hours. The organics were removed in vacuo and the aqueous residue extracted three times with EtOAc 
(50 mL). The combined organics were dried over Na2SO4 and concentrated in vacuo. The residue was then 
taken up in anhydrous toluene (75 mL) and added slowly to a stirring solution of NCS (11.7 g, 87.5 mmol, 
1.75 eq.) in anhydrous toluene (75 mL) under argon at 0 °C. The reaction mixture was then allowed to warm 
to room temperature and left to stir for 16 hours. The reaction mixture was then filtered via gravity filtration 
and concentrated in vacuo. The residue was then taken up in anhydrous THF (50 mL) and added slowly to a 
stirring solution of 4-hydroxybenzaldehyde (6.1 g, 50 mmol, 1 eq.) and anhydrous TEA (10.5 mL, 75 mmol, 
1.5 eq.) in anhydrous THF (50 mL) at 0 °C. The reaction mixture was allowed to warm to room temperature 
and stirred for 2 hours before being filtered via gravity filtration. The filtrate was then concentrated and the 
residue taken up in EtOAc (50 mL). The organics were then washed with NaHCO3 (sat.) (50 mL) and the 
organics separated. The combined aqueous washings were then back-extracted twice with EtOAc (50 mL). 
The combined organics were then washed with water (50 mL), dried over Na2SO4 and concentrated in vacuo. 
The residue was then taken up in anhydrous THF (50 mL) and cooled to 0 °C. Sodium borohydride (3.8 g, 
100 mmol, 2 eq.) was added portion-wise and the reaction mixture was then allowed to warm to room 
temperature and stirred for 2 hours. The reaction was then concentrated in vacuo and the residue quenched 
with NH4Cl (sat.) (50 mL). The aqueous layer was then extracted three times with EtOAc (50 mL). The 
combined organics were then washed twice with 1M NaOH (aq.) (50 mL) and twice with water (50 mL) before 
being dried over Na2SO4 and concentrated in vacuo to afford the crude product. Purification by silica gel 
column chromatography (hexane 1:1 EtOAc, Rf = 0.20) gave the title compound as a colourless liquid (4.0 g, 
28%). IR (film, cm
−1); ν 3419 (O–H), 2881 (C–H), 1651 (C=C), 1267 (P=O), 1013 (P–O), 988 (C=C–H). 1H 
NMR (300 MHz, CDCl3); δH 7.22 (2H, d, J = 8.6 Hz, ArH), 7.08 (2H, d, J = 8.6 Hz, ArH), 5.89‒5.80 (2H, 
m, C=CH), 5.29 (2H, ddd, J = 17.1, 2.6, 1.5 Hz, C=CH2), 5.18 (2H, ddd, J = 10.4, 2.6, 1.1 Hz, C=CH2), 
4.56‒4.51 (6H, m, CH2OP + CH2OH), 2.90 (1H, br s, OH). 
13
C NMR (75.5 MHz, CDCl3); δC 149.7 (d, 
2
JC‒P 
= 7 Hz, ArC), 138.3 (d, 
5
JC‒P = 1 Hz, ArC), 132.0 (d, 
3
JC‒P = 7 Hz, CHCH2OP), 128.2 (ArC), 119.9 (d, 
3
JC‒P = 
5 Hz, ArC), 118.8 (C=CH), 68.9 (d, 
2




H} NMR (121.5 MHz, 
CDCl3); δP −5.52. HRMS (ESI): calc’d for C13H17NaO5P [M+Na]
+
 m/z 307.0706, found 307.0760.  
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4.2.5 Ferrocenoyl Azide 117 
  
To a stirring suspension of ferrocenecarboxylic acid (2.00 g, 8.7 mmol, 1 eq.) in anhydrous CH2Cl2 (20 mL) 
and anhydrous DMF (1 drop) at 0 °C was added oxalyl chloride (1.5 mL, 17.4 mmol, 2 eq.) drop-wise. The 
reaction mixture was allowed to warm to room temperature and stirred for 3 hours. The reaction mixture was 
then concentrated in vacuo and the remaining residue was taken up in CH2Cl2 (20 mL) before being cooled to 
0 °C. Tetrabutylammonium bromide (0.03 g, 0.1 mmol, 0.01 eq.) was then added followed by a solution of 
sodium azide (0.85 g, 13.1 mmol, 1.5 eq.) in water (4 mL). The reaction mixture was then allowed to warm 
to room temperature and left to stir for 16 hours. The reaction was then diluted with water (20 mL) and the 
organics separated. The aqueous layer was then extracted with CH2Cl2 (25 mL) and the combined organics 
were dried over MgSO4 and concentrated in vacuo to afford the crude product. Purification by silica gel 
column chromatography (hexane 1:1 CH2Cl2, Rf = 0.45) gave the title compound as a crystalline orange solid 
(1.75 g, 79%). MP: 86‒87 °C (lit.367 84‒86 °C). IR (solid, cm−1); 2149 (N3), 1671 (C=O). 
1
H NMR (300 
MHz, C6D6); δH 4.74 (2H, s, FcH), 4.02 (2H, s, FcH), 3.91 (5H, s, FcH). 
13
C NMR (75.5 MHz, C6D6); δC 






4.2.6 4-((Bis(2,2,2-trichloroethoxy)phosphoryl)oxy)benzyl Ferrocenylcarbamate 131 
  
Ferrocenoyl azide (128 mg, 0.5 mmol) and 4-(hydroxymethyl)phenyl bis(2,2,2-trichloroethyl) phosphate 129 
(233 mg, 0.5 mmol) were reacted together according to general procedure A to afford the crude product. 
Purification by silica gel column chromatography (hexane 8:2 EtOAc, Rf = 0.50) gave the title compound as 
an orange oil (108 mg, 31%). IR (film, cm
−1
); ν 3096 (N–H), 3014 (C–H), 2953 (C–H), 1707 (C=O), 1287 
(P=O), 1024 (P–O), 722 (C–Cl). 1H NMR (300 MHz, CDCl3); δH 7.40 (2H, d, J = 8.5 Hz, ArH), 7.28 (2H, d, 
J = 8.5 Hz, ArH), 6.09 (1H, br s, NH), 5.13 (2H, s, ArCH2), 4.85 (2H, dd, J = 11.1, 
3
JH‒P = 6.9 Hz, POCH2), 
4.80 (2H, dd, J = 11.1, 
3
JH‒P = 6.9 Hz, POCH2), 4.48 (2H, s, FcH), 4.82 (5H, s, FcH), 3.98 (2H, s, FcH). 
13
C 
NMR (75.5 MHz, CDCl3); δC 153.6 (C=O), 149.7 (d, 
2
JC‒P = 7 Hz, ArC), 134.3 (ArC), 130.0 (ArC), 120.4 
(d, 
3
JC‒P = 5 Hz, ArC), 95.4 (FcC), 94.4 (d, 
3
JC‒P = 11 Hz, CCl3), 77.6 (d, 
2
JC‒P = 5 Hz, CCCl3), 69.3(FcC), 









 m/z 713.8424, found 713.8407. 
 
4.2.7 4-((Bis(benzyloxy)phosphoryl)oxy)benzyl Ferrocenylcarbamate 137 
  
Ferrocenoyl azide (255 mg, 1 mmol) and dibenzyl (4-(hydroxymethyl)phenyl) phosphate 136 (384 mg, 1 
mmol) were reacted together according to general procedure A to afford the crude product. Purification by 
silica gel column chromatography (hexane 1:1 EtOAc, Rf = 0.45) gave the title compound as an orange solid 
(271 mg, 44%). MP: 118‒119 °C. IR (solid, cm−1); ν 3093 (N–H), 3048 (C–H), 1721 (C=O), 1263 (P=O), 
1075 (P–O). 1H NMR (300 MHz, CDCl3); δH 7.33‒7.30 (12H, m, ArH), 7.14 (2H, d, J = 8.2 Hz, ArH), 6.24 
(1H, br s, NH), 5.13 (2H, s, ArCH2), 5.10 (4H, s, POCH2), 4.49 (2H, s, FcH), 4.15 (5H, s, FcH), 3.97 (2H, s, 
FcH). 
13
C NMR (75.5 MHz, CDCl3); δC 153.7 (C=O), 150.5 (d, JC‒P = 7 Hz, ArC), 135.4 (d, JC‒P = 7 Hz, 
ArC), 133.4 (ArC), 129.8 (ArC), 128.8 (ArC), 128.7 (ArC), 128.1 (ArC), 120.2 (d, JC‒P = 5 Hz, ArC), 95.4 





(121.5 MHz, CDCl3); δP −5.39. HRMS (ESI): calc’d for C32H31FeNO6P [M+H]
+





4.2.8 4-((Bis(allyloxy)phosphoryl)oxy)benzyl Ferrocenylcarbamate 150 
  
Ferrocenoyl azide (255 mg, 1 mmol) and diallyl (4-(hydroxymethyl)phenyl phosphate 149 (284 mg, 1 mmol) 
were reacted together according to general procedure A to afford the crude product. Purification by silica gel 
column chromatography (hexane 1:1 EtOAc (Rf = 0.45, KMnO4)) gave the title compound as a dark orange 
oil (377 mg, 74%). IR (film, cm
−1); ν 3094 (N–H), 2953 (C–H), 1726 (C=O), 1259 (P=O), 1017 (P–O), 951 
(C=C–H). 1H NMR (300 MHz, C6D6); δH 7.26 (2H, d, J = 8.3 Hz, ArH), 7.12 (2H, d, J = 8.3 Hz, ArH), 6.81 
(1H, br s, NH), 5.71‒5.58 (2H, m, C=CH), 5.14 (2H, dd, J = 17.1, 1.3 Hz, C=CH2), 4.99 (2H, s, ArCH2), 4.92 
(2H, dd, J = 10.4, 1.3 Hz, C=CH2), 4.47‒4.33 (4H, m, CH2OP + FcH), 4.10 (5H, s, FcH), 3.81 (2H, s, FcH). 
13
C NMR (75.5 MHz, C6D6); δC 154.1 (C=O), 150.9 (d, 
2
JC‒P = 7 Hz, ArC), 134.3 (ArC), 132.5 (d, 
3
JC‒P = 7 
Hz, ArC), 130.1 (ArC), 120.5 (d, 
3
JC‒P = 5 Hz), 118.4 (C=CH), 97.0 (FcC), 69.5 (ArCH2), 68.9 (d, 
2
JC‒P = 6 




H} NMR (121.5 MHz, C6D6); δP −4.70. HRMS 
(ESI): calc’d for C24H26NaFeNO6P [M+Na]
+
 m/z 534.0745, found 534.0760. 
 
4.2.9 2-(Trimethylsilyl)ethyl Ferrocenylcarbamate 151 
  
Ferrocenoyl azide (1.02 g, 4 mmol) and 2-(trimethylsilyl)ethanol (0.57 mL, 4 mmol) were reacted together 
according to general procedure A to afford the crude product. Purification by silica gel column 
chromatography (hexane 1:1 EtOAc (Rf = 0.82)) gave the title compound as a pale orange solid (1.09 g, 
79%). MP: 87‒89 °C. IR (solid, cm−1); ν 3095 (N–H), 2954 (C–H), 2899 (C–H), 1698 (C=O), 1241 (Si–
CH3). 
1
H NMR (300 MHz, d6‒DMSO); δH 8.73 (1H, br s, NH), 4.46 (2H, s, FcH), 4.14‒4.09 (7H, m, FcH + 
OCH2), 3.91 (2H, s, FcH), 1.00 (2H, t, J = 8.1 Hz, SiCH2), 0.05 (9H, s, SiCH3). 
13
C NMR (75.5 MHz, 
d6‒DMSO); δC 153.8 (C=O), 97.0 (FcC), 68.7 (FcC), 63.5 (OCH2), 61.9 (FcC), 59.8 (FcC), 17.3 (SiCH2), 
−1.3 (SiCH3). HRMS (ESI): calc’d for C16H23FeNNaO2Si [M+Na]
+




4.2.10 4-(((Ferrocenylcarbamoyl)oxy)methyl)phenyl Phosphate 112 
  
4-((Bis(allyloxy)phosphoryl)oxy)benzyl ferrocenylcarbamate 150 (377 mg, 0.74 mmol), polymer-bound 
Pd(PPh3)4 (11 mg, 7.4 μmol), formic acid (0.4 mL, 11.1 mmol), anhydrous TEA (1.0 mL, 7.4 mmol) and 1M 
NaOH(aq.) (8.8 mL, 8.8 mmol) were all reacted together according to general procedure B to afford the crude 
product. Purification by preparative reverse phase C18-silica gel column chromatography (water) gave the 
title compound as an amorphous orange solid (241 mg, 69%). IR (solid, cm
−1); ν 1687 (C=O), 1233 (P=O), 
1071 (P–O). 1H NMR (300 MHz, D2O); δH 7.32 (2H, d, J = 8.3 Hz, ArH), 7.17 (2H, d, J = 8.3 Hz, ArH), 
5.05 (2H, s, CH2), 4.47 (2H, s, FcH), 4.17 (5H, s, FcH), 4.03 (2H, s, FcH). 
13
C NMR (75.5 MHz, D2O); δC 
156.5 (C=O), 154.2 (d, 
2
JC‒P = 6 Hz, ArC), 130.3 (ArC), 129.5 (ArC), 120.8 (d, 
3
JC‒P = 5 Hz, ArC), 95.1 




H} NMR (121.5 MHz, D2O); δP 0.95. HRMS 
(ESI); calc’d for C18H18FeNO6P [M−H]
−
 : m/z 430.0143, found 430.0180. Eox (1 mM, pH 9 Tris buffer): 85 
mV vs. Ag/AgCl. 
 
4.2.11 4-((((2-((2,4,6-Trimethylphenyl)sulfonamido)ethyl)carbomyl)oxy)methyl)phenyl Phosphate 
 198 
  
4-((Bis(allyloxy)phosphoryl)oxy)benzyl (2-((2,4,6-trimethylphenyl)sulfonamido)ethyl)  carbamate 201 
(276 mg, 0.5 mmol), polymer-bound Pd(PPh3)4 (7 mg, 5 μmol), formic acid (0.3 mL, 7.5 mmol) and 
anhydrous TEA (0.7 mL, 5 mmol) and 1M NaOH(aq.) (6 mL, 6 mmol) were all reacted together according to 
general procedure B to afford the crude product as a white solid (257 mg, quant.). MP: 255‒260 °C 
(decomp.). IR (solid, cm
−1); ν 3299 (N–H), 1707 (C=O), 1382 (SO2–N), 1255 (P=O), 1153 (SO2–N), 1095 
(S=O), 1015 (P–O). 1H NMR (300 MHz, D2O/NaOD); δH 7.23 (2H, d, J = 8.2 Hz, ArH), 7.12 (2H, d, J = 8.2 
Hz, ArH), 6.92 (2H, s, ArH), 4.79 (2H, s, ArCH2), 2.93 (2H, m, SO2NHCH2), 2.78 (2H, br s, CO2NHCH2), 




H} NMR (121.5 MHz, D2O/NaOD); δP 1.05. HRMS (ESI); 
calc’d for C19H24N2O8PS [M−H]
−




4.2.12 Aminoferrocene 111 
  
2-(Trimethylsilyl)ethyl ferrocenylcarbamate 151 (1.04 g, 3 mmol, 1 eq.) was dissolved in a 1M TBAF in 
THF solution (12 mL, 12 mmol, 4 eq.) and heated to 50 °C for 2 hours. After allowing to cool to room 
temperature, the reaction mixture was concentrated and the residue was quenched with water (20 mL). The 
aqueous layer was then extracted three times with CH2Cl2 (20 mL). The combined organics were then dried 
over MgSO4 and concentrated in vacuo to afford the crude product. Purification by silica gel column 
chromatography (hexane 8:2 EtOAc, Rf = 0.20) gave the title compound as an orange crystalline solid (0.51 
g, 85%). MP: 151‒153 °C decomp. (lit.423 155 °C decomp.). 1H NMR (300 MHz, C6D6); δH 3.98 (5H, s, 
FcH), 3.73 (2H, s, FcH), 3.69 (2H, s, FcH), 1.86 (2H, br s, NH2). 
13
C NMR (75.5 MHz, C6D6); δC 106.7 
(FcC), 69.1 (FcC), 63.5 (FcC), 58.3 (FcC). Eox (1 mM, pH 9 Tris buffer): −130 mV vs. Ag/AgCl. NMR data 






4.2.13 Ferrocenemethanol 170 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (0.4 mg, 0.5 μmol, 0.005 mol%) and N-(2-
aminoethyl)-4-methylbenzenesulfonamide 171 (0.2 mg, 1 μmol, 0.01 mol%) were suspended in degassed and 
distilled water (0.6 mL) and heated to 80 °C. The reaction mixture was allowed to stir for 1 hour before being 
cooled to room temperature. Sodium formate (340 mg, 5 mmol, 5 eq.) and ferrocenecarboxaldehyde (214 mg, 
1 mmol, 1 eq.) were then added and heated to 80 °C. The reaction mixture was allowed to stir for 1 hour 
before being cooled to room temperature. The reaction mixture was then diluted with water (6 mL) and 
extracted three times with Et2O (6 mL). The combined organics were then dried over MgSO4 and 
concentrated in vacuo to afford the crude product. Purification by silica gel column chromatography (CHCl3, 
Rf = 0.22) gave the title compound as a crystalline yellow solid (153 mg, 71%). MP: 76‒78 °C (lit.
424
 77 °C). 
1
H NMR (300 MHz, C6D6); δH 4.17 (2H, d, J = 5.5 Hz, CH2), 4.05 (2H, t, J = 1.7 Hz, FcH), 3.94‒3.92 (7H, 
m, FcH), 1.36 (1H, br t, J = 5.5 Hz, OH). 
13
C NMR (75.5 MHz, C6D6); δC 89.5 (FcC), 69.0 (FcC), 68.7 
(FcC), 68.5 (FcC), 61.1 (CH2). Eox (1 mM, pH 9 Tris buffer): −170 mV vs. Ag/AgCl. Eox (1 mM, pH 9.8 
CO3
2−
 buffer): −5 mV vs. Ag/AgCl. NMR data in accordance with literature precedent.425  
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4.2.14 N-(2-Aminoethyl)-4-methylbenzenesulfonamide 171 
  
4-Methylbenzenesulfonyl chloride (1.77 g, 10 mmol) was reacted according to general procedure C to afford 
the crude product. Purification by silica gel column chromatography (CH2Cl2 9:1 MeOH + 1% TEA, Rf = 
0.10) gave the title compound as a white solid (1.06 g, 49%). MP: 121‒122 °C (lit.426 122‒123 °C). 1H NMR 
(300 MHz, d6-DMSO); δH 7.66 (2H, d, J = 8.2 Hz, ArH), 7.37 (2H, d, J = 8.2 Hz, ArH), 3.37 (2H, br s, NH2), 
2.68 (2H, br t, J = 6.5 Hz, CH2NH), 2.49 (2H, br t, J = 6.5 Hz, CH2NH2), 2.36 (3H, s, CH3). 
13
C NMR (75.5 
MHz, d6-DMSO); δC 142.8 (ArC), 138.1 (ArC), 130.0 (ArC), 126.9 (ArC), 46.6 (CH2NH), 41.7 (CH2NH2), 




4.2.15 N-(2-Aminoethyl)benzenesulfonamide 173 
  
Benzenesulfonyl chloride (1.28 mL, 10 mmol) was reacted according to general procedure C to afford the 
crude product. Purification by silica gel column chromatography (CH2Cl2 9:1 MeOH + 1% TEA, Rf = 0.10) 
gave the title compound as a beige solid (0.49 g, 25%). MP: 50‒56 °C (lit.419 67‒69 °C). 1H NMR (300 
MHz, d6-DMSO); δH 7.79 (2H, m, ArH), 7.59 (3H, m, ArH), 3.90 (2H, br s, NH2), 2.73 (2H, br t, J = 6.4 Hz, 
CH2NH), 2.52 (2H, m, CH2NH2). 
13
C NMR (75.5 MHz, d6-DMSO); δC 140.6 (ArC), 132.3 (ArC), 129.2 




4.2.16 N-(2-Aminoethyl)-4-(tert-butyl)benzenesulfonamide 174 
  
4-(tert-Butyl)benzenesulfonyl chloride (2.33 g, 10 mmol) was reacted according to general procedure C to 
afford the crude product. Purification by silica gel column chromatography (CH2Cl2 9:1 MeOH + 1% TEA, 
Rf = 0.10) gave the title compound as a white solid (1.87 g, 77%). MP: 117‒119 °C (lit.
419
 79‒81 °C). 1H 
NMR (300 MHz, d6-DMSO); δH 7.70 (2H, d, J = 8.7 Hz, ArH), 7.59 (2H, d, J = 8.7 Hz, ArH), 3.36 (2H, br s, 
NH2), 2.69 (2H, br t, J = 6.4 Hz, CH2NH), 2.50 (2H, m, CH2NH2), 1.29 (9H, s, CH3). 
13
C NMR (75.5 MHz, 
d6-DMSO); δC 155.2 (ArC), 137.7 (ArC), 126.3 (ArC), 126.0 (ArC), 46.2 (CH2NH), 41.4 (CH2NH2), 34.8 





4.2.17 N-(2-Aminoethyl)-2,4,6-trimethylbenzenesulfonamide 175 
  
2,4,6-Trimethylbenzenesulfonyl chloride (2.19 g, 10 mmol) was reacted according to general procedure C to 
afford the crude product. Purification by silica gel column chromatography (CH2Cl2 9:1 MeOH + 1% TEA, 
Rf = 0.10) gave the title compound as a white solid (1.87 g, 77%). MP: 96‒99 °C (lit.
427
 90 °C). 
1
H NMR 
(300 MHz, d6-DMSO); δH 7.01 (2H, s, ArH), 3.31 (2H, br s, NH2), 2.68 (2H, br t, J = 6.5 Hz, CH2NH), 2.54 
(6H, s, ArCH3), 2.47 (2H, br t, J = 6.5 Hz, CH2NH2), 2.24 (3H, s, ArCH3). 
13
C NMR (75.5 MHz, d6-DMSO); 
δC 141.6 (ArC), 138.6 (ArC), 134.9 (ArC), 132.0 (ArC), 45.7 (CH2NH), 41.6 (CH2NH2), 22.9 (ArCH3), 20.7 




4.2.18 N-(2-Aminoethyl)-2,4,6-triisopropylbenzenesulfonamide 176 
  
2,4,6-Triisopropylbenzenesulfonyl chloride (3.03 g, 10 mmol) was reacted according to general procedure C 
to afford the crude product. Purification by silica gel column chromatography (CH2Cl2 9:1 MeOH + 1% 





H NMR (300 MHz, d6-DMSO); δH 7.21 (2H, s, ArH), 4.13 (2H, sept, J = 6.7 Hz, CH(CH3)2), 3.39 (2H, 
br s, NH2), 2.89 (1H, sept, J = 6.9 Hz, CH(CH3)2), 2.78 (2H, br t, J = 6.4 Hz, CH2NH), 2.53 (2H, br t, J = 6.4 
Hz, CH2NH2), 2.49 (1H, br t, J = 1.8 Hz, NH), 1.20‒1.17 (18H, m, CH(CH3)2). 
13
C NMR (75.5 MHz, d6-
DMSO); δC 152.2 (ArC), 149.9 (ArC), 133.6 (ArC), 123.8 (ArC), 45.7 (CH2NH), 41.7 (CH2NH2), 33.7 




4.2.19 N-(2-Aminoethyl)-4-fluorobenzenesulfonamide 177 
  
4-Fluorobenzenesulfonyl chloride (2.45 g, 10 mmol) was reacted according to general procedure C to afford 
the crude product. Purification by silica gel column chromatography (CH2Cl2 9:1 MeOH + 1% TEA, Rf = 
0.10) gave the title compound as a white solid (0.46 g, 21%). MP: 81‒85 °C. IR (solid, cm−1); ν 3349 (N–H), 
3298 (N–H), 3068 (C–H), 2951 (C–H), 2897 (C–H), 2854 (C–H), 2591 (N–H), 1658 (N–H), 1590 (N–H), 
1512 (N–H), 1490 (N–H), 1315 (SO2–N), 1286 (C–F), 1155 (SO2–N), 1063 (S=O). 
1
H NMR (400 MHz, d6-
DMSO); δH 7.86 (2H, m, ArH), 7.43 (2H, m, ArH), 3.50 (2H, br s, NH2), 2.73 (2H, br t, J = 6.4 Hz, CH2NH), 
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2.52 (2H, m, CH2NH2). 
13
C NMR (101 MHz, d6-DMSO); δC 164.1 (d, 
1
JC–F = 251 Hz, ArC), 137.0 (d, 
4
JC–F = 
3 Hz, ArC), 129.5 (d, 
3
JC–F = 9 Hz, ArC), 116.3 (d, 
2
JC–F = 23 Hz, ArC), 46.2 (CH2NH), 41.3 (CH2NH2). 
19
F 
NMR (376.5 MHz, d6-DMSO); δF −107.2. HRMS (ESI); calc’d for C8H12 FN2O2S [M+H]
+
 : m/z 219.0598, 
found 219.0547.  
 
4.2.20 N-(2-Aminoethyl)-4-bromobenzenesulfonamide 178 
  
4-Bromobenzenesulfonyl chloride (2.56 g, 10 mmol) was reacted according to general procedure C to afford 
the crude product. Purification by silica gel column chromatography (CH2Cl2 9:1 MeOH + 1% TEA, Rf = 
0.10) gave the title compound as a white solid (1.84 g, 66%). MP: 127‒128 °C (lit.428 124‒126 °C). IR 
(solid, cm
−1); ν 3350 (N–H), 3299 (N–H), 3056 (C–H), 2951 (C–H), 2861 (C–H), 2582 (N–H), 1591 (N–H), 
1574 (N–H), 1491 (N–H), 1316 (SO2–N), 1145 (SO2–N), 1065 (S=O), 662 (C–Br). 
1
H NMR (300 MHz, d6-
DMSO); δH 7.81 (2H, d, J = 8.7 Hz, ArH), 7.72 (2H, d, J = 8.7 Hz, ArH), 3.48 (2H, br s, NH2), 2.73 (2H, br t, 
J = 6.5 Hz, CH2NH), 2.50 (2H, m, CH2NH2). 
13
C NMR (75.5 MHz, d6-DMSO); δC 139.9 (ArC), 132.3 
(ArC), 128.5 (ArC), 126.1 (ArC), 46.2 (CH2NH), 41.3 (CH2NH2). HRMS (ESI); calc’d for C8H12BrN2O2S 
[M+H]
+
 : m/z 278.9797, found 278.9715.  
 
4.2.21 N-(2-Aminoethyl)-4-methoxybenzenesulfonamide 179 
  
4-Methoxybenzenesulfonyl chloride (2.07 g, 10 mmol) was reacted according to general procedure C to 
afford the crude product. Purification by silica gel column chromatography (CH2Cl2 9:1 MeOH + 1% TEA, 
Rf = 0.10) gave the title compound as a white crystalline solid (0.84 g, 37%). MP: 95‒97 °C (lit.
429
 90‒91 
°C). IR (solid, cm
−1); ν 3367 (N–H), 3307 (N–H), 3056 (C–H), 2944 (C–H), 2839 (C–H), 2603 (N–H), 1595 
(N–H), 1577 (N–H), 1495 (N–H), 1319 (SO2–N), 1143 (SO2–N), 1092 (C–O). 
1
H NMR (300 MHz, d6-
DMSO); δH 7.71 (2H, d, J = 8.9 Hz, ArH), 7.09 (2H, d, J = 8.9 Hz, ArH), 3.82 (3H, s, OCH3), 3.36 (2H, br s, 
NH2), 2.67 (2H, br t, J = 6.5 Hz, CH2NH), 2.49 (2H, t, J = 6.5 Hz, CH2NH2). 
13
C NMR (75.5 MHz, d6-
DMSO); δC 162.4 (ArC), 132.6 (ArC), 129.0 (ArC), 114.6 (ArC), 56.0 (OCH3), 46.5 (CH2NH), 41.7 
(CH2NH2). HRMS (ESI); calc’d for C9H14N2O3S [M+H]
+




4.2.22 N-(2-Aminoethyl)-4-nitrobenzenesulfonamide 180 
  
4-Nitrobenzenesulfonyl chloride (2.22 g, 10 mmol) was reacted according to general procedure C to afford 
the crude product. Purification by silica gel column chromatography (CH2Cl2 9:1 MeOH + 1% TEA, Rf = 
0.10) gave the title compound as a pale-yellow crystalline solid (0.71 g, 29%). MP: 147‒150 °C (lit.430 
149‒150 °C). IR (solid, cm−1); ν 3362 (N–H), 3274 (N–H), 3111 (C–H), 2931 (C–H), 2868 (C–H), 1602 (N–
H), 1528 (NO2), 1469 (N–H), 1349 (NO2), 1297 (SO2–N), 1154 (SO2–N), 1055 (S=O). 
1
H NMR (300 MHz, 
d6-DMSO); δH 8.40 (2H, d, J = 8.9 Hz, ArH), 8.03 (2H, d, J = 8.9 Hz, ArH), 3.67 (2H, br s, NH2), 2.78 (2H, 
br t, J = 6.5 Hz, CH2NH), 2.51 (2H, t, J = 6.5 Hz, CH2NH2). 
13
C NMR (75.5 MHz, d6-DMSO); δC 149.9 
(ArC), 146.7 (ArC), 128.4 (ArC), 124.9 (ArC), 46.4 (CH2NH), 41.7 (CH2NH2). HRMS (ESI); calc’d for 
C8H12N3O4S [M+H]
+
 : m/z 246.0543, found 246.0482. 
 
4.2.23 N-(2-Aminoethyl)-4-(trifluoromethyl)-benzenesulfonamide 181 
  
4-(Trifluoromethyl)benzenesulfonyl chloride (2.45 g, 10 mmol) was reacted according to general procedure 
C to afford the crude product. Purification by silica gel column chromatography (CH2Cl2 9:1 MeOH + 1% 
TEA, Rf = 0.10) gave the title compound as a white crystalline solid (1.58 g, 59%). MP: 112‒114 °C (lit.
419
 
103‒105 °C). 1H NMR (400 MHz, d6-DMSO); δH 8.03‒8.00 (4H, m, ArH), 3.59 (2H, br s, NH2), 2.77 (2H, 
br t, J = 6.0 Hz, CH2NH), 2.53 (2H, br t, J = 6.0 Hz, CH2NH2). 
13
C NMR (101 MHz, d6-DMSO); δC 145.1 
(ArC), 132.6 (q, 
2
JC–F = 32 Hz, ArC), 127.9 (ArC), 126.9 (q, 
3
JC–F = 4 Hz, ArC), 124.0 (q, 
1
JC–F = 273 Hz, 
ArC), 46.6 (CH2NH), 41.8 (CH2NH2). 
19







4.2.24 2,4,6-Trimethyl-N-(2-(methylamino)ethyl)benzenesulfonamide 184 
  
N-Methylethylenediamine (1.0 mL, 11.5 mmol) and mesitylsulfonyl chloride (838 mg, 3.8 mmol) were 
reacted together according to general procedure D to afford the crude product. Purification by silica gel 
column chromatography (CHCl3 9:1 MeOH + 1% TEA, Rf = 0.10) gave the title compound as a pale-yellow 
amorphous solid (180 mg, 18%). IR (film, cm
−1); ν 3318 (N–H), 2975 (N–H), 2935 (C–H), 2846 (C–H), 
1603 (N–H), 1563 (N–H), 1310 (SO2–N), 1146 (SO2–N). 
1
H NMR (300 MHz, CDCl3); δH 6.92 (2H, s, ArH), 
3.95 (2H, br s, NH2), 2.94‒2.91 (2H, m, CH2NHSO2), 2.69‒2.65 (2H, m, CH2NHCH3), 2.61 (6H, s, ArCH3), 
2.31 (3H, s, NHCH3), 2.26 (3H, s, ArCH3). 
13
C NMR (75.5 MHz, CDCl3); δC 142.1 (ArC), 139.1 (ArC), 
133.5 (ArC), 131.9 (ArC), 49.8 (CH2NHSO2), 41.1 (CH2NHCH3), 35.4 (NCH3), 22.9 (ArCH3), 20.9 
(ArCH3). HRMS (ESI); calc’d for C12H21N2O2S [M+H]
+
 : m/z 257.1324, found 257.1357. 
 
4.2.25 N-(2-Aminomethyl)-N,2,4,6-tetramethylbenzenesulfonamide 185 
  
N-Methylethylenediamine (1.0 mL, 11.5 mmol) and mesitylsulfonyl chloride (838 mg, 3.8 mmol) were 
reacted together according to general procedure D to afford the crude product. Purification by silica gel 
column chromatography (CHCl3 9:1 MeOH + 1% TEA, Rf = 0.05) gave the title compound as a dark-yellow 
amorphous solid (550 mg, 56%). IR (film, cm
−1); ν 3357 (N–H), 2975 (N–H), 2935 (C–H), 1603 (N–H), 
1563 (N–H), 1309 (SO2–N), 1143 (SO2–N). 
1
H NMR (300 MHz, CDCl3); δH 6.84 (2H, s, ArH), 3.11 (2H, t, 
J = 6.2 Hz, CH2NSO2), 2.74 (2H, t, J = 6.2 Hz, CH2NH2), 2.62 (3H, s, NCH3), 2.50 (6H, s, ArCH3), 2.19 
(3H, s, ArCH3), 1.27 (2H, br s, NH2). 
13
C NMR (75.5 MHz, CDCl3); δC 142.3 (ArC), 140.0 (ArC), 132.1 
(ArC), 131.8 (ArC), 51.9 (CH2NSO2), 39.3 (CH2NH2), 32.9 (NCH3), 22.6 (ArCH3), 20.7 (ArCH3). HRMS 
(ESI); calc’d for C12H21N2O2S [M+H]
+




4.2.26 N,2,4,6-Tetramethyl-N-(2-(methylamino)ethyl)benzenesulfonamide 187 
  
N,N’-Dimethylethylenediamine (1.1 mL, 10 mmol) was reacted according to general procedure E to afford 
the crude product. Purification by silica gel column chromatography (CH2Cl2 9:1 MeOH + 1% TEA, Rf = 
0.10) gave the title compound as a yellow oil (201 mg, 7%). IR (film, cm
−1); ν 2937 (C–H), 1603 (N–H), 
1564 (N–H), 1312 (SO2–N), 1148 (SO2–N). 
1
H NMR (300 MHz, CDCl3); δH 6.90 (2H, s, ArH), 3.22 (2H, t, 
J = 6.4 Hz, CH2NSO2), 2.74‒2.69 (5H, m, CH2NH + CH3NSO2), 2.56 (6H, s, ArCH3), 2.32 (3H, s, CH3NH), 
2.25 (3H, s, ArCH3), 1.56 (1H, br s, NH). 
13
C NMR (75.5 MHz, CDCl3); δC 142.5 (ArC), 140.3 (ArC), 132.1 
(ArC), 132.0 (ArC), 48.9 (CH2NSO2), 48.2 (CH2NH), 36.0 (CH3NSO2), 33.3 (CH3NH), 22.8 (ArCH3), 20.9 
(ArCH3). HRMS (ESI); calc’d for C13H23N2O2S [M+H]
+
 : m/z 271.1480, found 271.1517. 
 
4.2.27 N-(Dimethylamino)ethyl)-2,4,6-trimethylbenzenesulfonamide 189 
  
N,N-Dimethylethylenediamine (1.1 mL, 10 mmol) was reacted according to general procedure E to afford the 
crude product. Purification by silica gel column chromatography (CH2Cl2 9:1 MeOH + 1% TEA, Rf = 0.10) 
gave the title compound as pale-yellow oil (2.20 g, 81%). IR (film, cm
−1); ν 3303 (N–H), 2943 (C–H), 2862 
(C–H), 2824 (C–H), 2775 (C–H), 1604 (N–H), 1564 (N–H), 1319 (SO2–N), 1152 (SO2–N). 
1
H NMR (300 
MHz, CDCl3); δH 6.95 (2H, s, ArH), 5.45 (1H, br s, NH), 2.95‒2.91 (2H, m, CH2NH), 2.64 (6H, s, ArCH3), 
2.39‒2.35 (2H, m, CH2N(CH3)2), 2.29 (3H, s, ArCH3), 2.15 (6H, s, N(CH3)2). 
13
C NMR (75.5 MHz, CDCl3); 
δC 142.1 (ArC), 139.2 (ArC), 133.5 (ArC), 131.9 (ArC), 57.0 (CH2N(CH3)2), 44.7 (CH2N(CH3)2), 39.4 
(CH2NH), 22.8 (ArCH3), 20.9 (ArCH3). HRMS (ESI); calc’d for C13H23N2O2S [M+H]
+
 : m/z 271.1480, 
found 271.1504.  
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4.2.28 tert-Butyl (2-((2,4,6-Trimethylphenyl)sulfonamido)ethyl)carbamate 193 
  
To a stirring solution of ethylenediamine (0.67 mL, 10 mmol, 5 eq.) in chloroform (50 mL) at 0 °C was 
added di-tert-butyl dicarbonate (436 mg, 2 mmol, 1 eq.) in chloroform (50 mL) dropwise. After complete 
addition, the reaction mixture was allowed to warm to room temperature and left to stir for 16 hours. The 
reaction was then quenched with NaHCO3 (sat.) (50 mL) and the organics separated. The organics were then 
washed with brine before being dried over Na2SO4 and concentrated in vacuo. The residue was then taken up 
in anhydrous CH2Cl2 (10 mL) and cooled to 0 °C. A solution of 2,4,6-trimethylbenzenesulfonyl chloride (437 
mg, 2 mmol, 1 eq.) in anhydrous CH2Cl2 (50 mL) was then added dropwise. After complete addition, the 
reaction mixture was then quenched with water (50 mL) and the organics separated. The aqueous layer was 
then extracted twice with CH2Cl2 (50 mL). The combined organics were then washed with water (50 mL), 
dried over Na2SO4 and concentrated in vacuo to afford the crude product. Purification by silica gel column 
chromatography (hexane 8:2 EtOAc, Rf = 0.20) gave the title compound as a white solid (137 mg, 20%). 
MP: 86‒88 °C (lit.431 91‒94 °C). 1H NMR (300 MHz, CDCl3); δH 6.92 (2H, s, ArH), 5.57 (1H, br s, 
NHSO2), 5.04 (1H, br s, NHCO2), 3.20‒3.19 (2H, m, CH2NHSO2), 3.00‒2.94 (2H, m, CH2NHCO2), 2.60 
(6H, s, ArCH3), 2.27 (3H, s, ArCH3), 1.39 (9H, s, C(CH3)3). 
13
C NMR (75.5 MHz, CDCl3); δC 156.5 (C=O), 
142.2 (ArC), 139.1 (ArC), 133.5 (ArC), 132.0 (ArC), 79.7 (C(CH3)3), 43.0 (CH2NHSO2), 40.3 (CH2NHCO2), 







4.2.29 Benzyl (2-((2,4,6-Trimethylphenyl)sulfonamido)ethyl)carbamate 196 
  
Benzyl alcohol (0.52 mL, 5 mmol), 1,1’-carbonyldiimidazole (1.05 g, 6.5 mmol) and N-(2-aminoethyl)-2,4,6-
trimethylbenzenesulfonamide 175 (1.21 g, 5 mmol) were reacted together according to general procedure F 
to afford the crude product. Purification by silica gel column chromatography (hexane 7:3 EtOAc, Rf = 0.35) 
gave the title compound as a white solid (0.95 g, 50%). MP: 125‒126 °C. IR (solid, cm−1); ν 3435 (N–H), 
3200 (N–H), 2956 (C–H), 1680 (C=O), 1604 (N–H), 1311 (SO2–N), 1149 (SO2–N), 1094 (C–O), 1046 
(S=O). 
1
H NMR (300 MHz, CDCl3); δH 7.34‒7.29 (5H, m, ArH), 6.92 (2H, s, ArH), 5.47 (1H, br s, NHSO2), 
5.34 (1H, br s, NHCO2), 5.05 (2H, s, ArCH2), 3.30‒3.24 (2H, m, CH2NHSO2), 3.01‒2.99 (2H, m, 
CH2NHCO2), 2.60 (6H, s, ArCH3), 2.28 (3H, s, ArCH3). 
13
C NMR (75.5 MHz, CDCl3); δC 157.0 (C=O), 
142.4 (ArC), 139.1 (ArC), 136.4 (ArC), 133.4 (ArC), 132.1 (ArC), 128.6 (ArC), 128.2 (ArC), 128.1 (ArC), 
66.9 (ArCH2), 42.7 (CH2NHSO2), 40.8 (CH2NHCO2), 23.0 (ArCH3), 21.0 (ArCH3). HRMS (ESI); calc’d for 
C19H24N2O4SNa [M+Na]
+
 : m/z 399.1354, found 399.1322. 
 
4.2.30 4-Methoxybenzyl (2-((2,4,6-Trimethylphenyl)sulfonamido)ethyl)carbamate 197 
  
4-Methoxybenzyl alcohol (0.12 mL, 1 mmol), 1,1’-carbonyldiimidazole (221 mg, 1.3 mmol) and N-(2-
aminoethyl)-2,4,6-trimethylbenzenesulfonamide 175 (242 mg, 1 mmol) were reacted together according to 
general procedure F to afford the crude product. Purification by silica gel column chromatography (hexane 
1:1 EtOAc, Rf = 0.55) gave the title compound as a white crystalline solid (283 mg, 72%). MP: 78‒79 °C. IR 
(solid, cm
−1); ν 3328 (N–H), 2939 (C–H), 1682 (C=O), 1616 (N–H), 1329 (SO2–N), 1157 (SO2–N), 1077 (C–
O), 1027 (S=O). 
1
H NMR (300 MHz, CDCl3); δH 7.27 (2H, d, J = 8.6 Hz, ArH), 6.93 (2H, d, J = 8.6 Hz, 
ArH), 5.21 (1H, br t, J = 5.4 Hz, NHSO2), 5.10 (1H, br t, J = 5.7 Hz, NHCO2), 5.00 (2H, s, ArCH2), 3.80 
(3H, s, OCH3), 3.29‒3.24 (2H, m, CH2NHSO2), 3.04‒2.98 (2H, m, CH2NHCO2), 2.60 (6H, s, ArCH3), 2.29 
(3H, s, ArCH3). 
13
C NMR (75.5 MHz, CDCl3); δC 159.7 (C=O), 157.1 (ArC), 142.4 (ArC), 139.2 (ArC), 
133.5 (ArC), 132.2 (ArC), 130.1 (ArC), 128.4 (ArC), 114.0 (ArC), 66.9 (ArCH2), 55.4 (OCH3), 42.9 
(CH2NHSO2), 40.9 (CH2NHCO2), 23.0 (ArCH3), 21.1 (ArCH3). HRMS (ESI); calc’d for C20H26N2O5SNa 
[M+Na]
+





 (2-((2,4,6-Trimethylphenyl)sulfonamido)ethyl)carbamate 201 
  
Diallyl (4-(hydroxymethyl)phenyl) phosphate 149 (1.86 g, 6.5 mmol), 1,1’-carbonyldiimidazole (1.36 g, 8.4 
mmol) and N-(2-aminoethyl)-2,4,6-trimethylbenzenesulfonamide 175 (2.71 g, 8.4 mmol) were reacted 
together according to general procedure F to afford the crude product. Purification by silica gel column 
chromatography (hexane 1:1 EtOAc, Rf = 0.10) gave the title compound as a colourless oil (2.71 g, 76%). IR 
(film, cm
−1); ν 3299 (N–H), 2942 (C–H), 1707 (C=O), 1605 (N–H), 1324 (SO2–N), 1255 (P=O), 1153 (SO2–
N), 1095 (C–O), 1015 (P–O), 989 (C=C–H). 1H NMR (300 MHz, CDCl3); δH 7.23 (2H, d, J = 8.3 Hz, ArH), 
7.12 (2H, d, J = 8.3 Hz, ArH), 6.87 (2H, s, ArH), 5.88 (2H, app ddd, J = 22.6, 11.0, 5.6 Hz, C=CH), 5.78 
(2H, br t, J = 5.8 Hz, CO2NH), 5.32 (2H, ddd, J = 17.1, 2.9, 1.4 Hz, C=CH2), 5.21 (2H, dd, J = 10.4, 1.4 Hz, 
C=CH2), 4.95 (2H, s, ArCH2), 4.59 (4H, ddd, J = 8.4, 5.7, 1.3 Hz, CH2OP), 3.17 (2H, app q, J = 5.5 Hz, 
CH2NHSO2), 2.91 (2H, app q, J = 5.5 Hz, CH2NHCO2), 2.54 (6H, s, ArCH3), 2.22 (3H, s, ArCH3). 
13
C NMR 
(75.5 MHz, CDCl3); δC 156.8 (C=O), 150.2 (d, JC–P = 7 Hz, ArC), 142.1 (ArC), 139.0 (ArC), 133.6 (ArC), 
132.0 (ArC), 132.0 (CHCH2OP), 131.9 (ArC), 129.6 (ArC), 121.1 (d, JC–P = 5 Hz, ArC), 118.8 (C=CH), 69.0 
(d, JC–P = 5 Hz, CH2OP), 65.9 (CH2O2C), 42.5 (CH2NHSO2), 40.7 (CH2NHCO2), 22.9 (ArCH3), 20.9 
(ArCH3). 
31
P NMR (121.5 MHz, CDCl3); δP −5.65. HRMS (ESI); calc’d for C25H33N2O8PS [M+H]
+
 : m/z 
553.1773, found 553.1765.  
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4.2.32 Allyl (2-((2,4,6-Trimethylphenyl)sulfonamido)ethyl)carbamate 208 
  
To a stirring solution of N-(2-aminoethyl)-2,4,6-trimethylbenzenesulfonamide 175 (2.42 g, 10 mmol, 1 eq.) 
in anhydrous THF (100 mL) at 0 °C was added allyl chloroformate (1.3 mL, 10 mmol, 1 eq.) dropwise, 
followed by anhydrous TEA (1.4 mL, 10 mmol, 1 eq.). The reaction mixture was allowed to warm to room 
temperature and left to stir for 16 hours before being concentrated in vacuo. The residue was then quenched 
with NaHCO3 (sat.) (50 mL) and extracted three times with EtOAc (50 mL). The combined organics were then 
washed with water (50 mL), then brine (50 mL) before being dried over MgSO4 and concentrated in vacuo to 
afford the crude product. Purification by silica gel column chromatography (hexane 1:1 EtOAc, Rf = 0.50) 
gave the title compound as a white solid (2.61 g, 80%). MP: 82‒83 °C. IR (solid, cm−1); ν 3365 (N–H), 3287 
(N–H), 2942 (C–H), 1699 (C=O), 1603 (N–H), 1323 (SO2–N), 1152 (SO2–N), 1072 (C–O), 1013 (S=O), 990 
(C=C–H). 1H NMR (300 MHz, CDCl3); δH 6.92 (2H, s, ArH), 5.85 (1H, ddt, J = 17.2, 10.5, 5.5 Hz, C=CH), 
5.61 (1H, br t, J = 5.5 Hz, SO2NH), 5.42 (1H, br s, CO2NH), 5.25 (1H, dd, J = 17.2, 1.4 Hz, C=CH2), 5.16 
(1H, dd, J = 10.5, 1.4 Hz, C=CH2), 4.49 (2H, d, J = 5.5 Hz, OCH2), 3.26 (2H, app q, J = 5.7 Hz, 
SO2NHCH2), 3.00 (2H, app q, J = 5.7 Hz, CO2NHCH2), 2.59 (6H, s, ArCH3), 2.27 (3H, s, ArCH3). 
13
C NMR 
(75.5 MHz, CDCl3); δC 156.9 (C=O), 142.3 (ArC), 139.1 (ArC), 133.5 (ArC), 132.7 (H2C=C), 132.0 (ArC), 
117.7 (H2C=C), 65.7 (OCH2), 42.7 (SO2NHCH2), 40.7 (CO2NHCH2), 22.9 (CH3), 20.9 (CH3). HRMS (ESI); 
calc’d for C15H22N2NaO4S [M+Na]
+






 (2(((Allyoxy)carbonyl)amino)ethyl)(mesitylsulfonyl)carbamate 207 
  
Diallyl (4-(hydroxymethyl)phenyl) phosphate 149 (182 mg, 0.64 mmol), phosgene solution (0.3 mL, 0.64 
mmol), allyl (2-((2,4,6-trimethylphenyl)sulfonamido)ethyl)carbamate 208 (191 mg, 0.59 mmol), DIPEA (0.2 
mL, 0.88 mmol) and DMAP (7 mg, 0.059 mmol) were all reacted together according to general procedure G 
to afford the crude product. Purification by silica gel column chromatography (hexane 1:1 EtOAc, Rf = 0.40) 
gave the title compound as an amorphous pale-yellow solid (114 mg, 31%). IR (film, cm
−1); ν 1719 (C=O), 
1604 (N–H), 1346 (SO2–N), 1221 (P=O), 1167 (SO2–N), 1017 (P–O), 930 (C=C–H). 
1
H NMR (300 MHz, 
CDCl3); δH 7.08 (2H, d, J = 7.8 Hz, ArH), 6.96 (2H, d, J = 7.8 Hz, ArH), 6.83 (2H, s, ArH), 5.99‒5.84 (3H, 
m, C=CH), 5.39‒5.15 (7H, m, C=CH2 + NH), 4.97 (2H, s, ArCH2), 4.65‒4.55 (6H, m, C=CHCH2), 4.04 (2H, 
br s, CH2), 3.49 (2H, br s, CH2), 2.41 (6H, s, ArCH3), 2.27 (3H, s, ArCH3). 
13
C NMR (75.5 MHz, CDCl3); δC 
156.4 (SO2NC=O), 152.4 (NHC=O), 150.8 (d, 
2
JC‒P = 7 Hz, PO4ArC), 143.3 (SO2ArC), 139.9 (ArC), 139.9 
(ArC), 133.9 (ArC), 132.0 (H2C=C), 131.9 (H2C=C), 131.2 (ArC), 130.1 (ArC), 120.1 (d, 
3
JC‒P = 5 Hz, ArC), 
118.8 (H2C=C), 117.4 (H2C=C), 68.9 (d, 
2
JC‒P = 5 Hz, PO4CH2), 68.3 (NHCO2CH2), 65.6 (ArCH2), 46.2 




H} NMR (121.5 MHz, CDCl3); δP −5.38. HRMS (ESI); 
calc’d for C29H38N2O10PS [M+H]
+
 : m/z 637.1985, found 637.1979. 
 
4.2.34 4-((Bis(allyloxy)phosphoryl)oxy)benzyl (2-((((4-((Bis(allyloxy)phosphoryl)oxy)carbonyl) 
 amino)ethyl)(mesitylsulfonyl)carbamate 210 
  
Diallyl (4-(hydroxymethyl)phenyl) phosphate 149 (313 mg, 1.1 mmol), phosgene solution (0.6 mL, 1.1 
mmol), 4-((bis(allyloxy)phosphoryl)oxy)benzyl (2-((2,4,6-trimethylphenyl)sulfonamido)ethyl) carbamate 
201 (553 mg, 1 mmol), DIPEA (0.3 mL, 1.5 mmol) and DMAP (12 mg, 0.1 mmol) were all reacted together 
according to general procedure G to afford the crude product. Purification by silica gel column 
chromatography (hexane 1:1 EtOAc, Rf = 0.10) gave the title compound as a colourless oil (346 mg, 40%). 
IR (film, cm
−1); ν 1719 (C=O), 1346 (SO2–N), 1218 (P=O). 
1
H NMR (300 MHz, CDCl3); δH 7.34 (2H, d, J = 
8.3 Hz, ArH), 7.18 (2H, d, J = 8.3 Hz), 7.09 (2H, d, J = 8.3 Hz, ArH), 6.96 (2H, d, J = 8.3 Hz, ArH), 6.85 
(2H, s, ArH), 5.93 (4H, dtd, J = 16.7, 10.7, 5.4 Hz, C=CH), 5.40‒5.33 (4H, m, C=CH2), 5.29‒5.23 (5H, m, 
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C=CH2 + NH), 5.08 (2H, s, ArCH2), 4.97 (2H, s, ArCH2), 4.66‒4.60 (8H, m, C=CHCH2), 4.06 (2H, t, J = 5.4 
Hz, SO2NCH2), 3.52 (2H, app q, J = 5.4 Hz, NHCH2), 2.42 (6H, s, ArCH3), 2.29 (3H, s, ArCH3). 
13
C NMR 
(75.5 MHz, CDCl3); δC 156.6 (SO2NC=O), 152.5 (NHC=O), 150.9 (d, J = 7 Hz, PO4ArC), 150.4 (d, J = 7 
Hz, PO4ArC), 143.5 (SO2ArC), 140.0 (ArC), 133.9 (ArC), 133.7 (ArC), 132.2 (H2C=C), 132.1 (H2C=C), 
132.0 (ArC), 131.3 (ArC), 130.3 (ArC), 129.7 (ArC), 120.2 (d, 
3
JC‒P = 5 Hz, ArC), 120.1 (d, 
3
JC‒P = 5 Hz, 
ArC), 119.0 (H2C=C), 118.8 (H2C=C), 69.0 (d, 
2
JC‒P = 6 Hz, PO4CH2), 69.0 (d, 
2
JC‒P = 6 Hz, PO4CH2), 68.5 




H} NMR (121.5 MHz, 
CDCl3); δP −5.35, −5.37. HRMS (ESI); calc’d for C39H49N2O14P2S [M+H]
+





 phenyl Phosphate 211 
  
To a stirring solution of 4-((bis(allyloxy)phosphoryl)oxy)benzyl(2-((((4-((bis(allyloxy)phosphoryl)oxy) 
carbonyl)amino)ethyl)(mesitylsulfonyl)carbamate 210 (346 mg, 0.4 mmol, 1 eq.) in anhydrous THF (4 mL) 
at 0 °C was added polymer-bound Pd(PPh3)4 (57 mg, 0.04 mmol, 0.1 eq.) followed by formic acid (0.2 mL, 6 
mmol, 15 eq.) then anhydrous TEA (0.6 mL, 4 mmol, 10 eq.). The reaction mixture was allowed to warm to 
room temperature and left to stir for 16 hours. The reaction was then filtered via gravity filtration and the 
filtrate concentrated in vacuo. The residue was then cooled to 0 °C and 1M NaHCO3(aq.) (5.6 mL, 5.6 mmol, 
14 eq.) was added slowly. The reaction mixture was allowed to warm to room temperature and stirred for 1 
hour before being concentrated in vacuo to afford the crude product. Purification by preparative reverse 
phase C18-silica gel column chromatography (water) gave the title compound as a white solid (316 mg, 
quant.). MP: 275‒280 °C (decomp.). IR (solid, cm−1); ν 1619 (C=O), 1425 (P=O). 1H NMR (300 MHz, 
CDCl3); δH 7.16 (2H, d, J = 8.3 Hz, ArH), 7.03‒7.00 (6H, m, ArH), 6.57 (2H, s, ArH, ArH), 4.58 (2H, s, 
ArCH2), 4.38 (2H, s, ArCH2), 2.78 (2H, br s, SO2NCH2), 2.55 (2H, br s, O2CNHCH2), 2.32 (6H, s, ArCH3), 
1.84 (3H, s, ArCH3). 
13
C NMR (75.5 MHz, CDCl3); δC 158.0 (C=O), 153.9 (d, 
2
JC‒P = 6 Hz, PO4ArC), 153.3 
(d, 
2
JC‒P = 6 Hz, PO4ArC), 140.4 (ArC), 138.4 (ArC), 137.1 (ArC), 135.4 (ArC), 131.5 (ArC), 130.5 (ArC), 
130.1 (ArC), 129.3 (ArC), 129.2 (ArC), 120.7 (d, 
3
JC‒P = 4 Hz, ArC), 68.7 (ArCH2), 63.8 (ArCH2), 44.1 








4.2.36 Naphthalen-1-ylmethanol 212 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (170 mg, 2.5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and 1-naphthaldehyde (68 µL, 
0.5 mmol) were all reacted together according to general procedure H to afford the crude product. 
Purification by silica gel column chromatography (hexane 9:1 EtOAc) gave the title compound as a 
colourless oil. 
1
H NMR (300 MHz, CDCl3); δH 8.13‒8.10 (1H, m, ArH), 7.91‒7.88 (1H, m, ArH), 7.84‒7.81 
(1H, m, ArH), 7.59‒7.42 (4H, m, ArH), 5.13 (2H, s, CH2), 1.95 (1H, br s, OH). 
13
C NMR (75.5 MHz, 
CDCl3); δC 136.3 (ArC), 133.9 (ArC), 131.3 (ArC), 128.8 (ArC), 128.7 (ArC), 126.5 (ArC), 126.0 (ArC), 
125.5 (ArC), 125.4 (ArC), 123.8 (ArC), 63.8 (CH2). NMR data in accordance with literature precedent.
432 
 
4.2.37 Anthracen-9-ylmethanol 213 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (170 mg, 2.5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and anthracene-9-
carboxaldehyde (103 mg, 0.5 mmol) were all reacted together according to general procedure H to afford the 
crude product. Purification by silica gel column chromatography (hexane 9:1 EtOAc) gave the title 
compound as a pale yellow crystalline solid.
 
MP: 161‒164 °C. (lit.433 159‒162 °C). 1H NMR (300 MHz, 
CDCl3); δH 8.44 (1H, s, ArH), 8.37 (2H, d, J = 8.7 Hz, ArH), 8.02 (2H, d, J = 8.2 Hz, ArH), 7.58‒7.46 (4H, 
m, ArH), 5.61 (2H, s, CH2), 1.87 (1H, br s, OH). 
13
C NMR (75.5 MHz, CDCl3); δC 131.6 (ArC), 131.1 
(ArC), 130.2 (ArC), 129.3 (ArC), 128.5 (ArC), 126.6 (ArC), 125.2 (ArC), 124.0 (ArC), 57.5 (CH2).NMR 
data in accordance with literature precedent.
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4.2.38 Pyren-1-ylmethanol 214 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
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sodium formate (170 mg, 2.5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and pyrene-1-carboxaldehyde 
(115 mg, 0.5 mmol) were all reacted together according to general procedure H to afford the crude product. 
Purification by silica gel column chromatography (hexane 9:1 EtOAc) gave the title compound as a pale 
yellow crystalline solid. MP: 94‒98 °C. (lit.435 124‒126 °C). 1H NMR (300 MHz, CDCl3); δH 8.26 (1H, d, J 
= 9.2 Hz, ArH), 8.17 (2H, d, J = 7.6 Hz, ArH), 8.09‒7.94 (6H, m, ArH), 5.31 (2H, s, CH2), 2.02 (1H, br s, 
OH). 
13
C NMR (75.5 MHz, CDCl3); δC 133.8 (ArC), 131.3 (ArC), 131.3 (ArC), 130.8 (ArC), 128.8 (ArC), 
127.9 (ArC), 127.5 (ArC), 127.5 (ArC), 126.0 (ArC), 126.0 (ArC), 125.4 (ArC), 125.3 (ArC), 124.9 (ArC), 




4.2.39 2,6-Difluorobenzyl Alcohol 215 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (340 mg, 5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and 2,6-difluorobenzaldehyde 
(108 µL, 1 mmol) were all reacted together according to general procedure I to afford the crude product. 
Purification by silica gel column chromatography (hexane 9:1 EtOAc) gave the title compound as a 
colourless oil.
 1
H NMR (300 MHz, CDCl3); δH 7.31‒7.21 (1H, m, ArH), 6.95‒6.85 (2H, m, ArH), 4.78 (2H, 
s, CH2), 2.05 (1H, br s, OH). 
13
C NMR (75.5 MHz, CDCl3); δC 161.7 (dd, 
1
JC–F = 249 Hz & 
3
JC–F = 8 Hz, 
ArC), 130.0 (t, 
3
JC–F = 10 Hz, ArC), 116.4 (t, 
2
JC–F = 19 Hz, ArC), 111.5 (dd, 
2
JC–F = 25 Hz & 
4
JC–F = 8 Hz, 
ArC), 53.1 (t, 
3
JC–F = 4 Hz, CH2). 
19





4.2.40 4-Fluorobenzyl Alcohol 216 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (340 mg, 5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and 4-fluorobenzaldehyde (94 
µL, 1 mmol) were all reacted together according to general procedure I to afford the crude product. 
Purification by silica gel column chromatography (hexane 9:1 EtOAc) gave the title compound as a 
colourless oil. 
1
H NMR (300 MHz, CDCl3); δH 7.35‒7.29 (2H, m, ArH), 7.08‒7.00 (2H, m, ArH), 4.64 (2H, 
s, CH2), 1.97 (1H, br s, OH). 
13
C NMR (75.5 MHz, CDCl3); δC 162.4 (d, 
1
JC–F = 246 Hz, ArC), 136.7 (d, 
4
JC–
F = 3 Hz, ArC), 128.9 (d, 
3
JC–F = 8 Hz, ArC), 115.5 (d, 
2
JC–F = 21 Hz, ArC), 64.7 (CH2). 
19
F NMR (470.5 





4.2.41 4-(Trifluoromethyl)benzyl Alcohol 217 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (340 mg, 5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and 4-
(trifluoromethyl)benzaldehyde (136 µL, 1 mmol) were all reacted together according to general procedure I 
to afford the crude product. Purification by silica gel column chromatography (hexane 9:1 EtOAc) gave the 
title compound as a colourless oil. 
1
H NMR (300 MHz, CDCl3); δH 7.57 (2H, d, J = 8.1 Hz, ArH), 7.39 (2H, 
d, J = 8.1 Hz, ArH), 4.65 (2H, s, CH2), 3.24 (1H, br s, OH). 
13
C NMR (75.5 MHz, CDCl3); δC 144.8 (q, 
4
JC–F 
= 1 Hz, ArC), 129.8 (q, 
2
JC–F = 32 Hz, ArC), 126.9 (ArC), 125.5 (q, 
3
JC–F = 32 Hz, ArC), 124.3 (q, 
1
JC–F = 
272 Hz, ArC), 64.3 (CH2). 
19




4.2.42 4-Nitrobenzyl Alcohol 218 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (340 mg, 5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and 4-nitrobenzaldehyde (153 
mg, 1 mmol) were all reacted together according to general procedure I to afford the crude product. 
Purification by silica gel column chromatography (hexane 9:1 EtOAc) gave the title compound as a white 
solid. MP: 89‒91 °C (lit.439 91‒93 °C). 1H NMR (300 MHz, CDCl3); δH 8.18 (2H, d, J = 8.2 Hz, ArH), 7.51 
(2H, d, J = 8.2 Hz, ArH), 4.82 (2H, s, CH2), 2.29 (1H, br s, OH). 
13
C NMR (75.5 MHz, CDCl3); δC 148.4 




4.2.43 4-Methoxybenzyl Alcohol 219 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (170 mg, 2.5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and p-anisaldehyde (61 µL, 
0.5 mmol) were all reacted together according to general procedure H to afford the crude product. 





H NMR (300 MHz, CDCl3); δH 7.20 (2H, d, J = 8.7 Hz, ArH), 6.81 (2H, d, J = 8.7 Hz, ArH), 
4.51 (2H, s, CH2), 3.72 (3H, s, OCH3), 1.89 (1H, br s, OH). 
13
C NMR (75.5 MHz, CDCl3); δ 159.3 (ArC), 




4.2.44 4-Hydroxy-3-methoxybenzyl Alcohol 220 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (170 mg, 2.5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and vanillin (76 mg, 0.5 
mmol) were all reacted together according to general procedure H to afford the crude product. Purification by 
silica gel column chromatography (hexane 9:1 EtOAc) gave the title compound as a white solid.
 
MP: 
114‒115 °C (lit.442 112‒114 °C). 1H NMR (300 MHz, d6-DMSO); δH 8.80 (1H, s, ArOH), 6.88 (1H, s, ArH), 
6.74‒6.68 (2H, m, ArH), 5.02 (1H, t, J = 5.7 Hz, CH2OH), 4.38 (2H, d, J = 5.7 Hz, CH2OH), 3.75 (3H, s 
OCH3). 
13
C NMR (75.5 MHz, d6-DMSO); δC 147.4 (ArC), 145.3 (ArC), 133.6 (ArC), 119.2 (ArC), 115.1 
(ArC), 111.1 (ArC), 63.1 (CH2), 55.5 (OCH3). NMR data in accordance with literature precedent.
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4.2.45 2-Hydroxybenzyl Alcohol 221 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (170 mg, 2.5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and salicylaldehyde (53 µL, 
0.5 mmol) were all reacted together according to general procedure H to afford the crude product. 
Purification by silica gel column chromatography (hexane 9:1 EtOAc) gave the title compound as a white 
crystalline solid. MP: 82‒84 °C. (lit.444 82‒84 °C). 1H NMR (300 MHz, CDCl3); δH 7.34 (1H, br s, ArOH), 
7.24‒7.18 (1H, m, ArH), 7.04 (1H, dd, J = 7.4, 1.3 Hz, ArH), 6.89‒6.83 (2H, m, ArH), 4.85 (2H, s, CH2), 
2.46 (1H, br s, CH2OH). 
13
C NMR (75.5 MHz, CDCl3); δC 156.1 (ArC), 129.7 (ArC), 128.0 (ArC), 124.8 





4.2.46 4-Isopropylbenzyl Alcohol 222 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (170 mg, 2.5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and cuminaldehyde (76 µL, 
0.5 mmol) were all reacted together according to general procedure H to afford the crude product. 
Purification by silica gel column chromatography (hexane 9:1 EtOAc) gave the title compound as a 
colourless oil.
 1
H NMR (300 MHz, CDCl3); δH 7.31 (2H, d, J = 8.2 Hz, ArH), 7.24 (2H, d, J = 8.2 Hz, ArH), 
4.66 (2H, s, CH2), 2.92 (1H, sept, J = 6.9 Hz, CH), 1.71 (1H, br s, OH), 1.26 (6H, d, J = 6.9 Hz, CH3). 
13
C 
NMR (75.5 MHz, CDCl3); δC 148.5 (ArC), 138.3 (ArC), 127.2 (ArC), 126.7 (ArC), 65.3 (CH2), 33.9 (CH), 
24.1 (CH3). NMR data in accordance with literature precedent.
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4.2.47 4-(Hydroxymethyl)benzaldehyde 223 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (170 mg, 2.5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and terephthalaldehyde (67 
mg, 0.5 mmol) were all reacted together according to general procedure H to afford the crude product. 
Purification by silica gel column chromatography (hexane 9:1 EtOAc) gave the title compound as a white 
solid.
 
MP: 41‒43 °C (lit.446 43‒44 °C). 1H NMR (300 MHz, CDCl3); δH 9.98 (1H, s, CHO), 7.85 (2H, d, J = 
8.1 Hz, ArH), 7.51 (2H, d, J = 8.1 Hz, ArH), 4.79 (2H, s, CH2), 2.28 (1H, br s, OH). 
13
C NMR (75.5 MHz, 
CDCl3); δC 192.2 (C=O, 148.0 (ArC), 135.8 (ArC), 130.1 (ArC), 127.1 (ArC), 64.6 (CH2). NMR data in 
accordance with literature precedent.
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4.2.48 Cyclohexanemethanol 224 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (170 mg, 2.5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and 
cyclohexanecarboxaldehyde (61 μL, 0.5 mmol) were all reacted together according to general procedure H to 
afford the crude product. Purification by silica gel column chromatography (hexane 9:1 EtOAc) gave the title 
compound as a colourless oil.
 1
H NMR (300 MHz, CDCl3); δH 3.44 (2H, d, J = 6.3 Hz, CH2), 1.77‒1.66 (5H, 
 
191 
m, CH), 1.56 (1H, br s, OH), 1.53‒1.41 (1H, m, CH), 1.32‒1.21 (3H, m, CH), 1.00‒0.83 (2H, m, CH). 13C 
NMR (75.5 MHz, CDCl3); δC 69.0 (CH2OH), 40.7 (CH), 29.7 (CH2), 26.7 (CH2), 26.0 (CH2). NMR data in 




4.2.49 1-Octanol 225 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (170 mg, 2.5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and octanal (79 µL, 0.5 
mmol) were all reacted together according to general procedure H to afford the crude product. Purification by 
silica gel column chromatography (hexane 9:1 EtOAc) gave the title compound as a colourless oil. 
1
H NMR 
(300 MHz, CDCl3); δH 3.64 (2H, t, J = 6.6 Hz, CH2OH), 1.61‒1.52 (2H, m, CH2), 1.39‒1.28 (11H, m, CH2 + 
OH), 0.88 (3H, t, J = 6.8 Hz, CH3). 
13
C NMR (75.5 MHz, CDCl3); δ 63.2 (CH2OH), 33.0 (CH2), 29.5 (CH2), 
29.4 (CH2), 25.9 (CH2), 22.8 (CH2), 14.2 (CH3). NMR data in accordance with literature precedent.
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4.2.50 2-Methoxycinnamyl Alcohol 226 
  
Dichloro(pentamethylcyclopentadienyl)iridium(III) dimer (1 mg, 0.00125 mmol), 4-((((2-((2,4,6-
trimethylphenyl)sulfonamido)ethyl)carbamoyl)oxy) methyl)phenyl phosphate 198 (1.3 mg, 0.0025 mmol), 
sodium formate (170 mg, 2.5 mmol), alkaline phosphatase (2.5 mg, 10 Umg
−1
) and 2-
Methoxycinnamaldehyde (81 mg, 0.5 mmol) were all reacted together according to general procedure H to 
afford the crude product. Purification by silica gel column chromatography (hexane 9:1 EtOAc) gave the title 
compound as a colourless oil.
 1
H NMR (300 MHz, CDCl3); δH 7.44 (1H, dd, J = 7.6, 1.7 Hz, ArH), 
7.27‒7.21 (1H, m, ArH), 6.96‒6.86 (3H, m, ArH + ArCH), 6.38 (1H, dt, J = 16.0, 5.9 Hz, CH2CH), 4.32 (2H, 
d, J = 5.0 Hz, CH2OH), 3.84 (3H, s, OCH3), 1.81 (1H, br s, OH).
 13
C NMR (75.5 MHz, CDCl3); δC 156.8 
(ArC), 129.4 (ArC), 128.9 (ArC), 127.1 (ArC), 126.2 (ArC), 125.8 (ArC), 120.8 (C=CHCH2), 110.9 






1. R. G. Macfarlane, Nature, 1964, 202, 498. 
2. G. Wald, Science, 1965, 150, 1028. 
3. A. L. Lehninger, D. L. Nelson and M. M. Cox, Lehninger Principles of Biochemistry, 
W. H. Freeman, New York, 4
th
 edn., 2004, ch. 12, pp. 421–439. 
4. G. Krauss, Biochemistry of Signal Transduction and Regulation, Wiley–VCH, 
Weinheim, 3
rd
 edn., 2008, ch. 3, pp. 115–149. 
5. J. M. Bowness, Science, 1966, 152, 1370. 
6. P. Scrimin and L. J. Prins, Chem. Soc. Rev., 2011, 40, 4488. 
7. Y.-W. Tang, G. W. Procop and D. H. Persing, Clin. Chem., 1997, 43, 2021. 
8. S. Bell, Annu. Rev. Anal. Chem., 2009, 2, 297. 
9. M. Vanderlaan, B. E. Watkins and L. Stanker, Environ. Sci. Technol., 1988, 22, 247. 
10. S. C. Andras, J. B. Power, E. C. Cocking and M. R. Davey, Mol. Biotechnol., 2001, 
19, 29. 
11. R. K. Saiki, D. H. Gelfand, S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Horn, K. B. 
Mullis and H. A. Erlich, Science, 1988, 239, 487. 
12. N. Arnheim and H. Erlich, Annu. Rev. Biochem., 1992, 61, 131. 
13. The Polymerase Chain Reaction, eds. K. B. Mullis, F. Ferré and R. A. Gibbs, 
Birkhäuser, Boston, 1994, pp. 233–415. 
14. P. Gill and A. Ghaemi, Nucleosides Nucleotides Nucleic Acids, 2008, 27, 224. 
15. L. Yan, J. Zhou, Y. Zheng, A. S. Gamson, B. T. Roembke, S. Nakayama and H. O. 
Sintim, Mol. BioSyst., 2014, 10, 970. 
16. P. Craw and W. Balachandran, Lab Chip, 2012, 12, 2469. 
17. Y. V. Gerasimova and D. M. Kolpashchikov, Chem. Soc. Rev., 2014, 43, 6405. 
18. M. Zhang, Y.-M. Guan and B.-C. Ye, Chem. Commun., 2011, 47, 3478. 
19. F. Wang, J. Elbaz and I. Willner, J. Am. Chem. Soc., 2012, 134, 5504. 
20. S. Sando, T. Sasaki, K. Kanatani and Y. Aoyama, J. Am. Chem. Soc., 2003, 125, 
15720. 
21. Z. J. Gartner, B. N. Tse, R. Grubina, J. B. Doyon, T. M. Snyder and D. R. Liu, 
Science, 2004, 305, 1601. 
22. A. Shibata, T. Uzawa, Y. Nakashima, M. Ito, Y. Nakano, S. Shuto, Y. Ito and H. Abe, 
J. Am. Chem. Soc., 2013, 135, 14172. 
23. H. Wang, Y. Wang, S. Liu, J. Yu, W. Xu, Y. Guo and J. Huang, Chem. Commun., 
2015, 51, 8377. 
24. J. Nie, M.-Z. Zhao, W. J. Xie, L.-Y. Cai, Y.-L. Zhou and X.-X. Zhang, Chem. Sci., 
2015, 6, 1225. 
 
193 
25. F. Wang, C.-H. Lu and I. Willner, Chem. Rev., 2014, 114, 2881. 
26. Metal-catalyzed Cross-coupling Reactions, eds. A. de Meijere and F. Diederich, 
Wiley‒VCH, Weinheim, 2nd edn., 2004. 
27. C. E. Garrett and K. Prasad, Adv. Synth. Catal., 2004, 346, 889. 
28. F. Song, A. L. Garner and K. Koide, J. Am. Chem. Soc., 2007, 129, 12354. 
29. J. Tsuji, Organic Synthesis with Palladium Compounds, Springer‒Verlag, Berlin, 
1980, pp. 125–132. 
30. B. M. Trost, Acc. Chem. Res., 1980, 13, 385. 
31. C. G. Frost, J. Howarth and J. M. J. Williams, Tetrahedron: Asymmetry, 1992, 3, 
1089. 
32. J. M. Williams and K. Koide, Ind. Eng. Chem. Res., 2013, 52, 8612. 
33. K. C. Majumdar, S. Alam and B. Chattopadhyay, Tetrahedron, 2008, 64, 597. 
34. A. L. Garner and K. Koide, J. Am. Chem. Soc., 2008, 130, 16472. 
35. A. L. Garner and K. Koide, Chem. Commun., 2009, 86. 
36. A. L. Garner, F. Song and K. Koide, J. Am. Chem. Soc., 2009, 131, 5163. 
37. F. Song, E. J. Carder, C. C. Kohler and K. Koide, Chem. – Eur. J., 2010, 16, 13500. 
38. W. R. Kitley, P. J. Santa Maria, R. A. Cloyd and L. M. Wysocki, Chem. Commun., 
2015, 51, 8520. 
39. M. Santra, S.-K. Ko, I. Shin and K. H. Ahn, Chem. Commun., 2010, 46, 3964. 
40. B. Zhu, C. Gao, Y. Zhao, C. Liu, Y. Li, Q. Wei, Z. Ma, B. Du and X. Zhang, Chem. 
Commun., 2011, 47, 8656. 
41. J. Jiang, H. Jiang, W. Liu, X. Tang, X. Zhou, W. Liu and R. Liu, Org. Lett. 2011, 13, 
4922. 
42. M. E. Jun and K. H. Ahn, Org. Lett., 2010, 12, 2790. 
43. H. N. Kim, M. H. Lee, H. J. Kim, J. S. Kim and J. Yoon, Chem. Soc. Rev., 2008, 37, 
1465. 
44. H. Li, J. Fan and X. Peng, Chem. Soc. Rev., 2013, 42, 7943. 
45. M. P. Tracey, D. Pham and K. Koide, Chem. Soc. Rev., 2015, DOI: 
10.1039/C4CS00323C. 
46. J.-P. Goddard and J.-L. Reymond, Trends in Biotechnology, 2004, 22, 363. 
47. J.-L. Reymond, V. S. Fluxá and N. Maillard, Chem. Commun., 2009, 34. 
48. X. Li, X. Gao, W. Shi and H. Ma, Chem. Rev., 2014, 114, 590. 
49. D. J. Yee, V. Balsanek and D. Sames, J. Am. Chem. Soc., 2004, 126, 2282. 
50. T. M. Penning, M. E. Burczynski, J. M. Jez, C.-F. Hung, H. K. Lin, H. Ma, M. Moore, 
N. Palackal and K. Ratnam, Biochem. J., 2000, 351, 67. 
51. M. Halim, D. J. Yee and D. Sames, J. Am. Chem. Soc., 2008, 130, 14123. 
52. H. Yun and S. J. Danishefsky, J. Org. Chem., 2003, 68, 4519. 




54. A. S. Kalgutkar, D.K. Dalvie, N. Castagnoli and T. J. Taylor, Chem. Res. Toxicol., 
2001, 14, 1139. 
55. R. B. Silverman, Acc. Chem. Res., 1995, 28, 335. 
56. P. M. Lizardi, X. Huang, Z. Zhu, P. Bray-Ward, D. C. Thomas and D. C. Ward, 
Nature Genetics, 1998, 19, 225. 
57. M. M. Ali, F. Li, Z. Zhang, K. Zhang, D.-K. Kang, J. A. Ankrum, X. C. Le and W. 
Zhao, Chem. Soc. Rev., 2014, 43, 3324. 
58. W. Zhao, M. M. Ali, M. A. Brook and Y. Li, Angew. Chem., Int. Ed., 2008, 47, 6330. 
59. B. Schweitzer, S. Wiltshire, J. Lambert, S. O’Malley, K. Kukanskis, Z. Zhu, S. F. 
Kingsmore, P. M. Lizardi and D. C. Ward, Proc. Natl. Acad. Sci. U. S. A., 2000, 97, 
10113. 
60. Q. Xue, Z. Wang, L. Wang and W. Jiang,  Bioconjugate Chem., 2012, 23, 734. 
61. C. Ding, H. Liu, N. Wang and Z. Wang, Chem. Commun., 2012, 48, 5019. 
62. T. Sano, C. L. Smith and C. R. Cantor, Science, 1992, 258, 120. 
63. C. M. Niemeyer, M. Adler and R. Wacker, Trends Biotechnol., 2005, 23, 208. 
64. M. Adler, R. Wacker and C. M. Niemeyer, Analyst, 2008, 133, 702. 
65. R. M. Dirks and N. A. Pierce, Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 15275. 
66. J. M. Jean and K. B. Hall, Proc. Natl. Acad. Sci. U. S. A., 2000, 98, 37. 
67. J. Huang, Y. Wu, Y. Chen, Z. Zhu, X. Yang, C. J. Yang, K. Wang and W. Tan, 
Angew. Chem., Int. Ed., 2011, 50, 401. 
68. H. M. T. Choi, V. A. Beck and N. A. Pierce, ACS Nano, 2014, 8, 4284. 
69. J. Zhuang, L. Fu, M. Xu, H. Yang, G. Chen and D. Tang, Anal. Chim. Acta, 2013, 
783, 17. 
70. H. D. Sikes, R. R. Hansen, L. M. Johnson, R. Jenison, J. W. Birks, K. L. Rowlen and 
C. N. Bowman, Nat. Mater., 2008, 7, 52. 
71. R. R. Hansen, H. D. Sikes and C. N. Bowman, Biomacromolecules, 2007, 9, 355. 
72. H. D. Sikes, R. Jenison and C. N. Bowman, Lab Chip, 2009, 9, 653. 
73. R. R. Hansen, H. J. Avens, R. Shenoy and C. N. Bowman, Anal. Bioanal. Chem., 
2008, 392, 167. 
74. H. J. Avens and C. N. Bowman, Acta Biomater., 2010, 6, 83. 
75. A. Sagi, R. Weinstain, N. Karton and D. Shabat, J. Am. Chem. Soc., 2008, 130, 5434. 
76. N. Jourdain, R. P. Carlón and J.-L. Reymond, Tetrahedron Lett., 1998, 39, 9415. 
77. S. T. Phillips and A. M. DiLauro, ACS Macro Lett., 2014, 3, 298. 
78. R. Weinstain, A. Sagi, N. Karton and D. Shabat, Chem. – Eur. J., 2008, 14, 6857.  
79. C. de las Heras Alarcón, S. Pennadam and C. Alexander, Chem. Soc. Rev., 2005, 34, 
276. 
80. W. Wang and C. Alexander, Angew. Chem., Int. Ed., 2008, 47, 7804. 
81. Rapid Detection of Infectious Agents, eds. S. Spector, M. Bendinelli and H. Friedman, 
Plenum Press, New York, 1998, ch. 10, pp. 159–173. 
 
195 
82. M. N. Bobrow, T. D. Harris, K. J. Shaughnessy and G. J. Litt, J. Immunol. Methods, 
1989, 125, 279. 
83. H. M. Kerstens, P. J. Poddighe and A. G. Hanselaar, J. Histochem. Cytochem., 1995, 
43, 347. 
84. A. J. Gross and I. W. Sizer, J. Biomol. Chem., 1959, 234, 1611. 
85. E. P. Diamandis and T. K. Christopoulos, Clin. Chem., 1991, 37, 625. 
86. I. M. Grumbach and R. W. Veh, J. Histochem. Cytochem., 1995, 43, 31. 
87. S.-M. Hsu, L. Raine and H. Fanger, J. Histochem. Cytochem., 1981, 29, 577. 
88. M. Wilchek and E. A. Bayer, Anal. Biochem., 1988, 171, 1. 
89. E. A. Bayer and M. Wilchek, Methods Biochem. Anal., 1980, 26, 1. 
90. N. L. Rossi and C. A. Mirkin, Chem. Rev., 2005, 105, 1547. 
91. J. Wang, Small, 2005, 1, 1036. 
92. J. Lei and H. Ju, Chem. Soc. Rev., 2012, 41, 2122. 
93. X. Yu, B. S. Munge, V. Patel, G. Jensen, A. Bhirde, J. D. Gong, S. N. Kim, J. 
Gillespie, J. S. Gutkind, F. Papadimitrakopoulos and J. F. Rusling, J. Am. Chem. Soc., 
2006, 128, 11199. 
94. B. Munge, G. Liu, G. Collins and J. Wang, Anal. Chem., 2005, 77, 4662. 
95. B. S. Munge, A. L. Coffey, J. M. Doucette, B. K. Somba, R. Malhotra, V. Patel, J. S. 
Gutkind and J. F. Rusling, Angew. Chem., Int. Ed., 2011, 50, 7915. 
96. K. Saha, S. S. Agasti, C. Kim, X. Li and V. M. Rotello, Chem. Rev., 2012, 112, 2739. 
97. J.-M. Nam, S.-J. Park and C. A. Mirkin, J. Am. Chem. Soc., 2002, 124, 3820. 
98. J.-M. Nam, C. S. Thaxton and C. A. Mirkin, Science, 2003, 301, 1884. 
99. C. S. Thaxton, H. D. Hill, D. G. Georganopoulou, S. I. Stoeva and C. A. Mirkin, Anal. 
Chem., 2005, 77, 8174. 
100. T. A. Taton, C. A. Mirkin and R. L. Letsinger, Science, 2000, 289, 1757. 
101. B.-K. Oh, J.-M. Nam, S. W. Lee and C. A. Mirkin, Small, 2006, 2, 103. 
102. J.-M. Nam, S. I. Stoeva and C. A. Mirkin, J. Am. Chem. Soc., 2004, 126, 5932. 
103. S. I. Stoeva, J.-S. Lee, C. S. Thaxton and C. A. Mirkin, Angew. Chem., Int. Ed., 2006, 
45, 3303. 
104. S. I. Stoeva, J.-S. Lee, J. E. Smith, S. T. Rosen and C. A. Mirkin, J. Am. Chem. Soc., 
2006, 128, 8378. 
105. U. Kreibig and L. Genzel, Surf. Sci., 1985, 156, 678. 
106. R. Elghanian, J. J. Storhoff, R. C. Mucic, R. L. Letsinger and C. A. Mirkin, Science, 
1997, 277, 1078. 
107. J. Liu and Y. Lu, J. Am. Chem. Soc., 2003, 125, 6642. 
108. Y. Lu and J. Liu, Curr. Opin. Biotechnol., 2006, 17, 580. 
109. D. G. Blackmond, Angew. Chem., Int. Ed., 2009, 48, 386. 
110. O. V. Makhlynets and I. V. Korendovych, Biomolecules, 2014, 4, 402. 
111. B. Kobe and B. E. Kemp, Nature, 1999, 402, 373. 
 
196 
112. C.-W. Wang, W.-T. Yu, H.-P. Lai, B.-Y. Lee, R.-C. Gao and K.-T. Tan, Anal. Chem., 
2015, 87, 4231. 
113. O. R. Miranda, H.-T. Chen, C.-C. You, D. E. Mortenson, X.-C. Yang, U. H. F. Bunz 
and V. M. Rotello, J. Am. Chem. Soc., 2010, 132, 5285. 
114. M. De, S. Rana, H. Akpinar, O. R. Miranda, R. R. Arvizo, U. H. F. Bunz and V. M. 
Rotello, Nat. Chem., 2009, 1, 461. 
115. M. De, C.-C. You, S. Srivastava and V. M. Rotello, J. Am. Chem. Soc., 2007, 129, 
10747. 
116. O. R. Miranda, X. Li, L. Garcia-Gonzalez, Z.-J. Zhu, B. Yan, U. H. F. Bunz and V. M. 
Rotello, J. Am. Chem. Soc., 2011, 133, 9650. 
117. C.-C. You, O. R. Miranda, B. Gider, P. S. Ghosh, I.-B. Kim, B. Erdogan, S. A. Krovi, 
U. H. F. Bunz and V. M. Rotello, Nat. Nanotechnol., 2007, 2, 318. 
118. P. Miao, Y. Tang, B. Wang, J. Yin and L. Ning, TrAC, Trends Anal. Chem., 2015, 67, 
1. 
119. A. Saghatelian, K. M. Guckian, D. A. Thayer and M. R. Ghadiri, J. Am. Chem. Soc., 
2003, 125, 344. 
120. N. C. Gianneschi and M. R. Ghadiri, Angew. Chem., Int. Ed., 2007, 46, 3955. 
121. V. Pavlov, B. Shlyahovsky and I. Willner, J. Am. Chem. Soc., 2005, 127, 6522. 
122. B. M. G. Janssen, W. Engelen and M. Merkx, ACS Synth. Biol., 2015, 4, 547. 
123. A. Villaverde, FEBS Lett., 2003, 554, 169. 
124. J. D. Fischer, G. L. Holliday and J. M. Thornton, Bioinformatics, 2010, 26, 2496. 
125. C. Andreini, I. Bertini, G. Cavallaro, G. L. Holliday and J. M. Thornton, 
Bioinformatics, 2009, 25, 2088. 
126. P. Simon, C. Dueymes, M. Fontecave, J.-L. Décout, Angew. Chem., Int. Ed., 2005, 44, 
2764. 
127. M. Liu, J. Fu, C. Hejesen, Y. Yang, N. W. Woodbury, K. Gothelf, Y. Liu and H. Yan, 
Nat. Commun., 2013, 4, 2127. 
128. J. Leblond and A. Petitjean, ChemPhysChem, 2011, 12, 1043. 
129. N. Graf and R. Krämer, Chem. Commun., 2006, 4375. 
130. M. Göritz and R. Krämer, J. Am. Chem. Soc., 2005, 127, 18016. 
131. N. Graf, S. Kassube and R. Krämer, Bioorg. Med. Chem. Lett., 2008, 18, 4786. 
132. N. Graf, M. Göritz and R. Krämer, Angew. Chem., Int. Ed., 2006, 45, 4013. 
133. J. Brunner, A. Mokhir and R. Kraemer, J. Am. Chem. Soc., 2003, 125, 12410. 
134. R. Bonomi, A. Cazzolaro, A. Sansone, P. Scrimin and L. J. Prins, Angew. Chem., Int. 
Ed., 2011, 50, 2307. 
135. F. Manea, F. B. Houillon, L. Pasquato and P. Scrimin, Angew. Chem., Int. Ed., 2004, 
43, 6165. 
136. L. Zhu and E. V. Anslyn, Angew. Chem., Int. Ed., 2006, 45, 1190. 
137. L. Kovbasyuk and R. Krämer, Chem. Rev., 2004, 104, 3161. 
 
197 
138. J. G. Millán and L. J. Prins, in Supramolecular Systems in Biomedical Fields, ed. H.-J. 
Schneider, The Royal Society of Chemistry, Cambridge, 2013, ch. 2, pp. 7–34. 
139. L. Zhu, V. M. Lynch and E. V. Anslyn, Tetrahedron, 2004, 60, 7267. 
140. M. Meldal and C. W. Tornøe, Chem. Rev., 2008, 108, 2952. 
141. Q. Wu and E. V. Anslyn, J. Am. Chem. Soc., 2004, 126, 14682. 
142. R. F. Heck, J. Am. Chem. Soc., 1968, 90, 5518. 
143. Q. Wu and E. V. Anslyn, J. Mater. Chem., 2005, 15, 2815. 
144. R. J. T. Houk and E. V. Anslyn, New J. Chem., 2007, 31, 729. 
145. K. Sonogashira, Y. Tohda and N. Hagihara, Tetrahedron Lett., 1975, 16, 4467. 
146. S. C.Ritter and B. König, Chem. Commun., 2006, 4694. 
147. W. G. Lewis, F. G. Magallon, V. V. Fokin and M. G. Finn, J. Am. Chem. Soc., 2004, 
126, 9152. 
148. M. J. Wiester, P. A. Ulmann and C. A. Mirkin, Angew. Chem., Int. Ed., 2011, 50, 114. 
149. J. R. Farrell, C. A. Mirkin, I. A. Guzei, L. M. Liable-Sands and A. L. Rheingold, 
Angew. Chem., Int. Ed., 1998, 37, 465. 
150. N. C. Gianneschi, P. A. Bertin, S. T. Nguyen, C. A. Mirkin, L. N. Zakharov and A. L. 
Rheingold, J. Am. Chem. Soc., 2003, 125, 10508. 
151. E. N. Jacobsen, Acc. Chem. Res., 2000, 33, 421. 
152. C. G. Oliveri, P. A. Ulmann, M. J. Wiester and C. A. Mirkin, Acc. Chem. Res., 2008, 
41, 1618. 
153. K. B. Hansen, J. L. Leighton and E. N. Jacobsen, J. Am. Chem. Soc., 1996, 44, 10924. 
154. N. C. Gianneschi, S. T. Nguyen and C. A. Mirkin, J. Am. Chem. Soc., 2005, 127, 
1644. 
155. G. Greiner and I. Maier, J. Chem. Soc., Perkin Trans. 2, 2002, 1005. 
156. M. S. Masar III, N. C. Gianneschi, C. G. Olivieri, C. L. Stern, S. T. Nguyen and C. A. 
Mirkin, J. Am. Chem. Soc., 2007, 129, 10149. 
157. H. J. Yoon, J. Kuwabara, J.-H. Kim and C. A. Mirkin, Science, 2010, 330, 66. 
158. M. R. ten Breteler, Z. Zhong, P. J. Dijkstra, A. R. A. Palmans, J. Peeters and J. Feijen, 
J. Polym. Sci., Part A: Polym. Chem., 2007, 45, 429. 
159. T. Zauner, R. Berger-Hoffman, K. Müller, R. Hoffman and T. Zuchner, Anal. Chem., 
2011, 83, 7356. 
160. D. R. Edwards and G. Murphy, Nature, 1998, 394, 527. 
161. H. K. Yoon, S. T. Jung, J.-H. Kim and T. H. Yoo, Biotechnol. Bioprocess Eng., 2012, 
17, 1113. 
162. J. V. Olsen, S.-E. Ong and M. Mann, Mol. Cell. Proteomics, 2004, 3, 608. 
163. A. Light and H. Janska, Trends Biochem. Sci., 1989, 14, 110. 
164. A. Holzinger, E. M. Maier, C. Bück, P. U. Mayerhofer, M. Kappler, J. C. Haworth, S. 




165. I. Yamashina, Biochim. Biophys. Acta, 1956, 20, 433. 
166. H. Kim, H. K. Yoon and T. H. Yoo, Chem. Commun., 2014, 50, 10155. 
167. R. N. Jones, H. W. Wilson, W. J. Novick, A. L. Barry and C. Thornsberry, J. Clin. 
Microbiol., 1982, 15, 954. 
168. C. Gialeli, A. D. Theocharis and N. K. Karamanos, FEBS J., 2010, 278, 16. 
169. S. S. Shekhawat and I. Ghosh, Curr. Opin. Chem. Biol., 2011, 15, 789. 
170. S. S. Shekhawat, J. R. Porter, A. Sriprasad and I. Ghosh, J. Am. Chem. Soc., 2009, 
131, 15284. 
171. L. Pauling, R. B. Corey and H. R. Branson, Proc. Natl. Acad. Sci. U. S. A., 1951, 37, 
205. 
172. F. H. C. Crick, Nature, 1952, 170, 882. 
173. S. S. Shekhawat, S. T. Campbell and I. Ghosh, ChemBioChem, 2011, 12, 2353. 
174. D. S. Tawfik, B. S. Green, R. Chap, M. Sela and Z. Eshhar, Proc. Natl. Acad. Sci. U. 
S. A., 1993, 90, 373. 
175. C. Créminon and F. Taran, Chem. Commun., 2015, 51, 7996. 
176. A. L. Garner and K. D. Janda, Angew. Chem., Int. Ed., 2010, 49, 9630. 
177. A. L. Garner and K. D. Janda, ChemBioChem, 2011, 12, 523. 
178. A. L. Garner and K. D. Janda, Chem. Commun., 2011, 47, 7512. 
179. Y. Tian, Y. Hu and C. Mao, ChemBioChem, 2006, 7, 1862. 
180. R. R. Breaker, Nat. Biotechnol., 1997, 15, 427. 
181. J. Li, Y. Jia, J. Zheng, W. Zhong, G. Shen, R. Yang, W. Tan, Chem. Commun., 2013, 
49, 6137. 
182. S. Sando, A. Narita, K. Abe and Y. Aoyama, J. Am. Chem. Soc., 2005, 127, 5300. 
183. S. Tyagi and F. R. Kramer, Nat. Biotechnol., 1996, 14, 303. 
184. A. Narita, K. Ogawa, S. Sando and Y. Aoyama, Angew. Chem., Int. Ed., 2006, 45, 
2879. 
185. M. Sinz, G. Wallace and J. Sahi, AAPS J., 2008, 10, 391. 
186. E. Sella and D. Shabat, J. Am. Chem. Soc., 2009, 131, 9934. 
187. D. A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder 
and P. Smith, Polym. J., 1985, 17, 117. 
188. D. Astruc, E. Boisselier and C. Ornelas, Chem. Rev., 2010, 110, 1857. 
189. F. M. H. de Groot, C. Albrecht, R. Koekkoek, P. H. Beusker and H. W. Scheeren, 
Angew. Chem., Int. Ed., 2003, 42, 4490. 
190. M. L. Szalai, R. M. Kevwitch and D. V. McGrath, J. Am. Chem. Soc., 2003, 125, 
15688. 
191. R. J. Amir, N. Pessah, M. Shamis and D. Shabat, Angew. Chem., Int. Ed., 2003, 42, 
4494. 
192. M. Avital-Schmilovici and D. Shabat, Soft Matter, 2010, 6, 1073. 
193. E. Sella and D. Shabat, Chem. Commun., 2008, 5701. 
 
199 
194. J. Simon, S. Salzbrunn, G. K. S. Prakash, N. A. Petasis and G. A. Olah, J. Org. Chem., 
2001, 66, 633. 
195. A. Baeyer and V. Villiger, Ber. Dtsch. Chem. Ges., 1899, 32, 3625. 
196. H. D. Dakin, Am. Chem. J., 1909, 42, 477. 
197. L.-C. Lo and C.-Y. Chu, Chem. Commun., 2003, 2728. 
198. S. Gnaim and D. Shabat, Acc. Chem. Res., 2014, 47, 2970. 
199. R. Perry-Feigenbaum, E. Sella and D. Shabat, Chem. – Eur. J., 2011, 17, 12123. 
200. M. Avital-Shmilovici and D. Shabat, Bioorg. Med. Chem., 2010, 18, 3643. 
201. M. A. Swiderska and J.-L. Reymond, Nat. Chem., 2009, 1, 527. 
202. E. Sella, A. Lubelski, J. Klafter and D. Shabat, J. Am. Chem. Soc., 2010, 132, 3945. 
203. N. Karton-Lifshin and D. Shabat, New J. Chem., 2012, 36, 386.  
204. E. Sella, R. Weinstain, R. Erez, N. Z. Burns, P. S. Baran and D. Shabat, 
Chem.Commun., 2010, 46, 6575. 
205. K. Yeung, K. M. Schmid and S. T. Phillips, Chem. Commun., 2013, 49, 394. 
206. E. Sella and D. Shabat, Org. Biomol. Chem., 2013, 11, 5074. 
207. M. S. Baker and S. T. Phillips, J. Am. Chem. Soc., 2011, 133, 5170. 
208. M. S. Baker and S. T. Phillips, Org. Biomol. Chem., 2012, 10, 3595. 
209. V. F. Hodge and M. O. Stallard, Environ. Sci. Technol., 1986, 20, 1058. 
210. A. D. Brooks, K. Yeung, G. G Lewis and S. T. Phillips, Anal. Methods, 2015, 7, 7186. 
211. J.-A. Gu, V. Mani and S.-T. Huang, Analyst, 2015, 140, 346. 
212. G. A. M. King, Chem. Soc. Rev., 1978, 7, 297. 
213. G. A. M. King, Origins Life, 1977, 8, 39. 
214. L. E. Orgel, Nature, 1992, 358, 203. 
215. W. S. Zielinski and L. E. Orgel, Nature, 1987, 327, 346. 
216. D. Sievers and G. Von Kiedrowski, Nature, 1994, 369, 221. 
217. G. von Kiedrowski, B. Wlotzka, J. Helbing, M. Matzen and S. Jordan, Angew. Chem., 
Int. Ed., 1991, 30, 423. 
218. N. Paul and G. F. Joyce, Curr. Opin. Chem. Biol., 2004, 8, 634. 
219. V. Patzke and G. von Kiedrowski, ARKIVOC, 2007, 293. 
220. D. H. Lee, J. R. Granja, J. A. Martinez, K. Severin and M. R. Ghadiri, Nature, 1996, 
382, 525. 
221. V. Rotello, J.-I. Hong and J. Rebek, J. Am. Chem. Soc., 1991, 113, 9422. 
222. K. Soai, S. Niwa and H. Hori, J. Chem. Soc., Chem. Commun., 1990, 982. 
223. K. Soai, T. Shibata, H. Morioka and K. Choji, Nature, 1995, 378, 767. 
224. K. Soai, T. Shibata and I. Sato, Acc. Chem. Res., 2000, 33, 382. 
225. M. H. Todd, Chem. Soc. Rev., 2002, 31, 211. 
226. K. Mikami and M. Yamanaka, Chem. Rev., 2003, 103, 3369. 
227. T. Kawasaki, Y. Matsumura, T. Tsutsumi, K. Suzuki, M. Ito and K. Soai, Science, 
2009, 24, 492. 
 
200 
228. J. L. Bada, Nature, 1995, 374, 594. 
229. D. G. Blackmond, Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 5732. 
230. K. Soai, Top. Curr. Chem., 2008, 284, 1. 
231. H. J. Yoon and C. A. Mirkin, J. Am. Chem. Soc., 2008, 130, 11590. 
232. M. Frenklach and D. Clary, Ind. Eng. Chem. Fundamen., 1983, 22, 433. 
233. H. Mohapatra, K. M. Schmid and S. T. Phillips, Chem. Commun., 2012, 48, 3018. 
234. K. Arimitsu, M. Miyamoto and K. Ichimura, Angew. Chem., Int. Ed., 2000, 39, 3425. 
235. J. S. Robbins, K. M. Schmid and S. T. Phillips, J. Org. Chem., 2013, 78, 3159. 
236. P. Theato, B. S. Sumerlin, R. K. O’Reilly and T. H. Epps III, Chem. Soc. Rev., 2013, 
42, 7055. 
237. R. J. Amir and D. Shabat, Chem. Commun., 2004, 1614. 
238. R. J. Amir, E. Danieli and D. Shabat, Chem. – Eur. J., 2007, 13, 812. 
239. S. A. Jenekhe and J. A. Osaheni, Science, 1994, 265, 765. 
240. T. M. Swager, Acc. Chem. Res., 1998, 31, 201. 
241. Q. Zhou and T. M. Swager, J. Am. Chem. Soc., 1995, 117, 7017. 
242. B. L. Allwood, N. Spencer, H. Shahriari-Zavareh, J. F. Stoddart and D. J. Williams, J. 
Chem. Soc., Chem. Commun., 1987, 1064. 
243. Q. Zhou and T. M. Swager, J. Am. Chem. Soc., 1995, 117, 12593. 
244. I. A. Levitsky, J. Kim and T. M. Swager, J. Am. Chem. Soc., 1999, 121, 1466. 
245. D. T. McQuade, A. E. Pullen and T. M. Swager, Chem. Rev., 2000, 100, 2537. 
246. S. W. Thomas III, G. D. Joly and T. M. Swager, Chem. Rev., 2007, 107, 1339. 
247. H. N. Kim, Z. Guo, W. Zhu, J. Yoon and H. Tian, Chem. Soc. Rev., 2011, 40, 79. 
248. K. Doré, S. Dubus, H.-A. Ho, I. Lévesque, M. Brunette, G. Corbeil, M. Boissinot, G. 
Boivin, M. G. Bergeron, D. Boudreau and M. Leclerc, J. Am. Chem. Soc., 2004, 126, 
4240. 
249. X. Feng, L. Liu, S. Wang and D. Zhu, Chem. Soc. Rev., 2010, 39, 2411. 
250. H.-A. Ho, M. Boissinot, M. G. Bergeron, G. Corbeil, K. Doré, D. Boudreau and M. 
Leclerc, Angew. Chem., Int. Ed., 2002, 41, 1548. 
251. H. A. Ho, K. Doré, M. Boissinot, M. G. Bergeron, R. M. Tanguay, D. Boudreau and 
M. Leclerc, J. Am. Chem. Soc., 2005, 127, 12673. 
252. K. Doré, M. Leclerc and D. Boudreau, Reviews in Fluorescence 2007, eds. C. D. 
Geddes and J. R. Lakowicz, Springer, New York, 2009, ch. 9, pp. 179–197. 
253. K. Doré, M. Leclerc and D. Boudreau, J. Fluoresc., 2006, 16, 259. 
254. J. Chen, S. Körner, S. L. Craig, D. M. Rudkevich and J. Rebek, Nature, 2002, 415, 
385. 
255. J. Chen, S. Körner, S. L. Craig, S. L. Craig, D. M. Rudkevich and J. Rebek, Proc. 
Natl. Acad. Sci. U. S. A., 2002, 99, 2593. 
256. J. N. Weinstein, S. Yoshikami, P. Henkart, R. Blumenthal and W. A. Hagins, Science, 
1977, 195, 489. 
 
201 
257.  I. López Arbeloa, J. Photochem., 1982, 18, 161. 
258. C. Li and S. Liu, Chem. Commun., 2012, 48, 3262. 
259. G. Das, P. Talukdar and S. Matile, Science, 2002, 298, 1600. 
260. S. Matile, Chem. Soc. Rev., 2001, 30, 158. 
261. M. Komoszynski and A. Wojtczak, Biochim. Biophys. Acta, 1996, 1310, 233. 
262. T. Takeuchi and S. Matile, J. Am. Chem. Soc., 2009, 131, 18048. 
263. N. Sakai, J. Mareda and S. Matile, Acc. Chem. Res., 2005, 38, 79. 
264. S. Matile, H. Tanaka and S. Litvinchuk, Top. Curr. Chem., 2007, 277, 219. 
265. Y. Takaoka, K. Kiminami, K. Mizusawa, K. Matsuo, M. Narazaki, T. Matsuda and I. 
Hamachi, J. Am. Chem. Soc., 2011, 133, 11725. 
266. K. Matsuo, R. Kamada, K. Mizusawa, H. Imai, Y. Takayama, M. Narazaki, T. 
Matsuda, Y. Takaoka and I. Hamachi, Chem. – Eur. J., 2013, 19, 12875. 
267. K. Mizusawa, Y. Takoka and I. Hamachi, J. Am. Chem. Soc., 2012, 134, 13386. 
268. T. Yoshii, K. Mizusawa, Y. Takaoka and I. Hamachi, J. Am. Chem. Soc., 2014, 136, 
16635. 
269. A. P. Esser-Kahn, S. A. Odom, N. R. Sottos, S. R. White and J. S. Moore, 
Macromolecules, 2011, 44, 5539. 
270. A. P. Blum, J. K. Kammeyer, A. M. Rush, C. E. Callmann, M. E. Hahn and N. C. 
Gianneschi, J. Am. Chem. Soc., 2015, 137, 2140. 
271. M. A. Azagarsamy, P. Sokkalingam and S. Thayumanavan, J. Am. Chem. Soc., 2009, 
131, 14184. 
272. A. J. Harnoy, I. Rosenbaum, E. Tirosh, Y. Ebenstein, R. Shaharabani, R. Beck and R. 
J. Amir, J. Am. Chem. Soc., 2014, 136, 7531. 
273. G. Liu, X. Wang, J. Hu, G. Zhang and S. Liu, J. Am. Chem. Soc., 2014, 136, 7492. 
274. M. Xue and J. I. Zink, J. Am. Chem. Soc., 2013, 135, 17659. 
275. M. Xue, D. Cao, J. F. Stoddart and J. I. Zink, Nanoscale, 2012, 4, 7569. 
276. C. Wang, Z. Li, Y.-L. Zhao, J. W. Gaines, O. A. Bozdemir, M. W. Ambrogio, M. 
Frasconi, Y. Y. Botros, J. I. Zink and J. F. Stoddart, Angew. Chem., Int. Ed., 2012, 51, 
5460. 
277. D. Tarn, C. E. Ashley, M. Xue, E. C. Carnes, J. I. Zink and C. J. Brinker, Acc. Chem. 
Res., 2013, 46, 792. 
278. N. A. Peppas and A. S. Hoffman, Biomaterials Science: An Introduction to Materials 
in Medicine, eds. B. D. Ratner, A. S. Hoffman, F. J. Schoen and J. E. Lemons, 
Elsevier, Oxford, 3
rd
 ed., 2004, ch. 1.2.5, pp. 166–179. 
279. M. D. Segarra-Maset, V. J. Nebot, J. F. Miravet and B. Escuder, Chem. Soc. Rev., 
2013, 42, 7086. 
280. J. Hu, G. Zhang and S. Liu, Chem. Soc. Rev., 2012, 41, 5933. 
281. A. Richtar, G. Paschew, S. Klatt, J. Lienig, K.-F. Arndt and H.-J. Adler, Sensors, 
2008, 8, 561. 
 
202 
282. D. Buenger, F. Topuz and J. Groll, Prog. Polym. Sci., 2012, 37, 1678. 
283. Z. M. Shakhsher, I. Odeh, S. Jabr and W. R. Seitz, Microchim. Acta, 2004, 144, 147. 
284. L. A. DeLouise, P. M. Fauchet, B. L. Miller and A. A. Pentland, Adv. Mater., 2005, 
17, 2199. 
285. Z. Zhu, C. Wu, H. Liu, Y. Zou, X. Zhang, H. Kang, C. J. Yang and W. Tan, Angew. 
Chem., Int. Ed., 2010, 49, 1052. 
286. J. Liu and Y. Lu, Angew. Chem., Int. Ed., 2005, 45, 90. 
287. F. L. Bates, D. French and R. E. Rundle, J. Am. Chem. Soc., 1943, 65, 142. 
288. L. Yan, Z. Zhu, Y. Zou, Y. Huang, D. Liu, S. Jia, D. Xu, M. Wu, Y. Zhou, S. Zhou 
and C. J. Yang, J. Am. Chem. Soc., 2013, 135, 3748. 
289. M. Ikeda, T. Tanida, T. Yoshii and I. Hamachi, Adv. Mater., 2011, 23, 2819. 
290. M. Ikeda, R. Ochi and I. Hamachi, Lab Chip, 2010, 10, 3325. 
291. A. Wada, S. Tamaru, M. Ikeda and I. Hamachi, J. Am. Chem. Soc., 2009, 131, 5321. 
292. M. Ikeda, T. Yoshii, T. Matsui, T. Tanida, H. Komatsu and I. Hamachi, J. Am. Chem. 
Soc., 2011, 133, 1670. 
293. M. Ikeda, R. Ochi, A. Wada and I Hamachi, Chem. Sci., 2010, 1, 491. 
294. T. Yoshii, S. Onogi, H. Shigemitsu and I. Hamachi, J. Am. Chem. Soc., 2015, 137, 
3360. 
295. M. S. Hershfield, L. J. Roberts II, N. J. Ganson, S. J. Kelly, I. Santisteban, E. Scarlett, 
D. Jaggers and J. S. Sundy, Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 14351. 
296. M. Ikeda, T. Tanida, T. Yoshii, K. Kurotani, S. Onogi, K. Urayama and I. Hamachi, 
Nat. Chem., 2014, 6, 511. 
297. D.-G. Cho and J. L. Sessler, Chem. Soc. Rev., 2009, 38, 1647. 
298. S. Goggins, C. Naz, B. J. Marsh, Chem. Commun., 2015, 51, 561. 
299. http://www.atlasgenetics.com/the-company (accessed June 2015). 
300. R. W. Peeling, K. K. Holmes, D. Mabey and A. Ronald, Sex Transm. Infect., 2006, 82, 
v1. 
301. A. Y. Peleg and D. C. Hooper, N. Engl. J. Med., 2010, 362, 1804. 
302. B. J. Marsh, J. O. Sharp, S. E. Flower, C. G. Frost and Atlas Genetics Ltd., Int. Pat., 
WO2012/085591, 2012. 
303. N. J. Ronkainen, H. B. Halsall and W. R. Heineman, Chem. Soc. Rev., 2010, 39, 1747. 
304. J. Wang, Biosens. Bioelectron., 2006, 21, 1887. 
305. S. C. Hillier, C. G. Frost, A. T. A. Jenkins, H. T. Braven, R. W. Keay, S. E. Flower 
and J. M. Clarkson, Bioelectrochemistry, 2004, 63, 307. 
306. S. C. Hillier, S. E. Flower, C. G. Frost, A. T. A. Jenkins, R. W. Keay, H. T. Braven 
and J. M. Clarkson, Electrochem. Commun., 2004, 6, 1227. 
307. J. O. Sharp, PhD Thesis, University of Bath, 2012. 
308. B. J. Marsh, L. Hampton, S. Goggins and C. G. Frost, New J. Chem., 2014, 38, 5260. 
 
203 
309. D. M. Pearce, D. P. Shenton, J. Holden and C. A. Gaydos, IEEE Trans. Biomed. Eng., 
2011, 58, 755. 
310. K. A. Fenton and C. M. Lowndes, Sex Transm. Infect., 2004, 80, 255. 
311. L. Babuin and A. S. Jaffe, Can. Med. Assoc. J., 2005, 173, 1191. 
312. J. A. Ramos-Vara, Vet. Pathol., 2005, 42, 405. 
313. J. S. Bonifacino, E. S. Dell’Angelica and T. A. Springer, Curr. Protoc. Mol. Biol., 
2001, 48, 1. 
314. B. Weeke, Scand. J. Immunol. Suppl., 1973, 1, 47. 
315. J. P. Gosling, Clin. Chem., 1990, 36, 1408. 
316. Immunoassay, eds. E. P. Diamandis and T. K. Christopoulos, Academic Press, 
London, 1996, ch. 1, pp. 1–3. 
317. L. E. Miles and C. N. Hales, Nature, 1968, 219, 186. 
318. S. Avrameas, Immunochemistry, 1969, 6, 43. 
319. B. K. van Weemen and A. H. W. M. Schuurs, FEBS Lett., 1971, 15, 232. 
320. E. Engvall and P. Perlmann, Immunochemistry, 1971, 8, 871. 
321. R. Lequin, Clin. Chem., 2005, 51, 2415. 
322. D. M. Kemeny and S. Chantler, ELISA and Other Solid Phase Immunoassays, eds. D. 
M. Kemeny and S. J. Challacombe, John Wiley & Sons Ltd, Colchester, 1988, ch. 1, 
pp. 1–29. 
323. S. Chantler and J. A Diment, Immunoassays for the 80s, eds. A. Voller, A. Bartlett and 
D. Bidwell, MTP Press, Lancaster, ch. 28, pp. 417–430. 
324. R. H. Yolken and F. J. Leister, J. Clin. Microbiol., 1980, 13, 738. 
325. D. M. Kemeny and D. Richards, Immunological Techniques in Microbiology, vol. 24, 
eds. J. M. Grange, A. Fox and N. L. Morgan, Blackwell, Oxford, 1987, pp. 49–57. 
326. C. Blake and B. J. Gould, Analyst, 1984, 109, 533. 
327. N. C. Veitch, Phytochemistry, 2004, 65, 249. 
328. A.-C. Lee, G. Liu, C.-K. Heng, S.-N. Tan, T.-M. Lim and Y. Lin, Electroanalysis, 
2008, 20, 2040. 
329. Q. Husain, Crit. Rev. Biotechnol., 2010, 30, 41. 
330. F. H. Ko and H. G. Monbouquette, Biotechnol. Prog., 2006, 22, 860. 
331. U. Sharma, D. Pal and R. Prasad, Ind. J. Clin. Biochem., 2014, 29, 269. 
332. K. R. Wehnmeyer, H. B. Halsall and W. R. Heineman, Clin. Chem., 1985, 31, 1546. 
333. H. T. Tang, C. E. Lunte, H. B. Halsall and W. R. Heineman, Anal. Chim. Acta, 1988, 
214, 187. 
334. L. Della Ciana, G. Bernacca, C. De Nitti and A. Massaglia, J. Immunol. Methods, 
1996, 193, 51. 
335. C. Fernández-Sánchez and A. Costa-García, Biosens. Bioelectron., 1997, 12, 403. 
336. F. Tie, A. Pan, B. Ru, W. Wang and Y. Hu, J. Immunol. Methods, 1992, 149, 115. 
337. M. P. Kreuzer, C. K. O’Sullivan and G. G. Guilbault, Anal. Chim. Acta, 1999, 393, 95. 
 
204 
338. S Kobayashi and H. Higashimura, Prog. Polym. Sci., 2003, 28, 1015. 
339. C. Fernández-Sánchez and A. Costa-García, Electroanalysis, 1998, 10, 249. 
340. M. S. Wilson and R. D. Rauh, Biosens. Bioelectron., 2004, 20, 276. 
341. A. Kokado, H. Arakawa and M. Maeda, Anal. Chim. Acta, 2000, 407, 119. 
342. A. Preeschaworapun, Z. Dai, Y. Xiang, O. Chailapakul and J. Wang, Talanta, 2008, 
76, 424. 
343. B. Habibi and M. H. Pournaghi-Azar, Electrochim. Acta, 2010, 55, 5492. 
344. M. Díaz-González, M. B. González-García and A. Costa-García, Electroanalysis, 
2005, 17, 1901. 
345. D. R. van Staveren and N. Metzler-Nolte, Chem. Rev., 2004, 104, 5931. 
346. C. Degrand, B. Limoges and S. Rapicault, J. Pharm. Biomed. Anal., 1996, 14, 1343. 
347. C. J. McNeil, I. J. Higgins and J. V. Bannister, Biosensors, 1987/88, 3, 199. 
348. A. La Gal La Salle, B. Limoges, C. Degrand and P. Brossier, Anal. Chem., 1995, 67, 
1245. 
349. A. La Gal La Salle, B. Limoges and C. Degrand, J. Electroanal. Chem., 1994, 379, 
281. 
350. B. Limoges and C. Degrand, Anal. Chem., 1996, 68, 4141. 
351. J. M. Fowler, D. K. Y. Wong, H. B. Halsall and W. R. Heineman, Electrochemical 
Sensors, Biosensors and their Biomedical Applications, eds. X. Zhang, H. Ju and J. 
Wang, Academic Press, London, 1
st
 edn., 2008, ch. 5, pp. 115–140. 
352. R. Y. Tsien and A. T. Harootunian, Cell Calcium, 1990, 11, 93. 
353. J. Fan, M. Hu, P. Zhan and X. Peng, Chem. Soc. Rev., 2013, 42, 29. 
354. Y. Du, B. J. Lim, Y. S. Jiang, J. L. Sessler and A. D. Ellington, Anal. Chem., 2014, 86, 
8010.  
355. C. H. Fan, K. W. Plaxco and A. J. Heeger, Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 
9134. 
356. F. Gao, L. Du, Y. Zhang, D. Tang and Y. Du, Anal. Chim. Acta, 2015, 883, 67. 
357. K. Ren, J. Wu, F. Yan and H. Ju, Sci. Rep., 2014, 4, 4360. 
358. K. Ren, J. Wu, F. Yan, Y. Zhang and H. Ju, Biosens. Bioelectron., 2015, 66, 345. 
359. E. Xiong, L. Wu, J. Zhou, P. Yu, X. Zhang and J. Chen, Anal. Chim. Acta, 2015, 853, 
242. 
360. X. Chai, L. Zhang and Y. Tian, Anal. Chem., 2014, 86, 10668. 
361. X. Zhang, L. Wu, J. Zhou, X. Zhang and J. Chen, J. Electroanal. Chem., 2015, 742, 
97. 
362. A. Sagi, J. Rishpon and D. Shabat, Anal. Chem., 2006, 78, 1459. 
363. J. Li, X. Luo, Q. Wang, L.-M. Zheng, T. W. Doyle and S.-H. Chen, Bioorg. Med. 
Chem. Lett., 1998, 8, 3159. 
364. L. J. Silverberg, J. L. Dillon and P. Vemishetti, Tetrahedron Lett., 1996, 37, 771. 
365. M. Golkowski and T. Ziegler, Molecules, 2011, 16, 4695. 
 
205 
366. S. W. Chaikin and W. G. Brown, J. Am. Chem. Soc., 1949, 71, 122. 
367. J. Lapić, G. Pavlović, D. Siebler, K. Heinze and V. Rapić, Organometallics, 2008, 27, 
726. 
368. C. Schotten, Ber. Dtsch. Chem. Ges., 1884, 17, 2544. 
369. E. Baumann, Ber. Dtsch. Chem. Ges., 1886, 19, 3218. 
370. T. Curtius, Ber. Dtsch. Chem. Ges., 1890, 23, 3023. 
371. H. Franzyk, M. K. Christensen, R. M. Jørgensen, M. Meldal, H. Cordes, S. Mouritsen 
and K. Bock, Bioorg. Med. Chem., 1997, 5, 21. 
372. G. W. Kenner, A. R. Todd and F. J. Weymouth, J. Chem. Soc., 1952, 3875. 
373. K.-H. Chen, J.-S. Yang, C.-Y. Hwang and J.-M. Fang, Org. Lett., 2008, 10, 4401. 
374. J. Perruchon, R. Ortmann and M. Schlitzer, Synthesis, 2007, 22, 3553. 
375. J. Kotlarska, K. Binnemans and W. Dehaen, Tetrahedron, 2013, 69, 9947. 
376. M. Tercel, G. J. Atwell, S. Yang, A. Ashoorzadeh, R. J. Stevenson, K. J. Botting, Y. 
Gu, S. Y. Mehta, W. A. Denny, W. R. Wilson and F. B. Pruijn, Angew. Chem., Int. 
Ed., 2011, 50, 2606. 
377. J. D. Patrone, J. Yao, N. E. Scott and G. D. Dotson, J. Am. Chem. Soc., 2009, 131, 
16340. 
378. T. Tsuji, K. Suzuki, T. Nakamura, T. Goto, Y. Sekiguchi, T. Ikeda, T. Fukuda, T. 
Takemoto, Y. Mizuno, T. Kimura, Y. Kawase, F. Nara, T. Kagari, T. Shimozato, C. 
Yahara, S. Inaba, T. Honda, T. Izumi, M. Tamura and T. Nishi, Bioorg. Med. Chem., 
2014, 22, 4246. 
379. S. Hanashima, S. Manabe, K. Inamori, N. Taniguchi and Y. Ito, Angew. Chem., Int. 
Ed., 2004, 43, 5674. 
380. K. Shimada, Y. Kaburgi and T. Fukuyama, J. Am. Chem. Soc., 2003, 125, 4048. 
381. Y. G. Wang, R. Takeyama and Y. Kobayashi, Angew. Chem., Int. Ed., 2006, 45, 3320. 
382. M. Oikawa, H. Furuta, Y. Suda and S. Kusumoto, Tetrahedron Lett., 1999, 40, 5199. 
383. D. C. D. Butler and C. J. Richards, Organometallics, 2002, 21, 5433. 
384. R. Q. Thompson, M. Porter, C. Stuver, H. B. Halsall, W. R. Heineman, E. Buckley 
and M. R. Smyth, Anal. Chim. Acta, 1993, 271, 223. 
385. Y.-H. Hsieh, C. A. Gaydos, M. T. Hogan, O. M. Uy, J. Jackman, M. Jett-Goheen, A. 
Albertie, D. T. Dangerfield II, C. R. Neustadt, Z. S. Wiener and A. M. Rompalo, PLoS 
ONE, 2011, 6, e19263. 
386. L. Michaelis and M. L. Menten, Biochem. Z., 1913, 49, 333. 
387. K. A. Johnson and R. S. Goody, Biochemistry, 2011, 50, 8264. 
388. R. B. McComb, G. N. Bowers and S. Posen, Alkaline Phosphatase, Plenum Press, 
New York, 1979, ch. 7.8, pp. 334‒337. 
389. S. Black, I. Kushner and D. Samols, J. Biol. Chem., 2004, 279, 48487. 




391. S. Goggins, B. J. Marsh, A. T. Lubben and C. G. Frost, Chem. Sci., 2015, 6, 4978. 
392. N. Malou and D. Raoult, Trends Microbiol., 2011, 19, 295. 
393. X. Pei, B. Zhang, J. Tang, B. Liu, W. Lai and D. Tang, Anal. Chim. Acta, 2013, 758, 
1. 
394. Y. Zhang, Y. Guo, Y. Xianyu, W. Chen, Y. Zhao and X. Jiang, Adv. Mater., 2013, 25, 
3802. 
395. J. Das, M. A. Aziz and H. Yang, J. Am. Chem. Soc., 2006, 128, 16022. 
396. E. J. Nam, E. J. Kim, A. W. Wark, S. Rho, H. Kim and H. J. Lee, Analyst, 2012, 137, 
2011. 
397. R. Polsky, R. Gill, L. Kaganovsky and I. Willner, Anal. Chem., 2006, 78, 2268. 
398. W. Qu, Y. Liu, D. Liu, Z. Wang and X. Jiang, Angew. Chem., Int. Ed., 2011, 50, 3442. 
399. R. de la Rica and M. M. Stevens, Nat. Nanotechnol., 2012, 7, 821. 
400. P. D. Howes, S. Rana and M. M. Stevens, Chem. Soc. Rev., 2014, 43, 3835. 
401. R. de la Rica and M. M. Stevens, Nat. Protoc., 2013, 8, 1759. 
402. A. Johannsson and D. L. Bates, ELISA and Other Solid Phase Immunoassays, eds. D. 
M. Kemeny and S. J. Challacombe, John Wiley & Sons Ltd, Colchester, 1988, ch. 4, 
pp. 86. 
403. O. H. Lowry, Mol. Cell. Biochem., 1980, 32, 135. 
404. H. Yang, Curr. Opin. Chem. Biol., 2012, 16, 422. 
405. Z. Gao, L. Hou, M. Xu and D. Tang, Sci. Rep., 2014, 4, 3966. 
406. J.-H. Kim, H.-W. Chung and T. R. Lee, Chem. Mater., 2006, 18, 4115. 
407. S. Ge, F. Liu, W. Liu, M. Yan, X. Song and J. Yu, Chem. Commun., 2014, 50, 475. 
408. C.-J. Li and T.-H. Chan, Comprehensive Organic Reactions in Aqueous Media, John 
Wiley & Sons Ltd, Hoboken, 2
nd
 edn., 2007. 
409. J. F. Hull, Y. Himeda, W.-H. Wang, B. Hashiguchi, R. Periana, D. J. Szalda, J. T. 
Muckerman and E. Fujita, Nat. Chem., 2012, 4, 383. 
410. N. D. McDaniel, F. J. Coughlin, L. L. Tinker and S. Bernhard, J. Am. Chem. Soc., 
2008, 130, 210. 
411. J. M. McFarland and M. B. Francis, J. Am. Chem. Soc., 2005, 127, 13490. 
412. R. Kawahara, K. Fujita and R. Yamaguchi, J. Am. Chem. Soc., 2010, 132, 15108. 
413. R. Kawahara, K. Fujita and R. Yamaguchi, J. Am. Chem. Soc., 2012, 134, 3643. 
414. T. Abura, S. Ogo, Y. Watanabe and S. Fukuzumi, J. Am. Chem. Soc., 2003, 125, 4149. 
415. X. Wu, X. Li, A. Zanotti-Gerosa, A. Pettman, J. Liu, A. J. Mills and J. Xiao, Chem. – 
Eur. J., 2008, 14, 2209. 
416. V. Köhler, Y. M. Wilson, M. Dürrenberger, D. Ghislieri, E. Churakova, T. Quinto, L. 
Knörr, D. Häussinger, F. Hollmann, N. J. Turner and T. R. Ward, Nat. Chem., 2013, 5, 
93. 
417. Y. Wei, D. Xue, Q. Lei, C. Wang and J. Xiao, Green Chem., 2013, 15, 629. 
 
207 
418. X. Wu, J. Liu, X. Li, A. Zanotti-Gerosa, F. Hancock, D. Vinci, J. Ruan and J. Xiao, 
Angew. Chem. Int. Ed., 2006, 45, 6718. 
419. J. Tan, W. Tang, Y. Sun, Z. Jiang, F. Chen, L. Xu, Q. Fan and J. Xiao, Tetrahedron, 
2011, 67, 6206. 
420. H.E. Gottlieb, V. Kotlyar and A. Nudelman, J. Org. Chem., 1997, 62, 7512. 
421. Purification of Laboratory Chemicals 3rd ed., C. L. L. Chai and W. L. F. Amarego, 
Pergamon Press, Oxford, 1988. 
422. R. B. McComb and G. N. Bowers, Clin. Chem., 1972, 18, 97. 
423. D. van Leusen and B. Hessen, Organometallics, 2001, 20, 224. 
424. M. Merabet-Khellasi, L. Aribi-Zouioueche and O. Riant, Tetrahedron: Asymmetry, 
2009, 20, 1371. 
425. D. Kalita, M. Morisue and Y. Kobuke, New J. Chem., 2006, 30, 77. 
426. Z. Zhang, S. Mikkola and H. Lönnberg, Org. Biomol. Chem., 2003, 1, 854. 
427. T. Aubineau and J. Cossy, Chem. Commun., 2013, 49, 3303. 
428. A. V. Kirsanov and N. A. Kirsanova, Zh. Obshch. Khim., 1962, 32, 887. 
429. M. S. Abdel-Maksoud, M.-R. Kim, M. I. El-Gamal, M. M. G. El-Din, J. Tae, H. S. 
Choi, K.-T. Lee, K. H. Yoo and C.-H. Oh, Eur. J. Med. Chem., 2015, 95, 453. 
430. F. B. Zienty, J. Am. Chem. Soc., 1945, 67, 1138. 
431. D. G. Batt, J. J. Petraitis, G. C. Houghton, D. P. Modi, G. A. Cain, M. H. Corjay, S. A. 
Mousa, P. J. Bouchard, M. S. Forsythe, P. B. Harlow, F. A. Barbera, S. M. Spitz, R. R. 
Wexler and P. K. Jadhav, J. Med. Chem., 2000, 43, 41. 
432. U. Ragnarsson, L. Grehn, L. S. Monteiro and H. L. S. Maia, Synlett, 2013, 15, 2386. 
433. R.Khan, T. P. Singh and M. D. Singh, Synlett, 2014, 25, 696. 
434. N. Mase, T. Ando, F. Shibagaki, A. Sugita, T. Narumi, M. Toda, N. Watanabe and F. 
Tanaka, Tetrahedron Lett., 2014, 55, 1946. 
435. S. Chen, L. Wang, N. E. Fahmi, S. J. Benkovic and S. M. Hecht, J. Am. Chem. Soc., 
2012, 134, 18883. 
436. T. Schaefer, R. Sebastian, J. Peeling, G. H. Penner and K. Koh, Can. J. Chem., 1989, 
67, 1015. 
437. N. S. Shaikh, K. Junge and M. Beller, Org. Lett., 2007, 9, 5429. 
438. A. P. Dieskau, J.-M. Begouin and B. Plietker, Eur. J. Org. Chem., 2011, 2011, 5291. 
439. G. Nagendra, T. M. Vishwanatha and V. V. Sureshbabu, Tetrahedron Lett., 2012, 53, 
5059. 
440. N. Murai, M. Yonaga and K. Tanaka, Org. Lett., 2012, 14, 1278. 
441. R. Cano, M. Yus and D. J. Ramón, Tetrahedron, 2011, 67, 8079. 
442. M. R. Naimi-Jamal, J. Mokhtari, M. G. Dekamin and G. Kaupp, Eur. J. Org. Chem., 
2009, 2009, 3567. 
443. Y. Zhou, G. Gao, H. Li and J. Qu, Tetrahedron Lett., 2008, 49, 3260. 
 
208 
444. H.-J. Li, Y.-Y. Wu, Q.-X. Wu, R. Wang, C.-Y. Dai, Z.-L. Shen, C.-L. Xie and Y.-C. 
Wu, Org. Biomol. Chem., 2014, 12, 3100. 
445. B. Basu, B. Mandal, S. Das, P. Das and A. K. Nanda, Beilstein J. Org. Chem., 2008, 4, 
53. 
446. C. B. Kelly, M. A. Mercadante, T. A. Hamlin, M. H. Fletcher and N. E. Leadbeater, J. 
Org. Chem., 2012, 77, 8131. 
447. E. Kawabata, K. Kikuchi, Y. Urano, H. Kojima, A. Odani and T. Nagano, J. Am. 
Chem. Soc., 2005, 127, 818. 
448. C. Morrill and R. H. Grubbs, J. Am. Chem. Soc., 2005, 127, 2842. 
